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The ability of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) to 
immunomodulate offers therapeutic potential in liver injury but the inherent 
heterogeneity of unsorted MSC populations may explain varied/reduced function as well 
as posing regulatory challenges. Thus, we aimed to evaluate the therapeutic potential of 
purified CD362+ MSC infusion in murine models of acute liver injury. UC-MSCs were 
injected intravenously into mice injured by single dose of Carbon tetrachloride (CCl4) & 
OVA-BIL mice. MSC used were either unsorted or sorted CD362+. The extent of liver 
damage was determined by liver histology, serum analysis, gene expression and FACS 
analysis 3 or 5 days after cell infusion. Homing and bio-distribution of stem cells was 
determined by whole mouse cryo-imaging of Q-dot labelled MSC following infusion of 
UC-MSC into injured mice. CD362+ MSC were as effective as unsorted MSC in 
ameliorating liver injury, with reductions in serum ALT seen in both models. In contrast 
heat-inactivated MSC had no effect on liver injury. MSC also led to a reduction in 
CD45+staining on liver sections in both models of liver injury corroborated by an 
accompanying reduction in hepatic CD45+ cells in (FACS analysis of liver digest). In 
addition, there was a significant reduction in hepatic CD19+ B cells in digested liver in 
CCl4 injury. CD362+ MSCs were found to have the ability to reduce the level of adhesion 
molecules (ICAM and VCAM) in Ova-Bil mice. Cryo-imaging of time-course in both 
animal models indicated that MSC had migrated to the lung within 1 hour and were then 
cleared rapidly, although there was a liver-specific increase in MSC 2-3 day in Ova-Bil 
mice. CD362+ human MSC exert potent anti-inflammatory activity in toxic and immune-
mediated murine liver injury with demonstrable reductions in infiltrating inflammatory 
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1.1 The Liver  
 
 
1.1.1 Introduction to the human liver  
 
 
The liver is the largest internal organ and plays a significant role in many of the metabolic 
processes in the body. The human liver consists of several lobes and weighs about 2% of 
the total body weight, and about 5% in the case of a mouse (Arias et al., 2009). The liver 
is located on the right side of the abdominal cavity under the right lower rib, and has two 
separate blood supplies (Iwakiri et al., 2008), consisting of both arterial and venous 
hepatic blood vessels. The hepatic artery supplies and provides oxygenated blood to the 
liver and the hepatic portal vein provides blood rich in nutrients from the intestine, 
stomach, and spleen to the liver (Arias et al., 2009). 
 
1.1.2 Liver structure and function 
 
 
The human liver is composed of several types of cells, the majority of which are 
hepatocytes, which represent about 90% of the total weight of the liver. The other cells 
that are present in the liver are stellate and endothelial cells, blood vessels, bile duct 
epithelial cells, Kupffer cells, macrophages, and different phenotypes of lymphocyte cells 
(Szabo and Petrasek, 2015). At the microscopic level, hepatic lobules represent the 
functional unit of the liver (Braet and Wisse, 2002). Hepatic lobules have a vein at the 
center of each lobule, with a portal area at the borders. The portal area of the liver consists 
of a portal vein, hepatic artery and a bile duct (Figure 1-1). As mentioned above, the liver 
plays a vital role in many of the metabolic functions in the human body. The main 
functions are: 1) Metabolism of amino acids, proteins, carbohydrates, hormones, 
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bilirubin, bile acid, and lipids, and the synthesis of serum proteins, such as albumin, 
coagulation factors, and growth factors; 2) Storage of glycogen and some essential 
nutrients, such as vitamins and minerals; and 3) Breakdown and detoxification of 
xenobiotic substances and ammonia (Taub, 2004).  
     A 
 
     B 
 
Figure 1-1 Schematic overview of hepatic architecture. A) Representative image of hepatic 
lobules, which are the functional unit of the liver. B) Overview of the content of the cells 
between each lobule. Blood flows through the hepatic vein and hepatic arteries towards the 
central vein. Bile produced by the hepatocytes collects in the bile duct, which is surrounded by 
cell cholangiocytes. Liver macrophage cells line the sinusoid area and are known as Kupffer 
cells. Stellate cells are fibroblast-like cells located between hepatocytes and sinusoids. (Figure 
taken from Gordillo et al., 2015). 
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1.1.3 Liver immunology  
 
 
The liver represents one of the most complex systems in both normal and pathological 
conditions. In addition to its main metabolic function, the liver is also responsible for 
several immunological functions, such as producing chemokines and cytokines, which 
are essential in liver homeostasis (Racanelli and Rehermann, 2006).  
 
From anatomical point of view, liver is continuously exposed to nutrients and microbial 
antigen derived from the gut microbiota, which therefore trigger the immune system 
through formation of bacterial endotoxin. Thus, the liver microenvironment showed to 
have more risk of immune activation comparing with other organs in the body and must 
have capacity to tolerate this immunogenic load. The liver is the only organ in the body 
with unique function in terms of antigen presentations. The liver immune response can 
be triggered by different resident cells with specialized function such as the sinusoidal 
endothelial cells as well as kupffer cells (intravascular liver resident macrophages). Both 
cells were able to produce different cytokine and chemokines and more importantly 
capable of antigen presentation. On the other hand, the hepatic parenchymal cells, mainly 
hepatocyte and cholangiocytes have reported to expressed different Toll-like receptor 
which make them act as primary sensor for activation the immune system (Heymann and 
Tacke, 2016). 
 
Local resident macrophages in the liver (kupffer cells) have found to have potential 
function in liver homeostasis, they represent the major source of secretion IL-10 
cytokines following LPA activations as well as express of PD-L1. In addition, hepatic 
resident kupffer cells have potential role in respond to the bacterial endotoxin derived 
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from the gut microbiota by releasing IL-10 and prostaglandins (Callery et al., 1991). They 
also capable of recruit more monocyte into the liver, which later formed or polarized into 
more regulatory dendritic cells. Moreover, during homeostasis kupffer cells have shown 
to induce regulatory T cells (Treg) in a mouse model following systemic induction of 
particular antigen. Kupffer cells specifically interact with T cells antigen and expand IL10 
expressing T reg cells which therefore enhance the tissue protective function (Heymann 
et al., 2015). Additionally, in an in vitro experiment, purified kupffer cells have the ability 
to induce the Treg by secretion of prostaglandin (PG) E2 (You et al., 2008).  
 
Dendritic cells (DCs) are normally located in the portal area and around the central vein 
in the heathy liver and believed to form immunomodulatory function rather than 
immunogenic (Eckert et al., 2015). In a steady state condition, these cells have the ability 
to migrated from the liver tissue to the lymphoid organs where they act to present the 
antigens to T cells.  More interestingly, it has been shown that the DCs isolated from the 
liver have immature phenotype as they found to have low expression profile of MHC-11 
and some so-stimulatory molecules such as CD40 and CD80 (Tiegs and Lohse, 2010). 
This feature of hepatic DCs make them different from other DCs in other organs with 
unique immune tolerogenic function. One primary function of hepatic CDs is stimulate 
production of IL-10 which have a direct effect to generate regulatory T cells (Bamboat et 
al., 2009). In addition, Natural killer T (NKT) cells show sign of contribution in liver 
homeostasis by interacting with the hepatic endothelium. NKT cells function in the liver 
found to be directed by CXCL16 which secreted from the sinusoidal endothelial cells and 
kupffer cells (Geissmann et al., 2005).  
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In general, hepatic homeostasis and inflammation are regulated within the cells from 
different liver microenvironment.  
 
The inflammation system, for example, is triggered through different pathogens, viruses 
or toxic products, and subsequently enhances the response from the immune system. In 
addition, damaged cells in the liver can stimulate inflammatory cytokines, which can 
initiate and recruit more immune cells to protect injured cells and initiate a regenerative 
process (Tilg et al., 2006). However, the liver has limited ability to clear toxicity and 
other dangerous triggers, which leads to the development of pathological inflammation 
and causes damage to liver homeostasis (Robinson et al., 2016).  
 
Following the development of hepatic inflammation, macrophages from the liver secrete 
various chemokines and cytokines, which contribute to the activation of other signalling 
pathways and recruit more immune cells (Tacke and Zimmermann, 2014). For example, 
hepatic macrophages secrete CXC16, which is correlated with enhanced recruitment of 
natural killer (NK) cells and, markedly, with the activation of more pro-inflammatory 
activities (Wehr et al., 2013). Activated hepatic macrophages have also been proposed to 
increase the expression of matrix metalloproteinases, in particular, MMP-9 and MMP12, 
which have been found to be involved in matrix degradation. In experimental models of 
liver injury, two distinct populations were reported in mouse liver with different effects 
in response to liver inflammation: M1 macrophages were found to mediate the liver 
injury, whereas M2 had superior therapeutic functions in reducing liver inflammation 
(Possamai et al., 2014). In general, infiltrating monocytes and hepatic macrophages have 
not only demonstrated an essential role in liver homeostasis and immunity, but also have 
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an effect on liver pathological inflammation. Accordingly, more intervention strategies 
regarding their origins and further potential functions are in need of further investigation.  
The adaptive immune system has been shown to have a vital role in the regulation of liver 
inflammation. Different types of T lymphocytes have been studied in the literature, 
including CD4, CD8 and regulatory T cells (Tregs). In particular, CD4 cells are 
characterized and been found to have several populations with different biological 
functions. Tregs were found to suppress inflammation, but other CD4 subsets, such as 
type 1 helper T cells (Th1), Th2 and Th17, tend to stimulate the adaptive and innate 
immune responses (Shuai et al., 2016). In addition, CD8 T cells were found to show some 
protective immune response. However, the same cells were also found to be activated in 
the local microenvironment by antigen-presenting cells (APCs) and to mediate the 
autoimmune process in the liver (Derkow et al., 2007).  In general, the adaptive immune 
response has a very important role in liver inflammation and is mediated by different 
factors that are related to the pathology of the specific conditions of liver diseases.  
 
1.1.4 Oxidative stress and liver diseases  
 
Oxidative stress has been reported to play a critical role in the pathogenesis of many 
conditions due to the overproduction of reactive oxygen species (ROS) (Poli, 2000). Free 
radicals may have a beneficial role in normal metabolism, as they attach to foreign 
molecules, such as bacteria and pathogens, and have been reported to activate signalling 
pathways (Li et al., 2015). However, the balance between ROS and antioxidants is 
essential for normal physiological function. Under different conditions, such as hypoxia 
and inflammation, ROS levels can exceed the level of antioxidants, leading to an 
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imbalance in tissue levels in terms of oxidative stress and consequently generate tissue 
injury (Shimizu et al., 2012). 
 
Several studies have implicated ROS in liver disease. For example, the accumulation of 
ROS represents the main cause of alcoholic liver disease (ALD) (Li et al., 2015). Chronic 
consumption of ethanol can induce early damage in mitochondria due to the formation of 
ROS (Mantena et al., 2008; Bailey and Cunningham, 2002). The same finding was 
reported in vivo in rats fed long term with ethanol; hepatocytes from the control and 
treated groups were isolated and ROS levels increased in the treatment group, with 
hepatocyte damage and apoptosis (Nassir and Ibdah, 2014). These findings indicate that 
the free radicals formed during oxidative stress may play a significant role in liver injury. 
Many studies have illustrated the ability of mesenchymal stromal cells (MSCs) to 
modulate the immune system but the mechanism behind the effect of MSC on immune 
cells remains unclear, particularly their action in liver damage. Moreover, the impact of 
MSCs on oxidative stress is unclear. 
 
1.2 Animal Models for the Study of Acute Liver Injury  
 
Various investigations have developed different animal models for the study of liver 
diseases. Animal models have an important role in the study of biology, as well as the 
effectiveness of different treatments of various conditions related to human diseases. 
However, due to some limitations in various animal models of liver disease, a process has 
been undertaken to develop more reliable and accurate animal models to reflect the 
pathological features of human diseases.  
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In acute liver injury, most animal models are based on injecting hepatotoxic chemicals or 
through surgery to induce hepatic ischemia (Tuñón et al., 2009). Hepatotoxic chemicals 
have been intensively reported in the literature in investigations of acute liver injury, as 
well as chronic liver injury. The main chemical agents used in animal models of liver 
injury are acetaminophen (paracetamol), carbon tetrachloride (CCl4), thioacetamide 
(TAA), and concanavalin A (Con A) (Rahman and Hodgson, 2000). Acetaminophen has 
been shown to develop hepatotoxicity in humans as well as in experimental animals 
following the consumption of high doses (Bajt et al., 2003). This hepatotoxicity results 
in mitochondrial dysfunction, the formation of ROS, and a reduction in antioxidant 
enzymes (Rivera et al., 2017). It has been shown that toxicity caused by acetaminophen 
is mediated by the activation of P450 enzymes and c-Jun N-terminal kinases (JNK), 
which induce apoptosis in liver hepatocytes (Hur et al., 2012). 
 
CCl4 is another hepatotoxic substance that is used to induce liver injury in mice. CCl4 is 
metabolized in the liver and activated by cytochrome P450 (Noguchi et al., 1982). This 
step causes reduction in one electron from the CCL4 and forms a highly reactive radical 
known as trichloromethylperoxyl (CCl3*) (Packer et al., 1978).  These free radicals cause 
lipid peroxidation and consequently exacerbate cell membrane damage (Basu, 2003). 
CCl4 can also induce liver inflammation by activating macrophages to produce 
inflammatory cytokines, such as interleukin (IL)-6 and IL-10 (Kovalovich et al., 2000). 
CCl4 can also cause mitochondrial dysfunction in vivo - this finding was observed after 
chronic treatment of CCl4 for 6 weeks, which resulted in mitochondrial DNA damage 
with a reduction in glutathione level (Mitchell et al., 2009b). In addition, a recent study 
reported that a single dose of CCl4 can induce early alteration in mitochondrial DNA with 
 10 
elevation in lipid peroxidation in mouse liver (Knockaert et al., 2012). The induction of 
rat hepatocyte apoptosis has also been reported after the administration of CCl4, which 
augments the necrosis of hepatocytes (Shi et al., 1998a).   
 
Injecting Con A has also been used to induce acute liver injury in several preclinical 
studies and was consequently found to enhance the destruction of hepatocytes and 
develop liver injury. The mechanism which caused this injury is related to increased 
activity of macrophages and CD4+ cells in the liver microenvironment (Tuñón et al., 
2009). Consistent with the previous finding, another study has clearly shown that, 
following induction with Con A, mice were found to have increased activity of T 
lymphocytes, which released different cytokines to induce hepatic inflammation 
(Rahman and Hodgson, 2000).   
 
1.3 Mesenchymal Stromal Cells: Definition, Biology, and Origins 
 
 
MSCs were initially described in 1968 (Friedenstein et al., 1968) and are a subtype of 
adult fibroblast-like cells that have the capacity to self-renew with high proliferative 
ability. MSCs can undergo tri-lineage differentiation both in vivo and in vitro down 
connective tissue lineages to become osteoblasts, chondrocytes and adipocytes. 
  
MSCs are plastic adherent cells originally identified and isolated from bone marrow but, 
due to their limited number (0.01 to 0.001% of total bone marrow cells) (Gronthos et al., 
2003) and the invasive nature of their isolation from bone marrow, researchers have 
explored alternative sources. Several studies have reported the successful isolation of 
MSCs from different tissues with similar in vitro properties, including synovial 
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membrane (De Bari et al., 2001), adipose tissue (AT) (Zuk et al., 2001), umbilical cord 
blood (UCB) (Lee et al., 2004b), amniotic fluid (AF) (Antonucci et al., 2011) and placenta 
(He et al., 2017). Umbilical cord (UC) tissue has been a particularly promising source of 
MSCs, as the cells can be isolated from several compartments within the UC, including 
the umbilical vein, arteries, and perivascular tissue, Wharton’s jelly (WJ) and sub-
amniotic tissue. Furthermore, MSCs isolated from UC tissue are believed to be more 
primitive than other cells isolated from other tissues and are found in higher numbers, 
ensuring this source is now gaining prominence. Notably, MSCs from various sources 
display a similar expression profile to MSC surface markers and have similar 
morphological features in culture. However, MSCs from different sources have 
demonstrated different levels of tri-lineage differentiation potential (Baksh et al., 2007). 
 
In addition, differences have been reported with regard to culture conditions, particularly 
in the isolation procedure and culturing protocols, as well as the experiment protocol used 
(Bara et al., 2014). Thus, variations in studies have resulted in significant differences in 
the functional capabilities of MSCs found in vivo and in vitro. Direct comparisons of 
MSCs from different sources have been shown in a variety of studies and these cells have 
been demonstrated to share similar biological properties (Najar et al., 2010; Mattar and 
Bieback, 2015). Other authors have demonstrated differences in immunomodulatory 
properties between menstrual blood (MB)-MSCs, UC-MSCs, and AT-MSCs (Melief et 
al., 2013b; Chao et al., 2014). In addition to the biological variations between different 
sources of MSCs, UC-MSCs exhibit more proliferation capacity in comparison with some 
MSC populations obtained from other sources (Baksh et al., 2007). Despite the 
controversy in defining MSCs from different sources, these cells have shown great 
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potential in regenerative medicine. To fulfil the roles of MSCs in tissue regeneration, 
further progress in understanding the immunomodulatory mechanisms and heterogeneity 
of MSCs from different sources may provide clues in the future. 
 
1.4 Human Umbilical Cord MSCs (hUC-MSC) 
 
 
hUC-MSCs represent an attractive source of MSCs for use in clinical studies, as the 
isolation and collection of cells from umbilical cord does not require an invasive 
procedure. There are minimal ethical concerns, as UC is a postnatal organ that is usually 
disposed of as a waste product after delivery (Weiss et al., 2008).  
 
1.5 Anatomy of Umbilical Cord Tissue 
 
 
In order to understand the differences between MSCs derived from UC tissue and other 
sources, it is important to understand the anatomical and histological structure of 
umbilical cord. The UC represents a connection between the mother and the foetus during 
pregnancy, and its main function is to circulate blood from the placenta to the embryo. 
The UC is covered by a membrane known as the amniotic epithelium (amnion) and a sub-
amniotic zone that grows closely into the central connective tissue of the cord. This 
connective tissue of the cord is known as Wharton’s jelly and has been described in the 
literature as a cord matrix. Umbilical cord is composed of two arteries and one vein; a 
zone called the umbilical perivascular region surrounds these vessels (Nanaev et al., 
1997). Figure 1-2 represents a cross section of human umbilical cord.    
 
Human UC is formed at day 26 of embryonic development and in the fifth week of 
gestation. Human UC is usually 1–2 cm in diameter and 30–90 cm in length, with an 
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average of 55 cm (Sarugaser et al., 2005). When the amniotic cavity has expanded and 
surrounded the embryo, it causes the connective stalk and yolk sac to compress together 
to form the umbilical cord, which is then covered by the amniotic epithelial membrane 
and forms the outer layer of the umbilical cord (Baergen, 2013). 
 
As referred to above, the inner tissue structure of the umbilical cord contains two arteries 
and one vein and is surrounded by Wharton’s jelly. The two umbilical arteries carry 
deoxygenated blood from the foetus to the placenta, while the umbilical vein carries 
oxygenated blood from the placenta to the foetus (Kellow and Feldstein, 2011). Human 
umbilical vessels have different characteristics compared with the other major vessels of 
the human body (Ferguson and Dodson, 2009), having fewer organelles in their 
endothelial cells compared with the endothelium of other vessels. Moreover, umbilical 
arteries have no internal elastic membrane and less elastin than other arteries, whilst the 
vein, by contrast, has an elastic sub-intimal layer (Anthony Armson et al., 2015). Each 
umbilical vessel is surrounded by bunches of collagen fibers that form a type of 
adventitia: an elastic muscle-like tissue consisting of muscle cells to support the blood 
vessels (Jeschke et al., 2011).  
Wharton’s jelly is the connective tissue of the cord and is derived from the extra-
embryonic myoblast which surrounds the embryoblast, lying between the amniotic 
epithelium and umbilical perivascular region. The main function of WJ is to maintain 
umbilical vessel strength and flexibility, thus preventing any compression or torsion in 






Figure 1-2 Cross section representing the anatomical structure of umbilical cord tissue. 
 
 
1.6 Isolation of hUC-MSC 
 
 
MSCs can be isolated from several sources within the UC, such as the umbilical vein, 
umbilical arteries, umbilical cord perivascular tissue, WJ and sub-amnion layer. The 
amniotic membrane (amniotic epithelia) is not a source of MSCs, but represents a good 
source of epithelial cells. However, it has been reported that multipotent epithelial stem 
cells can be isolated from amniotic membrane isolated from human placenta, but not the 
umbilical cord (Miki et al., 2005).  
MSCs from umbilical cord can be obtained or isolated by different methods. There are 
two methods for isolating MSCs from UC tissue: (1) the enzymatic digestion method and 
(2) the explant culture method. The enzymatic digestion method has been used by many 
groups and uses collagenase either alone or in combination with other enzymes, such as 
trypsin or hyaluronidase. The other approach, which has been shown to be simpler and 
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more efficient, is the explant culture method, whereby UC is minced then placed in 
culture and seeded regularly on a tissue culture flask (Table 1-1).  
 
 




1.7 Phenotypic Characterization of MSCs Isolated from UC Tissue  
As described previously, investigators have used different protocols for both the isolation 
and characterization of human MSCs. As a result, the International Society for Cellular 
Therapy (ISCT) established minimal criteria for defining human MSCs (Dominici et al., 
2006). Dominici et al. summarized three main criteria for defining such cells: (1) MSCs 
must be adherent in plastic culture using tissue culture flasks; (2) MSCs exhibit surface 
antigen expression of CD105, CD73, and CD90 by flow cytometric analysis. In addition, 
these cells should lack expression of CD45, CD34, CD14, CD11b, CD79a, CD19 and 
HLA class II; and (3) MSCs must be capable of differentiation to adipogenic, osteogenic, 
and chondrogenic lineages (Dominici et al., 2006). UC-MSCs have been reported widely 
as being plastic adherent in culture, have the ability to differentiate into chondrogenic, 
adipogenic, and osteogenic lineages, and express the following surface antigen markers: 
CD90, CD73, and CD 105 whilst lacking expression of CD45, HLA class II, and CD34 











(No vessels removal 
or mincing the cord) 
Enzymatic Used an enzymatic cocktail contains 
collagenase type 1 and hyaluronidase. 
(Tsagias, N. et al, 2011) 
 
Wharton’s Jelly 
Enzymatic & explant Collagenase and Culture in (DMEM – 
low glucose +20%FBS+P/S Antibody) 
(Secunda, R. et al, 2014) 
Enzymatic Collagenase (Wang, H. et al, 2004) 
Explant Culture in (µMEM+10%FBS+P/S 
Antibody) 
(Ishige, I. et al, 2009) 
Umbilical Cord 
Vein 
Enzymatic Collagenase IV (Covas, D. et al, 2003) 
Explant Culture in (µMEM+10%FBS+P/S 
Antibody) 
(Ishige, I. et al, 2009) 
Umbilical cord 
Artery 
Explant Culture in (µMEM+10%FBS+P/S 
Antibody) 
(Ishige, I. et al, 2009) 
Perivascular 
 
Enzymatic Collagenase (Sarugaser, R. et al 2005) 
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Figure 1-3 Different cell surface antigens expressed on human umbilical cord-derived 
MSCs. 
 
1.8 UC-MSCs for the Treatment of Liver Diseases 
 
Liver disease is a major cause of mortality and morbidity that is rising globally (Shiels et 
al., 2017; Williams et al., 2017). There remain many inflammatory liver conditions for 
which treatments are not effective and such patients will often progress to end-stage liver 
disease and require liver transplantation. To prevent progression to end-stage liver disease 
and to treat those with advanced fibrosis, MSC therapies have been considered and shown 
to have potential in this regard (Zhang and Wang, 2013; Haldar et al., 2016).  
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MSCs have been shown to have beneficial effects in a range of clinical settings, including 
heart failure (Ji et al., 2017), lung injury (Matthay et al., 2017), graft-versus-host diseases 
(GVHD) (Chen et al., 2015), and stroke (Honmou et al., 2012), as well as being reported 
to ameliorate liver injury in both acute and chronic liver damage (Volarevic et al., 2014; 
Kuo et al., 2008). The pleiotropic effects of MSCs represent a potential advantage over 
pharmacological therapies and principally focus on their ability to modulate different 
components of the immune system, either directly or by the release of paracrine factors. 
In addition to these immunomodulatory effects, MSCs have been shown to reduce liver 
injury by ameliorating oxidative stress through the release of antioxidants (Kuo et al., 
2008) and through anti-fibrotic effects (Haldar et al., 2016). In addition, MSCs have been 
reported to have an ability to differentiate to hepatocyte-like cells, which may show 
promise in augmenting liver regeneration (Xingwei et al., 2009; Campard et al., 2008). 
Encouraging preclinical data have resulted in a number of clinical trials (Wang et al., 
2013b; Zhang et al., 2012b) and it is, therefore, timely to review the data underpinning 
these effects and address the important scientific questions remaining in order to establish 
MSC therapy for patients with liver disease.  
 
1.9 Clinical Trials  
 
 
Several clinical trials were found in literature that related to the treatment of liver disease 
using MSCs, focusing on the study design, cell sources, injection route, patient groups, 
and efficacy of the therapies. Table 1-2 summarizes various studies that used MSC-based 
therapy for liver disease for the 10 years until 15 July 2017. All the studies reported in 
this section have shown heterogeneity in the dosage of the injected cells, MSC source, 
and route of injection. Various liver disease conditions were also reported, including 
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acute-on-chronic liver failure (ACLF), liver failure including cirrhosis due to alcohol, 
hepatitis B virus (HBV) or hepatitis C virus (HCV), and primary biliary cirrhosis (PBC). 
Of the clinical studies considered (Peng et al., 2011), the majority used MSCs derived 
from bone marrow (BM) (14 studies), whereas UC-MSCs were used in only three studies. 
Among the studies reported, five used allogenic MSCs, which are derived from different 
sources (BM and UC) to treat liver disease. The functional ability of MSCs to reduce liver 
injury was also investigated using single or multiple doses, with different therapeutic 
efficacies reported in the literature. The efficacy of infused repeated dosage of MSCs at 
4 and 8 weeks was also investigated and found improvement in the liver function of 
patients with alcoholic liver cirrhosis (Jang et al., 2014). In this pilot study, hepatic 
fibrosis was found to be reduced following MSC infusion (54.5%) in six patients 
compared with the total of 11 patients involved in the phase ll clinical trial (Jang et al., 
2014). In contrast, a comparison study found that infusing two doses of BM-MSCs did 
not result in improvement in fibrosis over a single transplantation (Suk et al., 2016a). The 
routes of injection were reported in different clinical trials and it was found that peripheral 
vein (PV) was the most commonly used, followed by hepatic artery (HA), intrasplenic 
(IS), intrahepatic (IH), and portal vein. Interestingly, the route of injection has not been 
reported as having a potential impact on MSC efficacy in different liver diseases, based 
on the use of different routes, such as PV, IS, portal vein or IH (Mohamadnejad et al., 












Patient cohort Source of 
MSC 
Injection route Primary endpoint Main improvement 
(Mohamadnejad 
et al., 2007) 






Peripheral vein Safety and feasibility Creatinine and MELD score  




Liver cirrhosis (n=8) Autologous 
BM 
Portal vein (n=6) 
Peripheral vein (n=2) 
Feasibility, safety, and 
efficacy (LFT and MELD 
score) 
Creatinine, prothrombin time and 
MELD score  
(El-Ansary et al. 
2010) 
2010 Case control 
6 
Decompensated liver 





Peripheral vein (n=6) 
LFT and MELD score 
improvement 
Creatinine, prothrombin time, 
albumin, bilirubin and MELD 
score 
(Amer et al., 
2011) 
2011 Case control 
6 
Decompensated liver 






Safety and short-term 
efficacy (LFT, MELD 
improvement) 
Ascites, peripheral oedema, 
albumin, MELD score, and Child-
Pugh score 
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(Peng et al., 
2011) 
2011 Case control 
1, 48 




Hepatic artery Improvement of MELD and 
LFT (short term) or 
development of HCC and 
mortality (long term) 
Prothrombin time, albumin, 
bilirubin and MELD score 
(El-Ansary et al., 
2012) 
2012 Case control 
6 
Decompensated liver 




Peripheral vein  Improvement of MELD and 
LFT 
Albumin and MELD score 
(Shi et al., 
2012a) 
2012 Case control 
12 or 18 




Peripheral vein  LFT and MELD 
improvement, adverse 
events, and survival rates 
Albumin, prothrombin time, 
bilirubin, ALT, survival rates and 
MELD score 








Intrasplenic Safety and efficacy Albumin, prothrombin time, 
bilirubin, AST, ALT and MELD 
score 
(Mohamadnejad 








Peripheral vein  Safety and efficacy None 












Note: acute-on-chronic liver failure (ACLF); alanine aminotransferase (ALT); aspartate aminotransferase (AST); bone marrow (BM); follow-up (F/U); 
gamma-glutamyltransferase (γ-GGT); hepatitis B virus (HBV); hepatocellular carcinoma (HCC); hepatitis C virus (HCV); immunoglobulin M (IgM); 
liver function test (LFT); Model for End-Stage Liver Disease (MELD); primary biliary cirrhosis (PBC); randomized controlled trial (RCT); 
ursodeoxycholic acid (UDCA).  
 








Hepatic artery Safety and efficacy MELD score and liver histology 





liver disease (n=40) 
Autologous 
BM 
Peripheral vein  Safety and efficacy MELD score and Child-Pugh score 








Peripheral vein  Safety and efficacy ALT, AST, GGT and IgM 








Hepatic artery Safety and efficacy Histologic fibrosis and Child-Pugh 
score 









Hepatic artery Safety and efficacy None 
(Lin et al., 2017) 2017 RCT 
6 




Peripheral vein  Safety and efficacy Bilirubin, MELD score and survival 
rates 
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1.10 Immunomodulatory Properties of MSCs Derived from UC Tissue 
Compared with Other Sources 
 
MSCs can modulate and repair injured tissue by modulating injurious immune responses 
through a range of mechanisms, including direct cell-to-cell interaction or remotely by 
the secretion of paracrine and/or endocrine factors (Figure 1-4) (Christ et al., 2015). It is 
worth noting that MSCs have reduced immunogenicity due to a lack of expression of 
class II major histocompatibility complex (MHC) antigens when unprimed and do not 
express many of the molecules required for immune recognition, such as CD80, CD86n 



















Figure 1-4 Modes of MSC-based therapy. MSC-based therapy could be used to treat diseases 
through several mechanisms of action. A) Upon transplantation, MSCs can respond to the 
injury environment through endocrine mechanism by releasing factors in circulation that can 
stimulate the repair process via different therapeutic properties. B) Another therapeutic 
potential of MSCs relies on some of which require direct cell-to-cell contact mechanism. MSCs 
can modulate injury through expressing a number of molecules on their surface, which can 
subsequently enhance the regeneration process. C) MSCs can repair the injury via paracrine 
mechanism and secret trophic factors that mediate the terapuetic effect in the injured cells. D) 
As a result of the ability of MSCs to differentiate into multiple lineages, they can be recruited 
to the site of injury and are believed to differentiate into a new functional cell to replace injured 
tissue (cell replacement therapy). Figure modified from (Alfaifi et al., 2018). 
 
1.10.1 Immunomodulatory effect of MSCs on adaptive immunity 
 
MSCs can inhibit the proliferation of T cells in vitro either by the secretion of soluble 
factors or by direct interaction with T lymphocytes (Figure 1-5) (Nicola et al., 2002). 










Several different molecules secreted by MSCs have been reported to have an 
immunomodulatory effect on T-cell activities, including transforming growth factor-beta 
(TGF-b), hepatocyte growth factor (HGF) (Nicola et al., 2002), prostaglandin E2 (PGE2) 
(Aggarwal and Pittenger, 2005), and indoleamine 2,3-dioxygenase (IDO) (Meisel et al., 
2004). Notably, the production of these immunomodulatory molecules differs according 
to the source of the MSCs; for example, WJ-MSCs produce higher amounts of TGF-b 
than BM-MSCs (Meisel et al., 2004). 
  
The inflammatory environment is known to have an essential role during the interaction 
between MSCs and T cells; for example, the immunosuppressive capacity of MSCs is 
induced by treatment involving a combination of cytokines (interferon-gamma [IFN-g], 
IL-1a, tumour necrosis factor-alpha [TNF-a], and IL-1b) (Ren et al., 2008). These 
cytokines can enhance some chemokines and other immune cells to ease contact with 
MSCs and mediate the immune reaction. Another mechanism by which MSCs can 
suppress the proliferation of T cells is via the secretion of nitric oxide (NO), which causes 
inhibition of signal transducer and activator of transcription 5 (STAT5) pathways (Sato 
et al., 2007). Another study demonstrated that MSCs can secrete matrix 
metalloproteinases (MMPs), such as MMP-2 and MMP-9, which suppress T-cell 
activation by cleaving surface CD25 from T cells (Ding et al., 2009). 
 
MSCs have also been shown to promote the generation and development of Tregs, which 
can positively influence the balance of immune damage during tissue injury (Prevosto et 
al., 2007). For example, the induction of CD4+ CD25+ FOXP3+ Tregs is mediated by 
the secretion of TGF-b (Melief et al., 2013a) and is accompanied by inhibition of the 
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proliferation and differentiation of Th1 and Th17, which can further trigger the activation 
of Tregs. This mechanism has been associated with an increased production of IL-10 by 
MSCs (Luz-Crawford et al., 2013). 
 
MSCs can also inhibit the proliferation of B cells and reduce their production of 
immunoglobulin. CD40 and IL-4 were used to increase the proliferation rate of murine B 
cells and it was demonstrated that subsequent co-culture with MSCs significantly 
inhibited their proliferation (Glennie et al., 2005). In addition, MSCs have resulted in the 
significant stimulation of immunoglobulin production after co-culture of B cells in a 
Transwell experiment (Rasmusson et al., 2007). MSCs may also alter the surface 
expression of chemokine receptors on B cells; co-culture with MSCs in a 1:1 ratio resulted 
in a significant reduction of the expression of CXCR4, CCR7 and CXCR5 on B cells 
(Corcione et al., 2006a). CXCR4 was found to have been significantly reduced even with 
a 1:10 ratio when cultured with MSCs, suggesting that MSCs can specifically target 
CXCR4, which has a role in the homing and fate of MSCs (Nitzsche et al., 2017). 
 
NK cells represent a critical component in the immune response to viral infections and 
tumour cells (Sotiropoulou et al., 2006). Sotiropoulou et al. (2006) demonstrated that 
MSCs reduced IL-15 secretion from IL-2-induced NK cells. This reduction was presumed 
to be due either to cell-to-cell interaction or the release of soluble factors, such as PGE2 
and TGF-b (Klyushnenkova et al., 2005). Another group reported that MSCs can suppress 
NK cells after stimulation with IL-5 (Sotiropoulou et al., 2006). In models of acute liver 
injury, MSCs have ameliorated the hepatotoxicity of natural killer T (NKT) cells in an 
IDO-dependent manner, by reducing the number of IL-17 cells and stimulating FOXP3 
 26 
and IL-10 resulting from increased numbers of NK Tregs in the injured liver 
(Milosavljevic et al., 2017a).  
 
1.10.2 Immunomodulatory effect of MSCs in innate immunity 
 
Macrophages can be classified into classical pro-inflammatory macrophages (M1) or 
alternative macrophages (M2) that secret anti-inflammatory cytokines (Figure 1-5) 
(Milosavljevic et al., 2017a). MSCs have been reported to trigger polarization of M1 
towards M2 both in vivo and in vitro. The polarization is driven by the ability of MSCs 
to secrete soluble factors, such as IL-10 and IL-1Ra, which have been shown to attenuate 
liver injury by promoting the number of M2 macrophages (Lee et al., 2015). In addition 
to the IL-10-mediated ability of MSCs to promote the switching of phenotype 
macrophages from M1 to M2, MSCs can also help promote the survival of monocytes 
through upregulation of CCL18, which is found indirectly to mediate MSCs to induce 
Tregs formation (Melief et al., 2013a), as demonstrated in animal models of sepsis and 
colitis (Anderson et al., 2013). In this study, murine adipose-derived MSCs significantly 
increased the proportion of M2-like cells by increased production of IL-10 and arginase-
1 activities (Anderson et al., 2013).  
MSCs can also regulate, and interact with, dendritic cell (DC) function by blocking 
differentiation of APCs to monocytes and decreasing their expression of anti-
inflammatory molecules, such as IL-12, TNF-a, and IFN-g, whilst also enhancing their 
secretion of IL-10, which may induce regulatory T-cell numbers (Figure 1-5) (Beyth et 
al., 2005). Notably, WJ-MSC can also inhibit the differentiation of monocytes to mature 
DCs when cultured with CD14+ monocytes, indicating an indirect effect of WJ-MSCs on 
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the allogeneic response of T cells (Tipnis et al., 2010). There is now, therefore, a greater 
recognition of the importance of the microenvironment in the immunomodulatory 
capacity of MSCs (Ren et al., 2008), prompting a need for better understanding of the 
microenvironments associated with specific diseases in order to develop a more effective 
therapeutic efficacy for MSCs.  
 
 
Figure 1-5 Potential mechanisms of MSC interaction with immune cells. MSCs may 
regulate immune responses through interaction with different types of immune cell, such as T 
lymphocytes, B lymphocytes, NK cells, macrophages, and DCs. This immunosuppressive 
property of MSCs is due to their production and secretion of soluble factors and/or by direct 
interaction with immune cells. MSCs have an immunomodulatory effect on T-cell activities by 
releasing molecules, such as TGF-b, HGF, PGE2, IDO and NO. MSCs have also been shown 
to promote the generation and development of Tregs by the secretion of TGF-b. MSCs can also 
inhibit the proliferation of B cells and reduce the expression of CXCR4, CCR7 and CXCR5. 
MSCs supress NK cell activities by reducing IL-15 secretion; this reduction is due either to 
cell-to-cell interaction or the release of soluble factors, such as PGE2 and TGF-b. MSCs 
interact with macrophages and trigger the polarization of pro-inflammatory macrophages (M1) 
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towards alternative macrophages (M2), which is driven by the ability of MSCs to secrete 
soluble factors such as IL-10 and IL-1Ra. M2-polarized macrophages produce anti-
inflammatory cytokines, such as  IL-10, which can further trigger the activation of Tregs. 
MSCs can also regulate and interact with DC function by blocking the differentiation of APCs 
to monocytes. Figure taken from (Alfaifi et al., 2018). 
 
 
1.10.3 Antioxidant activities of MSCs  
 
 
MSCs have been proposed as producing or releasing local systemic molecules which help 
have a protective effect on injured tissue. Many studies have hypothesized that this effect 
could be associated with enhanced expression of antioxidants from MSCs, which is linked 
to the regenerative process in different disease conditions. MSCs have been shown to 
have potential therapeutic effect by the overexpression of superoxide dismutase 3 
(SDO3), which is reported to have immunosuppressive properties through the inhibition 
of Th17 (Sah et al., 2016). Another research group found that MSCs can mediate the 
suppression of neutrophils, which can be mediated through the upregulation of SOD3 
(Jiang et al., 2016). In addition, MSCs have been identified as upregulating the catalase 
enzyme in mice with CCl4 injury, resulting in improvement in liver injury following 8 
days of MSC treatment (Burra et al., 2012). Interestingly, this study confirmed that MSCs 
were able to influence the antioxidant enzyme in the hepatic microenvironment without 
engraftment to the liver. Although MSCs from bone marrow enhance the viability of 
neural cells as well as promoting survival in murine models of neural injury, these 
findings resulted from antioxidant and anti-apoptotic functions reported in response to 




1.11 Tracking and Monitoring the Homing of Transplanted UC-MSCs 
 
 
The homing of infused stem cells has been reported in several studies but accurate 
quantification of the location of the cells has not been undertaken. Researchers have 
reported different methods in studying the homing of transplanted stem cells in vivo. For 
example, Shenghong Ju et al. studied the migration of infused labelled BM-MSCs to the 
liver using magnetic resonance imaging (MRI) and found the cells in the liver after 3 
hours with a gradual reduction after 3, 7, and 14 days (Ju et al., 2007).  
Another technique that has been used in animals is the in vivo imaging system (IVIS), 
which represents a reliable optical means of detecting the migration of infused cells 
(Eisenblätter et al., 2009). It has also been shown that MSCs can be detected in a  number 
of organs, such as the lung, heart, liver, and kidney, from the first hour to 7 days after the 
intravenous injection of MSCs (Gao et al., 2001). In a similar finding, UC matrix stem 
cells were detected after 2 days but no cells were observed 6 and 12 days after infusion 
(Weiss et al., 2006). Another study determined the homing of MSCs administered by 
intravenous (IV) injection by testing the DNA expression of human albumin by using 
quantitative polymerase chain reaction (qPCR). They reported different expressions 
among different tissues, with the greatest expression in the lung (Briquet et al., 2014). 
More recently, an advanced system was developed that provided very high-resolution 
images for a whole mouse using CryoViz™ technology. This device is a fully automatic 
machine which has the sensitivity to detect a single live cell, and can provide a 3D 
structure for the whole animal or a specific organ of interest (Roy et al., 2009). In addition, 
one unique feature of this technique is the ability to quantify the number of live cells in 
vivo after fluorescent labelling of cells prior to injection. Using the CryoViz™ imaging 
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system, it was shown that 80% of hMSCs were detected within different organs 1 hour 
after systemic infusion and this dropped to 0.06% within 2 days post infusion (Schmuck 
et al., 2016). Generally, there are still limitations and complexity with regard to accurate 
techniques for studying the homing of MSCs in different preclinical experiments, and this 
will surely be more difficult in a human clinical study.  
 
 
1.12 Dosage and Route of Administration  
 
 
With regard to the important role of tracking MSCs in vivo, the number of MSCs injected 
as well as the route of administration have a strong impact on enhancing the therapeutic 
potential of these cells in the treatment of different disease conditions. Several research 
groups have reported various doses of MSCs in different animal experiments with 
different potential effects in response to the dose of injected cells. For example, in a 
mouse model with brain injury, an injection of a low dose of MSCs was reported to have 
more effective therapeutic outcomes compared with a high dose (Wu et al., 2008). In 
addition, several studies have reported different routes of MSC administration, such as 
intravascular (IV), intraperitoneal (IP), and intra-articular injection. In a murine model 
with arthritis, MSCs were shown to have a great effect in reducing inflammation 
following intra-articular injection of MSCs, with more engraftment ability to the site of 
the injury (Kehoe et al., 2014).  Recent work has shown that intramuscular injection was 
found to support the prolonged survival of MSCs compared with other routes of injection 
(Braid et al., 2017). Systemic administration of MSCs was the most common route of 
injection reported in the literature, with conflicting findings in the engraftment potential 
in different preclinical settings. However, it has been shown that IV injections have less 
engraftment potential compared with other routes, such as intra-cardiac and intra-arterial 
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routes of injection (Freyman et al., 2006). A study in a rat model with heart disease found 
that systemically injected MSCs migrated to the site of injury and had differentiation 
potential towards myocytes (Wu et al., 2003). The same finding was reported in lung 
injury and it was noted that MSCs were trapped in the lung and reduced inflammation, as 
well as collagen composition (Ortiz et al., 2003). In contrast with the previous findings, 
data from a liver injury murine model found that most MSCs were trapped in the lung 
and cleared from the body after 24 hours, and no MSCs were found to have engrafted to 
the injured site (De Witte et al., 2017). In addition, MSCs have shown significant 
improvement in mice with myocardial infarction via the secretion of TSG-6 from MSCs 
after activation following being trapped in the lung; these data suggest that MSCs have 
the ability to enhance treatment without engraftment to injured tissue (Lee et al., 2009).   
 
 
1.13 Future perspectives  
 
 
Whilst conventional unmanipulated MSC have been the mainstay of therapeutic studies 
thus far there have been extensive efforts to try and enhance their efficacy. This section 
will review some of the key strategies which include sorting MSC to enrich for greater 
functionality, priming of MSC with factors such as cytokines and finally genetic 
engineering of cells (Figure 1-6). The main driver for these approaches is to enhance 
efficacy and/or organ homing although there is also often a need to create/protect 
intellectual property so as to generate a viable business model. The challenge therefore 
is to balance the additional costs and potential logistical/safety concerns associated with 






Figure 1-6 Schematic diagram illustrating therapeutic strategies to enhance MSCs 
functions. Number of techniques are available to manipulate the MSCs for more functional 
therapeutic features, including MSC sorting or using enriched MSCs based on surface marker 
expression to achieve homogenous populations resulting in enriched subsets for greater 
functionality. Priming MSCs by pre-treating cells with factors such as cytokines or chemokines 
can improve their function within injured environment. Another approach can be applied is to 
modify MSCs by gene modification via editing or engineering specific gene expression for 




1.13.1 MSCs enrichment 
 
 
MSC represent heterogeneous populations of cells, therefore, sorting approaches are 
highly considered to achieve homogenous populations of MSC, resulting in enriched 
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subsets which could crucially produce various selected populations with different 
therapeutic functions and open new strategies for the modification of MSC for more 
beneficial effects.  
MSC are phenotypically diverse both morphologically and functionally and thus sorting 
cells based on marker expression may allow for the selection of cells with greater 
efficacy. This does require definition of which function is being focused on, and often 
markers of stemness or proliferation are reported, whereas immunomodulatory action 
may be the most important. 
Sorting of cells for pre-clinical studies is relatively straightforward and can use a range 
of modalities including flow cell sorting which should result in high purity yields. It is 
more challenging however when such approaches are attempted in clinical practice as 
they need to adhere more closely to good manufacturing practice (GMP) which can 
restrict the modality used. Clinically approved modalities such as the CliniMACS are 
clinically accredited but may not result in high purities of rare populations and thus the 
use of GMP fluorescence cell sorting analysis is encouraging. 
CD146+ is expressed on various cells types including endothelia cells (Baksh et al., 
2007b)  and can contribute to biological functions such as cell migration, proliferation 
and differentiation (Tsang et al., 2013; Ulrich et al., 2015) CD146 expression is correlated 
with cellular senescence of MSC and markedly affects the proliferation, differentiation, 
and stemness of hUCB-MSC. Sorted CD146+ MSC have delayed cellular senescence 
which is mediated by regulation of Bmi-1, id1, and Twist1 expression, which can regulate 
the cellular senescence process (Jin et al., 2016). This suggested that CD146+ could be a 
novel marker that control the senescence of MSCs and improve the therapeutic efficacy 
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of MSCs. In a recent study, sorting MSC sub-populations based on CD73+ expression has 
demonstrated greater self-renewal and differentiation properties (Suto et al., 2017). These 
sorted cells (CD73+) exhibited high levels of colony forming unit ability in contrast with 
an absence observed with CD73- cells.  
Another study has characterized populations of MSC using several markers, including 
CD271+, known as nerve growth factor receptor and proposed as a marker of BM stromal 
cells, adhesion molecule (CD56), and MSCA-1+ (mesenchymal stem cell antigen-1) 
(Battula et al., 2009). Sorted dual-positive MSCA-1+ and CD56+ MSC were reported to 
have 2-4 greater clonal efficiency than MSCA-1+ CD56-. However, MSCA-1+ CD56- 
were shown to have potential ability to differentiate into adipocytes, whereas MSCA-1+ 
CD56+ were restricted to chondrogenic and pancreatic like cells differentiation. Similarly, 
other reports indicate that enrichment of synovium-derived-MSC using CD271 in 
combination with THY-1 (CD90) results in greater chondrogenic differentiation ability 
and colony forming potential in the CFU-F assay compared to CD271+ CD90+ BM-MSC. 
Thus, this combination could be a good candidate for the isolation of MSC from different 
tissue sources for cartilage regeneration (Ogata et al., 2015). 
Sherman et al. (Sherman et al., 2017) have proposed aldehyde dehydrogenase (ALDH) 
as a marker for MSC which defines an enhanced ability to contribute to revascularization. 
MSC isolated from human bone marrow and purified into ALDHhi and ALDHlo 
populations had identical expression of MSC surface makers and ability to differentiate 
into adipocytes, osteoblasts, and chondroblasts in vitro. Notably though conditioned 
medium from ALDHhi MSC was shown to promote endothelial cell expansion in vitro 
and enhance recruitment of endogenous vascular cells after subcutaneously implanted in 
NOD/SCID mice, which was mediated by up-regulation of lectin  (Sherman et al., 2017).   
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Positive selection on the basis of expression of the Stro-1 specific marker has also been 
proposed and such MSC are enriched with respect to CFU-F progenitors (Dennis et al., 
2002). Stro-1+ expanded MSC were reported to have better migratory capacity in various 
tissues when compare to Stro-1- (Bensidhoum et al., 2004). Other research groups were 
able to increase expression of cytokines related cardiovascular which can be mediated 
through using Stro-1+ enriched MSC (Hiwase et al., 2009). 
Expression of CD200 has also been used to purify MSCs (Delorme et al., 2008), with its 
expression inhibiting osteoclast formation via inhibition of RANKL signalling pathways, 
which consequently reduce expression of osteoclast associated genes such as tartrate 
resistance acid phosphatase (TRAP) and nuclear factor of activated T cells cytoplasmic 1 
(NFARC1) (Varin et al., 2013). Another study has clearly shown that CD200+ BM-MSC 
can modulate the immune response of macrophages by inhibition of TNF-alpha secretion 
when compared to CD200low BM-MSC (Pietilä et al., 2012). Consisting with its role in 
immunomodulation, MSC have been identified to drive the expression of CD200 in T cell 
subsets following co-culture with MSC (Najar et al., 2012). This upregulation was 
reported in both CD4+ and CD8+ T lymphocyte.  
More recently, CD362+ (Syndecan-2) marker has been identified as a novel marker to 
select a homogeneous population of MSC with enhanced immunomodulatory properties 
(patent number WO 20131177661 A1). This marker has recently investigated for its 
ability to reduce immunogenicity and enhance the immunomodulatory ability in liver 
inflammation (De Witte et al., 2017; de Witte et al., 2015) Syndecan-2 found to be 
expressed in hematopoietic cells and myeloid cells (Teixé et al., 2008). And Functionally 
reported to upregulate upon T cell activation and play significance role in CD3 
downregulation through degradation of T-cell receptor (TCR) (Rovira-Clavé et al., 2012). 
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These findings strongly suggest that enrichment of syndecan-2 expression in MSC could 
play an essential role in immune modulation in injured tissue. The potential benefits of 
the various markers that have been used to select/enrich MSC are detailed in Table 1-3. 
 
Table 1-3 Reported selection and purification makers of Mesenchymal stromal cells for 






























Increase clonogenic and 
proliferation potential. 
Increase chondrocyte and 
pancreatic like cells 
differentiation.  














Enhance self-renewal and 
differentiation.  
Increase engraftment. 











                               
In-vitro Enhance regulation of bone 
resorption.  
Inhibit osteoclast formation 
via inhibition of RANKL 















Suppress TNF-a secretion 




(Pietilä et al., 
2012). 
                          




         
aSMA+  
                 
FACS 
                                 
In vitro Improve MSC fate through 
regulation of YAP/TAZ 
activation.  
(Talele et al., 
2015) 
                       
PAM 
       
Human 
          
CD34+ 
                 
FACS 




Reduce hepatic fibrosis and 
restore liver function by 
reduce collagen level and 
deactivate the hepatic 
stellate cells.  
 
(Lee et al., 
2016) 
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Significant potential in 
wound healing  
(Latifi-pupovci 
















Reduce MSCs senescence. 
(Jin et al., 
2016) 




         
LNGFR and 
THY-1 
                 
FACS 
                                 
In vitro Shown to have more 
chondrogenic differentiation 
ability    
56 
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ALDH 
               
FACS 
                                





Promote endothelial cell 
expansion. 
Enhance recruitment of 
endogenous vascular cells in 
vivo by upregulation of 
lectin.  
(Sherman et 




                         
SYN and BM 
 
Human 
                
LNGFR and 
THY-1 
              
FACS 
                                
In vitro Greater chondrogenic 
differentiation ability and 
colony forming potential 
than BM-MSC.   
(Ogata et al., 
2015). 
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(De Witte et 
al., 2017) 




           
STRO-1 
                 
FACS 
                                 
In vitro Increase expression of 
cardiovascular relate 
cytokines.  
(Hiwase et al., 
2009). 
 
Note: Bone Marrow (BM), Umbilical cord (UC), Umbilical cord blood (UCB), Synovium (SYN), Placenta 
amnion membrane (PAM), Adipose tissue (AT), Umbilical perivascular (AP), Aldehyde dehydrogenase 
(ALDH). Stromal Precursor antigen-1 (Stro-1), Acute liver failure (ALF), Receptor activator of nuclear 
factor kappa-B ligand (RANKL) 
 
1.13.2 MSCs priming 
 
 
As with selection of MSC, priming of cells before use is intended to enhance their 
biological properties for whichever clinical indication is being considered (Table 1-4). 
This may include improvements in MSC immunomodulatory effects, homing to injured 
organs and/or greater expansion of cells. 
1.13.2.1 Enhancing immunomodulatory properties of MSC 
 
Pre-treatment of MSC with the pro-inflammatory cytokines IL-1b, IL-23 and IL-6 for 96 
hours (Pourgholaminejad et al., 2016) was found to enhance secretion of TGF-b and 
reduce production of IL-4 by MSC, although notably no changes were reported in 
production of IFN-g and TNF-a. In addition, cytokine-treated MSC exhibited superior 
multi-lineage differentiation capacity compared to untreated MSC, with no associated 
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changes in their morphology. IL-1 appears to be important for pre-conditioning of MSC, 
as combined treatment with IL-1a and IL-1b increases production of granulocyte-colony 
stimulating factor (G-CSF) and secretion of anti-inflammatory mediators such as IL-10. 
Moreover, microglial cells incubated with conditioned medium from IL-1 primed MSC 
increase expression of anti-inflammatory cytokines such as IL10 and decrease secretion 
of pro-inflammatory cytokines as reported in TNF-a and IL-6 (Redondo-Castro et al., 
2017).   
Duijvestein et al. (Duijvestein et al., 2011) showed that stimulation MSC with IFN-g 
enhanced the anti-inflammatory response of MCS in experiment colitis animal model. In 
addition, IFN-g primed MSC exhibit a significant reduction in TNF-a and IL-6 in colon 
homogenates, while normal MSC had no effect. In the same model, activation of MSC 
with IFN-g further promote the immunomodulation via enhance production of IL-17 and 
Il-4, which therefore inhibit the Th1 and reduce T cell activation (Duijvestein et al., 2011). 
Under similar conditions, pre-stimulation of BM-MSC with IFN-g and TNF-a stimulate 
production of IL-6, HGF, TGF-b (Linero and Chaparro, 2014). More interestingly, an in 
vivo GVDH model, administration of MSC pre-treated with IFN-g have the capability to 
enhance survival rates of mice with GVHD, resulted in 100% survival (Polchert et al., 
2008). 
More recently, data from de Witte and colleagues have demonstrated that pre-treatment 
of UC-MSC with different treatments such as TGF-b, IFN-g, IFN-b or in combinations 
(TGF-b, IFN-g and retinoic acid) suppress expression of CD107a on NK cells, enhancing 
MSC immunomodulation. In addition, MSC treated with IFN-g and the multiple cytokine 
combination were found to significantly upregulate IDO activities which subsequently 
 39 
suppressed CD4 and CD8 proliferation when compare to untreated MSC. Notably, 
following infusion into mice injured with a single dose of CCl4, a higher percentage of 
TGF-b treated MSC homed to the injured liver (25%) compared with untreated MSC 
(13%) (De Witte et al., 2017). 
In another liver injury studies, IL-7 treated MSC had a superior therapeutic effect on liver 
injury mediated in part through increased activation of iNOS. IL-17 down-regulates gene 
expression of ARE/poly(U)-binding/ degradation factor 1 (AUF-1) in MSC which is a 
protein known to regulate immune related molecules (Han et al., 2014) and has a key role 
in regulation stromal cell fate (Chenette et al., 2016). Thus, AUF1 could have a novel role 
to enhance the effect of IL-17 on immunosuppression. Similarly, IL-17a modified MSC 
have been reported to suppress proliferation of T cell in vitro via mechanisms such as 
inhibition of Th1 cytokines (IFN-g, TNF-a, IL-10, and IL-2), enhance production of IL-
6 and induction of regulatory T cells (Sivanathan et al., 2015). 
IL-6 priming of MSC infused into an acute model of CCl4 injury resulted in improved 
viability of isolated hepatocytes as well as a reduction in expression of pro-apoptotic 
markers such as BAX, Caspase-3 and LDH activities. This finding was not observed 
when MSC or IL-6 treatment were applied alone (Nasir et al., 2013). In addition, 
administration of IL-6 with MSC was found to enhance repair of liver injury in a mouse 
model of liver fibrosis with reductions in fibrosis, improvements in liver synthetic 
function, promote hepatocyte survival, and decrease apoptosis in fibrotic liver (Nasir et 
al., 2013).   
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1.13.2.2 Enhancing homing of MSC 
 
 
A study demonstrated that adhesion molecules such as ICAM and VCAM can be highly 
expressed on MSC following priming with a combination of IFN-g, TNF-a and IL-1. 
This upregulation of expression of ICAM and VCAM led to increased recruiting of MSC 
to vascular endothelium, this close contact of MSC with immune cells could enhance the 
immunosuppressive properties of MSC (Ren et al., 2010, 2011) Similarly, MSC pre-
treated with IFN-g, TNF-a can induced regulatory T cells more efficiently than non-
treated MSC. Furthermore, MSC pre-incubated with IFN-g, TNF-a induced secretion of 
CCR6 and therefore increase the adhesion of Th17 cells to MSC, resulting in promote the 
generation of regulatory T cells (FOXP3+ cell) from Th17 cells and consequently improve 
their immunosuppressive properties (Luz-Crawford et al., 2013). 
Priming with CXCL9 has also been shown to enhance adherence of MSC to endothelial 
cells as well as increase spreading of MSC on the endothelial cells as characterized by 
the extension of pseudopodia in multiple directions (Chamberlain et al., 2011). Further 
characterization of the beneficial effect of chemokines on MSC behaviour was reported 
in the same study using trans-well migration experiments, in which MSC migrated across 
endothelial layers in the presence of chemokines such as CXCL9, CXCL16, and 
CXCL20, and CXCL25. Of note no migration was observed in the presence of TNF-a 
alone.  
 
MSC are commonly maintained in culture at an oxygen concentration of about 21% 
(Nitzsche et al., 2017), whereas in vivo they are exposed to oxygen tensions in the range 
of 0.4 to 2%. Under hypoxic condition, hBM-MSC significantly increase their expression 
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of chemotactic and angiogenic mediators such as VEGF-A, VEGF-C, IL-8, and MCP-
1(Mylotte et al., 2008), and also result in activation of Akt signaling pathways and 
expression of cMET (a major receptor for HFG)(Rosova et al., 2008), all of which are 
involved in homing and tissue repair ability of MSCs. Oxygen tensions as low as 0.1-
0.3% appears to stimulate expression of CXCR4, MMP-2 and MMP-9, which have been 
associated with enhanced cell migration(Wei et al., 2013). This maybe mediated by 
hypoxia inducible factor (HIF-1a) which is also activated under conditions of hypoxia 
and has been reported to drive expression of CXCR4 and CX3R1 (Hung et al., n.d.; 
Schioppa et al., 2003). Culture of MSC under hypoxic conditions appears to maintain 
their state of pluripotency and increase their proliferative capacity, resulting in an 
approximately 30-fold increase in cell number in compare to normal oxygen tension (Das 
et al., 2010). In a mouse model of liver injury, hypoxia preconditioned MSC significantly 
improved liver regeneration which was mediated by up regulation of VEGF secretion, the 
peak of VEGF expression (72 hours) was reported to be correlated with the proliferations 
of the sinusoidal endothelia cells in the liver, this finding showed that MSCs derived 
VEGF promote liver generation through regeneration of sinusoidal endothelia cells (Yu 
et al., 2013). Similarly, another study reported that hypoxia led to activation of MT1-
MMB in MSC which in turn was correlated with activation level of VEGF (Promotes et 
al., 2003). Notably, other studies have shown that whilst there is a decrease in 
differentiation of MSC into adipogenic and osteogenic lineages under low oxygen 
conditions (1%) when compared to normoxic condition, there is an up-regulation of both 




Table 1-4 Reported factors and their effect in PRIMING of Mesenchymal stromal cells for 





















• Enhance secretion of TGF-b.  
• Reduce production of IL-4. 
• Exhibit significance multi-lineage. 
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• Increase production of G-CSF. 
• Increase production of IL-10.  
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• Multiple cytokines cocktails improve 
the immunomodulatory properties of 
MSCs. 
• TGF-b treated MSCs increased 
recruitment of MSCs to the liver 
injury in-vivo. 










• Mediate liver injury through 
activation of iNOS. 











• Induction regulatory T cells.  
• Inhibition of Th1 cytokines.  
• Enhance production of IL-6.   








• Improve viability of hepatocytes 
treated with CCL4.  
• Decreased expression of pro-
apoptotic markers (BAX, caspase-3, 
and LDH).  
• Reduced liver fibrosis in vivo.  










• Increase upregulation of ICAM and 
VCAM.  












• Increase ability of MSC to inhibit T 
cell proliferations.  
• Enhance secretion of chemokines 
such as CXCl-9 and CXCL-10.    
 









• Ameliorate the adhesion of MSC to 
murine endothelial cells.   






1.13.3 Genetic modification of MSC (Gene editing) 
 
 
Beside enrichment and priming MSC in vitro, transplantation of MSC after genetic 
correction or modification (gene editing) represents a powerful approach to use of MSC 
in regenerative medicine (Table 1-5). This section will review progress with genetic 
engineering approaches that have reported with MSC, including viral and non-viral 
manipulations. Viral transfection of MSC can be achieved with several approaches 
including lentivirus, adenovirus and retrovirus (Park et al., 2015).  
 
Overexpression of Oct4 and Nanog in MSC can increase level of Dnmt1, a 
methyltrasferase known to have an essential role in maintaining DNA replication, through 
a direct binding to its promoters (Tsai et al., 2012), resulting in increased proliferation 









• Increase expression of HGF receptor 
(cMET) on MSCs.  
• Regulate survival, migration, and 
proliferation of MSC through 
regulation of Akt and Erk signalling 
pathway.    










• Stimulate expression of CXCR4, 
MMP-2, and MMP-9. 
 
(Wei et al., 2013). 
Rat MB O2 (1%) 24 hours • Significant improvement in liver 
injury by upregulation of VEGF.  
 
(Yu et al., 2013). 
Mouse BM O2 (1%) 4 hours • Increase activation of MT1-MMB in 
MSC.  
 




O2 (1%) 7 days  • Increases expression of CXCR4 and 
CX3CR1.  
(Hung et al., 2007). 
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transfected with Oct-4 have enhanced expression of Sox-2 and Nanog (Wang et al., 2015), 
thus potentially leading to enhanced pluripotency of MSC and possibly also function.  
 
MSC have also been genetically modified to increase expression of CXCR4, thereby 
improving their homing to the injured liver and reducing liver damage (Ma et al., 2014). 
Similarly, the same finding was reported in a rat model of lung injury, with increased 
expression of CXCR4 on MSC resulting in enhanced hepatic migration and improvement 
of their immunomodulatory properties mediated by increased production of IL-10 and 
reduction in TNF-a. Notably, these findings suggest that overexpression of CXCR4 not 
only enhanced MSC homing but also increased their immunosuppressive effects (Yang et 
al., 2015). 
Further examination of the beneficial effects of genetic modified MSC was reported in a 
mouse model of liver fibrosis, following overexpression of insulin growth factor like-1 
(IGF-1) (Sobrevals et al., 2016). After systemic administration, IGF-1 modified MSC 
were able to significantly reduce the degree of fibrosis, likely through the down regulation 
of a-SMA, TGF-b and COL1A2 in animal treated with IGF-1 MSC when compare with 
animal treated with normal MSC (Fiore et al., 2015). Over-expression of HGF in MSC 
was also found to reduce liver fibrosis, seemingly mediated by a reduction in TFG-b, 
platelet-derived growth factor-bb (PDGF-bb), and metalloprotease-14 (MMP-14) (Kim et 
al., 2014). HGF overexpressed MSC also act on hepatic stellate cells to reduce a-SMA 
and desmin expression, indicating that MSC that overexpress HGF decreased both the 
activation and number of hepatic stellate cells more greater level than MSC. This could 
have therapeutic effect to prevent diseases progression and foster liver restoration. 
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Another reprogramming approach showed that over-expression of miR-27b in adipose 
tissue derived MSC resulted in reduction in a rat model of ischemic liver injury in rat with 
improvements in ALT, AST, TNF-a, and IL-6 as well as significance suppression in 
TGF-b (Chen et al., 2016). Moreover, these transfected cells were shown to have anti-
fibrotic ability with suppression of MMP-2 and MMP-9 in liver tissue.  
Further study linked between the genetic modified MSC and their capacity to express 
endothelial cell (EC) markers with similar function. For example, silencing MMP-2 and 
MMP-14 with endothelial growth medium can induce the MSC differentiation into EC 
by enhance production of endothelial markers, such as PECAM and VE-cadherin. These 
markers were increase from 4 to 15% and from 4 to 30% after silencing MMP-2 and 
MMP-12, respectively. This observation was in comparison with MSC that treated with 
endothelial growth medium only (Almalki et al., 2017).  
 
In other work, the expression level of HO-1 was genetically modified in MSC and shown 
to have resistance to cell death under oxidative stress condition and enhance their anti-
apoptotic properties (Hamedi-Asl et al., 2012). Moreover, HO-1 overexpressed MSC 
have shown to have more surviving cells following exposure to H2O2 and hypoxia, 
indicating that HO-1 may shape the stress responsive and cytoprotective properties of 
MSC. Notably, in the murine model of myocardial infarction, overexpression of HO-1 
resulted in diminished oxidative stress and apoptosis as well as an enhanced effect on 
angiogenesis. This was associated with a 2.1-fold up-regulation of VEGF levels 
compared to normal MSC (Tsubokawa et al., 2010). 
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Table 1-5 example molecules to genetically modified mesenchymal stem cells (MSCs). 





























Ameliorate liver fibrosis by significant 
reduction in a-SMA, collagen deposition, 
and TGF-b1.  
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Significant improvement in both models, 
by suppress T cell proliferation 
(decreased in CD3+), increase MCP-1 
secretion, and enhancing expression of 
Fasl/Fas.  














Increase migration and engraftment of 
MSC to the site of injury.  
Enhance immunomodulatory effects of 
MSCs in vivo through inhibit of T cell 
proliferation and supress production of 
INF-g and IL-17.  













Enhance migration and improve liver 
regeneration.  
 














Improve migration and suppress 
inflammation of lung tissue by 
upregulation of IL-10 and 
downregulation of TNF-a. 















Micro RNA  
 
Enhance liver regeneration through 
reduction in ALT, TNF-a, and IL-6 in 
serum.  
 Reduce expression of TGF-b, MMP2, 
and MMP9.  
  






                               







Increase MSC proliferation and 
differentiation capacity by upregulation 
of Dnmt1 protein.  
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Reduce MSC proliferation rate and 
differentiation ability.  
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Increase expression of Oct-4, Nanog, and 
Sox-2.   
Increase colony forming ability.  





                          







Reduce scar formation and improve 
cardiac function in vivo. 
 

















 Enhance differentiation of MSC into 
endothelia cells by production of 
PECAM and V-caderen.  
Increase the formation of capillary like 
cells and Sc-LDL uptake.   
  
  





                              
HO-1   
overexpression 
                       
In-vitro 
 
     
Adenovirus 
 
Enhance MSC survival and resistant to 
oxidative stress.  
Enhanced anti-apoptotic and anti-
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Promote liver function and reduce liver 
fibrosis via significant reuction in TGF-b 
and PDGF-bb.  















Increase ability of BM-MSCs to 
differentiate into IPCs.  



















Enhance MSCs migration in vitro and in 
vivo through modulation expression of 
FAK and b-catenin.  





                       
Apoptin 
overexpression 





Inhibit the proliferation of liver 
carcinoma cells in vitro and tumour 
growth in vivo.  




1.14 Aims and Objectives  
 
The ability of UC-MSCs to immunomodulate offers therapeutic potential in liver injury 
but the inherent heterogeneity of unsorted MSC populations may explain varied/reduced 
function, as well as posing regulatory challenges. Thus, I set out to evaluate the 
therapeutic potential of purified CD362+ MSC infusion in murine models of acute liver 
injury. 
In this study, two different cell subsets were used: unsorted UC-MSCs and sorted UC-
MSCs based on the expression of CD362. The main aims of the project were as follows: 
 
1) Phenotypic characterization of unsorted UC-MSCs and sorted UC-MSCs based on 
the expression of CD362 by measuring the expression of surface markers using flow 
cytometry and analysing their ability to differentiate into adipocyte, chondrocyte and 
osteocyte lineages.   
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2) To investigate and evaluate the effects of CCl4 treatment in mice. The hepatotoxicity 
of CCl4 was evaluated at different time points by measuring hepatic injury, 
inflammatory response, cell proliferation, DNA damage, antioxidants, and the level 
of autophagy. 
 
3) Comparison of the immunomodulatory properties of unsorted UC-MSCs and          
CD362+ sorted UC-MSCs in vivo. The efficacy of unsorted/purified UC-MSCs in the 
CCl4 model was determined by measuring serum alanine aminotransferase (ALT) and 
inflammatory cytokines. The efficacy of sorted UC-MSCs in modulating the numbers 
of hepatic infiltrating lymphocytes and monocytes was studied using flow cytometric 
analysis. 
 
4) To investigate the immunosuppressive potential of unsorted/purified hUC-MSCs in 
vivo using an OVA-BIL model of acute liver injury.  
 


















































2.1 Isolation of human mesenchymal stromal cells from umbilical 
cord tissue. 
 
Orbsen Therapeutics Ltd developed a research protocol for the isolation of MSC from 
umbilical cord tissue using enzymatic digestion. Briefly, umbilical cord (5-6 cm) was 














Figure 2-1 Human umbilical cord. 
 
The cord was dissected into 1 cm3 pieces and washed free of contaminating blood with 
PBS throughout the process. For digestion, the cord was immersed in a 5 ml (x2 2.5ml in 
each 50ml Falcon tube) enzymatic mixture (α-MEM, Collagenase I, Hyaluronidase I and 
DNase) and incubated for 1 hour at 37°C with gentle agitation. After incubation, digested 
tissues were removed by squeezing with forceps to release cells into solution. The action 
of enzymes was stopped by addition of α-MEM media containing 10% FBS and the cell 
suspension was kept on ice.  Cell suspensions were further diluted to reduce the viscosity 
of the suspension and passed through a 100-µm filter. All digested explants were split 
Human	umbilical	cord	
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between two 10cm dishes and cultured in α-MEM media with fibroblast growth factor 
(FGF) and placed in a hypoxic incubator. The filtered cell suspension was centrifuged at 
400 relative centrifugal force (RCF) for 5 minutes. Viable cells were counted using by 
Trypan blue dye exclusion on hemocytometer.  Cells were washed and resuspended in 
sort buffer for staining (1:50, αCD362 – APC for 30 minutes at 4 °C). Cells were washed 
and centrifuged at 400 RCF for 5 minutes at 4 °C.  Cells were resuspended at a density 
of 80µl/107cells. αAPC beads were added at a concentration of 20µl/107cells and 
incubated at 4 °C for 15 minutes. Cells were washed in MACS buffer at a concentration 
of 1-2mls/107cells and cells resuspended in 500µl of MACS buffer. MACS column was 
prepared by adding 500µl of MACS buffer before addition of labelled cells. Column was 
then washed three times with 500µl of MACS buffer, and cells flushed from column (x2 
1ml CD362+ cells into 15ml tube). Cells were then counted and cultured in αMEM media 
(+FGF) and placed in CO2 in a 37°C incubator. 
 
2.2 Characterisation of MSC derived from UC by flow cytometry.   
 
After the MSC were isolated from umbilical cord, cells from passage 2 or 3 were seeded 
in a 175cm2 culture flask containing 30 ml of complete media, which was prepared by 
adding 50ml of fetal bovine serum (FBS, F9665; Sigma-Aldrich, UK) to 445 ml of 
minimum essential medium Eagle alpha modification (MEM-α, 32561029; Gibco, UK) 
with 5ml of penicillin/streptomycin solution (P/S, 10,000 U/mL, 15140122; Gibco, UK), 
and 10µl of 1 ng/ml basic human recombinant fibroblast growth factor (rhFGF, 100-18B; 
Peprotech, UK). Cells were fed every two to three days until the cells reached 70-80% 
confluent. Next, medium was discarded and the adherent cells were gently washed with 
sterile PBS. Finally, cells were detached by incubation with pre-warmed TrypLE™ 
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Express (12605010; Gibco,UK) for 3-5 minutes at 37 °C, and then diluted with complete 
media. Cells were centrifuged at 400 g for 5 minutes and resuspended at a concentration 
of 1x107 cells/ml in FACS buffer (2ml FBS with 98ml cold PBS). Tubes were labelled, 
and the amount of each antibody was added as per the following table (Table 2-1). 100µl 
of cell suspension was added into each tube and tubes were then incubated in the dark for 
30 minutes (all tubes were wrapped in foil to prevent exposure of samples to the light). 
After incubation, cells were washed twice with FACS buffer by adding 2 ml cold FACS 
buffer, vortexed, and centrifuged at 400 g for 5 minutes. Supernatant was discarded, and 
the pellet resuspended in 300-500µl of FACS Buffer (FBS). The cell suspension was 
filtered for each tube using a yellow strainer, and cells were analyzed using a flow 
cytometer (Cyan, ADP Flow cytometer analyzer).  
 
Table 2-1 A) hMSC analysis kit contents (BD). B) This table presented labelled tubes and the 






Positive Marker Cocktail CD105 PerCP-Cy5.5, CD73 APC, 
and CD90 FITC.  
Additional Positive Drop-In 
Marker 
CD44 PE. 
Negative Marker Cocktail 
 






mIgG1 PerCP-Cy5.5, mIgG1 APC, 
and mIgG1 FITC for positive cocktail 
IgG1 and IgG2b PE for negative 
cocktail 

















2.3 In vitro differentiation of UC-MSC.  
 
2.3.1 Adipogenic differentiation. 
 
Cells from passage 3 were cultured in a 12-well plate at a seeding density of 1x104 
cells/cm2 and incubated at 37°C in a humidified atmosphere of 5% CO2. Culture medium 
was replaced every three days using complete AMEM medium until the cells reached 
confluence (60-80%). At 80% confluence, media was replaced with pre-warmed 
adipogenesis differentiation medium consisting of 90 ml adipocyte differentiation 
medium, 10 ml of adipogenesis supplement, and 50ul of Gentamicin (10mg/ml) 
(Invitrogen Inc) and culture continued. MSC continued to undergo limited expansion as 
they differentiated under adipogenic conditions, with the medium being changed every 3 
to 4 days. Normal complete media AMEM was used as a negative control. Adipogenesis 
was assessed using Oil red-O staining.  
 
B 
Tube No Add Size 
1 FITC Mouse Anti-Human CD90 5µl 
2 PE Mouse Anti-Human CD44 5µl 
3 PerCP-Cy™5.5 Mouse Anti-Human CD105 5µl 
4 APC Mouse Anti-Human CD73 5µl 





hMSC Positive Isotype Control Cocktail 
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hMSC Positive Cocktail + PE hMSC Negative 
Cocktail 
 




hMSC Positive Isotype Control Cocktail 
+ 







hMSC Positive Cocktail (20µl) 
+ 








For Oil Red O staining, media was aspirated after 14 days and each well washed with 2ml 
of PBS. Cells were fixed with 10% formalin for 30 minutes. Formalin were aspirated 
from each well and rinsed again with PBS. Cells were stained with Oil red-O solution 
(15ml of stock oil red with 10ml distilled water). Stock solution was prepared by 
dissolving 300 mg of oil red-O powder (Sigma-Aldrich) in 100 ml of 99% isopropanol. 
2ml of the oil red-O working solution was added along the side of each well and left for 
15 minutes, before counterstaining with Mayer’s hematoxylin (Sigma-Aldrich) for 5 
minutes. Under the microscope, adipogenesis was assessed by staining for lipid droplets 
with red and the nuclei seen in blue. 
 
2.3.2 Osteogenic differentiation. 
 
Osteogenic differentiation was undertaken as described in the adipogeneic differentiation 
method, with a few modifications. Cells from passage 3 were cultured in a 12 well plate 
at a seeding density of 1x104 cells/cm2 and cells incubated at 37°C in a humidified 
atmosphere of 5% CO2. Cells were fed every three days using complete AMEM medium 
until the cells reached confluence (70-80%). At 80% confluence, medium was replaced 
with pre-warmed osteogenic differentiation medium consisting of 90 ml Osteocyte 
Differentiation Basal Medium, 10 ml of osteogenesis supplement, and 50ul of Penicillin 
and Streptomycin (10mg/ml) (Invitrogen Inc) and culture continued. MSC continued to 
undergo limited expansion with the media changed every 3 to 4 days. Normal complete 
media AMEM was used as a negative control for undifferentiated cells. Osteogenesis was 
assessed using 1% Alizarin Red S staining.  
Calcium deposition of osteogenic differentiation was analyzed by 1% Alizarin Red S 
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staining. In order to prepare 1% of Alizarin Red S, I dissolved 1g of Alizarin Red S 
powder (Sigma) with 100 ml of ionized distilled water. The pH was monitored to be 
between 4.1 to 4.3. Cells were fixed with 10% formalin for 30 minutes and stained with 
1% of Alizarin Red S staining for 20 minutes. After incubation with Alizarin staining, 
cells were washed with deionized water and then examined using a light microscope. 
 
2.3.3 Chondrogenic differentiation 
 
To induce chondrogenic differentiation, a pellet system was used. Cells were transferred 
into 15 ml Polypropylene tube and cells centrifuged at 150g for 5 minutes. Supernatant 
was discarded, and cells resuspended in 1 ml incomplete chondrogenic medium (mixture 
of 185ml differentiation basal chondrogenic medium with dexamethasone, ascorbate, 
insulin-transferrin-selenium (ITS) supplement, GA-1000, sodium pyruvate, proline, and 
L-glutamine) per 7.5 x 105 cells, centrifuged again at 150g for 5 minutes. MSC were 
resuspended in complete chondrogenic medium (2.5 µl of TGF-b3 was used to convert 5 
ml of incomplete media to complete media) to a concentration of 5.0 x 105 cells per ml. 
Cells were centrifuged at 150g for 5 minutes, and the tubes then incubated at 37°C in a 
humidified atmosphere of 5% CO2. Pellets were left undisturbed for 24 hours, after which 
0.5ml of freshly prepared complete chondrogenic medium was added to each tube. After 
21 days, pellets were snap frozen and kept in frozen medium at -20 °C. For histological 
analysis, sections were taking from each pellet and stained with 0.1% toluidine blue 
staining. This staining was prepared as follows: 0.1g of Toluidine Blue O powder was 
weighed out and suspended into 100ml of 0.1 Sodium Acetate buffer (1.36g of sodium 
acetate buffer with 100ml D.W, pH 4). Staining was performed on frozen sections; slides 
were defrosted for 30 minutes and 200µl of toluidine blue we added onto each section and 
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incubated for 2 minutes. Slides were washed in tap water and dehydrated, sections were 
mounted using DPX mounting (Leica 08600E) and examined under the light microscope.  
 
2.4 Preparation of hUC-MSCs for perfusion 
 
 
Cryopreserved human umbilical cord (UC) MSC from passages 2-3 were supplied by 
Orbsen Therapeutics Ltd (Galway, Ireland). Passage three to four UC-MSCs were used 
in all experiments. To expand a culture, a frozen vial of MSCs (1x106 cells) was plated in 
175-cm2 cell culture flask containing 30 ml complete minimum essential medium Eagle 
alpha modification (MEM-α, 32561029; Gibco, UK) supplemented with 1% 
penicillin/streptomycin solution (P/S, 10,000 U/mL, 15140122; Gibco, UK), 10% heat 
inactivated fetal bovine serum (FBS, F9665; Sigma-Aldrich, UK) and 1 ng/ml basic 
human recombinant fibroblast growth factor (rhFGF, 100-18B; Peprotech, UK). Cells 
were incubated at 37 °C, 5% CO2 and 20% O2 in humidified atmosphere. After 2-3 days, 
non-adherent cells were removed, and culture growth medium was replaced until they 
reached approximately 70-80% confluence. Finally, medium was discarded and the 
adherent cells were gently washed with sterile PBS and the MSC monolayer detached 
using 5 ml of pre-warmed TrypLE™ Express (12605010; Gibco,UK) following 
incubation for 3-5 minutes at 37 °C. Cells were then washed twice with sterile PBS, 
counted and checked for viability via trypan blue.  
 
2.5 In vivo transplantation of hUC-MSCs  
 
For intravenous delivery of MSC, mice were warmed in a thermal cage for 5-10 minutes 
to dilate their tail vein and make it more visible so as to perform the injection more easily. 
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Mice were held in a tail vein injection restrainer which can help to easily rotate the mice 
to position their tail for injection. MSCs (About 250 or 500 X 105) was suspended in 200 
µl of normal saline (PA931/1/1; Maco Pharma Ltd, UK) and were infused with a 29-
gauge needle through a tail vein. Control mice received normal saline via tail vein 
injection alone at the same time as MSC treated animals.  Prior to infusion, the cell 
suspension was filtered through a 50 µm Cell Tricks filter (04-004-2327; Sysmex, USA). 
The cells were maintained at 4° C, and they were gently mixed with a pipette to ensure 
they were not aggregated before infusion.  
2.6 Pre-clinical murine models of acute liver injury   
 
2.6.1 Animal breeding 
 
All the animals used in this study were bred and used under standard conditions in the 
BioMedical Services Unit (BMSU) at the University of Birmingham in accordance with 
the guidelines for animal care in compliance with UK Animals (Scientific Procedures) 
Act 1986. All protocols and procedures performed under Home Office Project license 
number 70/7707.  
 
Experimental mice (up to 5 mice/cage) were bred and maintained in a temperature-
controlled sterile animal facility with 12-hour light/dark cycles at 23°C and permitted ad 
libitum consumption of water and a standard laboratory chow diet. C57/BL6 mice were 
purchased from Charles River Laboratories (London, UK) whereas transgenic mice 
strains used for this study were bred in-house at the BMSU of the University of 
Birmingham. In all the animal experiments, mice were randomly allocated to control or 
experimental groups.  
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2.6.2 CCl4 model (induced acute liver injury) 
 
To induce acute liver injury, male C57/BL6 mice at 8-10 weeks of age were injected 
intra-peritoneally with a single dose of carbon tetrachloride (CCl4) (Sigma-Aldrich, 
product number 289116, MW=153.82g/mol, 99.95% concentration) 1 mg/kg diluted in 
mineral oil (Sigma-Aldrich). Mineral oil alone was used for control mice. Male C57Bl/6 
mice were purchased from Charles River Laboratories (London, UK) and used at an 
average age of 8 to 10 weeks. Five hours after CCl4 injection, animals were infused 
intravenously via tail vein with either 250K or 1M unsorted and sorted CD362+hUC-
MSCs in 200 µl normal saline, whilst control mice received normal saline. Three days 
after infusion of MSC, animals were sacrificed to collect blood and liver samples for 
further analyses as described above. 
2.6.3 Transgenic OVA-BIL (a model of antigen specific induction of 
hepatobiliary inflammation)  
 
OVA-BIL mouse model was previously developed by Buxbaum et al (2006)(Buxbaum 
et al., 2006). Ordinarily, OVA-BIL transgenic mice are tolerant of the over expression of 
ovalbumin (OVA) antigen on their biliary epithelium without any hepatic injury. 
However, adoptive transfer of OVA-specific CD8+ (OT-l) and OVA-specific CD4+(OT-
ll) T cells isolated from spleens of OT-l and OT-ll transgenic mice into naïve OVA-BIL 
mice leads to dose-dependent biliary-centered necro-inflammation.  
In this animal model, the author reported an increase in the serum ALT following adaptive 
transferred of OT-1 and OT-ll into Ova-Bil mice at different time and found to peak at 10 
days. In addition, liver histological sections showed bile duct damage with inflammation 
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around the portal area increasing across time points to a maximum level at day 10 and 
resolved by day 28.  
The inflammation response in this animal model is CD8 dependent, but the CD4 required 
to initiate more pathogenesis. CD4 alone have not shown to have any sign of 
inflammation or injury upon transferred to the OVA-BIL mice and the mechanism of 
CD4 in this animal model are not well defined. The immune cells were characterized in 
the liver during inflammation and found that the largest population was in the CD8+ cells 
(Most CD8+ cells were Va2+) and small increase was reported in the CD4+ cells.  
In addition, NK T cells were found to increase in the liver more than 6-fold after adaptive 
transfer for OT-1 and OT-11 solenocytes at day 10. Due to the heterogamous population 
of NKT cells in the liver, this animal model lacks the definition of the functional subsets 
of the NKT cells which is an area of feature study. The author also reported an increase 
in the inflammatory cytokines INFg and TNFa during the hepatobiliary inflammation. 
OVA-BIL mice strain used for this study were inbred and maintained as heterozygotes 
on a C57BL/6 background. Routine genotyping for heterozygous apical sodium-
dependent bile acid transporter (ASBT)-membrane-bound ovalbumin (mOVA) in 
animals was carried out using real time PCR (Transnetyx, Inc. Tennessee, USA).  
In this experiment, Induction of hepatobiliary injury was achieved by adaptive transfer of 
splenocytes from OT-l and OT-ll transgenic mice into male OVA-BIL mice. 10-12 weeks 
old male OT-l & OT-ll mice were sacrificed by schedule 1 method (cervical dislocation) 
and spleens from each animal were harvested and stored in cold RPMI medium. The 
harvested spleens were minced into small pieces and mashed through a 40µm cell 
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strainer. Cell suspensions were washed with cold 5% FBS/RPMI and the pellets were 
resuspended in 3 ml of red blood cell lysis buffer (Sigma-Aldrich) for 5-10 minutes.  
Samples were washed in PBS and centrifuged at 2000 rpm for 5 minutes. Cell pellets 
were resuspended in normal saline and an aliquot containing of 1x107 OT-l and 1x107 
OT-ll splenocytes was injected intra-peritoneally into male OVA-BIL mice at 8-12 weeks 
of age. Control mice were injected with sterile PBS alone. At day 4 post injury, animals 
were infused again with 250K, 500K or 1M unsorted and sorted CD362+hUC-MSC via 
tail vein. Animals were sacrificed 6 days after the administration of MSC to collect blood 




Figure 2-2 Experimental design. OVA-BIL mice were I.P. injected with 1x107 OT-l and 
1x107 OT-ll splenocytes, followed by I.V. injection with MSCs, or with PBS four days later. 
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2.7 Study of the time course of carbon tetrachloride (CCl4) induced 
hepatotoxicity in mince. 
 
 
In this experiment, acute liver injury was induced in mice by administration of a single 
intra-peritoneal (IP) dose of CCl4. At different time points (12, 24, 48, 72, and 96 hours) 
after CCl4 administration mice were anaesthetized using isopropanol and 0.6-1ml of 
blood collected by cardiac puncture and liver was harvested for further analyses. Blood 
was allowed to clot and then centrifuged at 10000 rpm for 10 minutes. After 
centrifugation, serum was separated and place in an Eppendorf tube for measurement of 














Harvest blood and liver
CCL4 injection ( IP ) or
M.O ( control ) 
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Experiment	Scheme	
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2.8 Mouse immune cell isolation 
 
2.8.1 Isolation of liver-infiltrating murine immune cells using 
OPTIPEP  
 
To isolate lymphocytes and monocytes from mice, the largest liver lobe was harvested 
from each mouse, weighed and kept in a 7ml tube containing cold RPMI on ice. Livers 
were transferred into gentle MACS “C” tubes with 3 ml of cold plain RPMI and 
homogenized using a Gentle MACS Dissociator. The homogenized suspension was 
passed through a 70µm strainer into a 50ml Falcon tube. The MACS tube and the strainer 
were washed with RPMI to remove all the cells and topped up with RPMI up to 30 ml.  
This wash filtrate was transferred to 2x 15 ml tubes and was centrifuged at 2000rpm for 
5 minutes with a brake. The pellet in each tube was resuspended in 5 ml RPMI (each 
sample has two separate tubes with 5 ml in each). 
 
For each tube, 7ml of mouse OptiPrep Density Gradient Medium (Sigma-Aldrich, 
product number, D1556) was added to a new 15 ml Falcon tube, and in the same tube I 
layered 5 ml of the cell suspension on top of the Optiprep medium and centrifuged it at 
1000g (with no break) for 25 minutes at room temperature. Following incubation, I 
carefully removed 2/3 of the medium using a plastic pipette and transferred the isolated 
layer from each tube into new 15 ml Falcon tubes. Isolated cells were washed with cold 
RPMI and centrifuged at 2000 rpm for 5 minutes. Cell pellets were washed again with 
MACS buffer (PBS+1mMEDTA+2% FCS), and then resuspended in 750µl of cold PBS 
(phosphate buffered saline) for flow cytometry analysis. For an overview of this method 
see (Figure 2-4 A).  
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2.8.2 Spleen mononuclear cell isolation 
 
 
To isolate splenocytes, spleens were harvested from animals and collected on cold 5% 
FBS/RPMI medium for further processing. The harvested spleens were minced into small 
pieces and mashed through a 40µm cell strainer. The cell suspensions were washed with 
cold 5% FBS/RPMI and the pellets were resuspended in 3 ml of red blood cell lysis buffer 
(Sigma-Aldrich), for 5-10 minutes. Following cell lysis, cell suspensions were then 
washed two times with cold 5% FBS/RPMI medium before staining. Cells were washed 
twice with flow cytometry buffer and further analyzed by flow cytometry.  
 
2.8.3 Isolation of circulating mononuclear cells   
 
 
At the indicated time points after MSC administration, mice were anesthetized with 
isoflurane and blood collected by cardiac puncture. Blood was immediately placed in 
200µl of EDTA blood tubes (459036; Greiner Bio-One Ltd). To lyse erythrocytes, blood 
was incubated at room temperature with 500 µl RBC lysis buffer (00-4333-57; 
eBioscience, UK) for 5 minutes, and then centrifuged at 2000 rpm for 5 minutes (Figure 
2-4 B). The pellet was washed twice with cold RPMI, and cells were then resuspended in 
FACS buffer and used later for flow cytometry analysis. A schematic of the protocol used 











Figure 2-4 Preparation scheme for the isolation of total leukocytes from liver, spleen and 
blood: A) Liver were harvested and homogenized to obtained liver cell suspensions. Cell 
suspension from liver were pelleted using Optiprep medium, and centrifuged (1000g, 25 
minutes, RT) to separate the MNCs layer. B) Blood was collected in EDTA tube and spleen 
was harvested and dissociated into single cell suspensions in PBS. Red blood cells lysis was 
performed using RBC lysis buffer.  
 
2.9 Antibody staining and flow cytometry analysis  
 
Cells from different sources were isolated and prepared as described earlier. Live dead 
staining (Fixable viability dye) was undertaken by addition of 0.5 µl of APC-CY7 
viability dye to all samples, vortexing and incubation at 4°C for 30 minutes. Negative 
controls (unstained cells) and isotype matched controls (IMC) for each panel were 






















cells, live/dead and IMC (lymphoid & myeloid). Following incubation, 2ml of FACS 
buffer were added and centrifuged at 2000 rpm for 5 minutes. Cells were resuspended in 
a total of 200µl cold FACS buffer. The 200µl cell suspension was divided into two clean-
labeled FACS tubes (100µl/tube) for flow cytometric analysis for both lymphocyte and 
monocyte panels.  
 
The master mix of primary antibodies for both lymphoid and myeloid panel (for cell 
surface markers only) was prepared and added to each sample and incubated in a cold 
room for 30-45 minutes (Table 2-2). After incubation with primary antibodies, 2ml of 
FACS buffer was added to all the tubes, which were then vortexed and centrifuged at 
2000 rpm for 5 minutes. Cells from the myeloid panel and unstained cells were 
resuspended in 400 µl FACS buffer and fixed by adding 100µl of 3% formalin (37% 
formaldehyde (sigma, Cat # F1635) and sterile PBS). Cells were then incubated at RT for 
10 minutes and washed with 2 ml FACS buffer and then resuspended in 400µl of FACS 
buffer. All the tubes were kept in the cold room and were analyzed on the flow cytometer 
(Cyan, ADP Flow cytometer analyzer). 
 
After staining cells with lymphoid antibodies specific for surface markers, I performed 
fixation and permeabilization procedure to detect the intracellular staining cells. The 
fixation and permeabilization working solution was prepared by diluting 1 part of fix and 
perm concentrate (ebioscience, Cat. 00-5123) with 3 parts of diluent (ebioscience, Cat. 
00-5223). Permeabilization buffer (X10) was diluted to 1X with deionized water. 100µl 
of fixation and permeabilization working solution were added to each sample, vortexed 
and incubated in the dark for 30 minutes in a cold room. Following incubation, 1 ml of 
 66 
permeabilization buffer was added to each tube and centrifuged at 2000 rpm for 5 
minutes. The supernatant was discarded, and the pellet resuspended in 100µl FACS 
buffer. After fixation and permeabilization steps, we added the required amount of FoxP3 
antibody to each tube of lymphoid panel and FoxP3 isotype to the IMC tube (lymphoid 
panel only). The tubes were incubated in the cold room for 30 minutes and washed twice 
with 2 ml of FACS buffer. Finally, the pellets were resuspended in 400µl FACS buffer 
and were filtered using a yellow filter before running them in Flow cytometer (Cyan, 
ADP Flow cytometer analyzer).  7 µl of AccuCheck counting beads (Invitrogen, PCB 
100) were added to each sample just before running them on the flow cytometer. A single-
cell suspension was prepared from each sample by passing the cells through a 40 µm cell 
strainer (08-771-1; Fisher Scientific, UK) and analyzed using a CyAn ADP flow 
cytometer (Beckman Coulter). All data were analyzed using FlowJo software version 8.7. 
The absolute cell count of cells was finally count according to this formula (Absolute cell 
count (cell/µl) = (number of cell counted/total number of beads counted) X number of 
counting beads per µl), and the final calculation was normalized to the total tissue weight. 
 
 
Table 2-2 Panels used in flow cytometer analysis for different lymphoid and myeloid 
markers 
 




Fluorochrome Isotype  Volume required/ 
test  
(µl)  






CD19 Brilliant violet 
(421) 
Rat IgG2a 1(1:200) 16.5 0.5 
CD3 Brilliant violet 
(510) 
Rat IgG2b 5(1:40) 82.5 2.5 
CD49b Alexa Fluor 
(488) 









PE Rat IgG2a 5 (1:40) 82.5 2.5 
CD25 PE/Dazzle 
(594) 
Rat IgG1 2.5 (1:80) 41.3 1.3 
CD8a PreCP-Cyanine 5.5 Rat IgG2a 1(1:200) 16.5 0.5 
CD69 PE/Cy7 Armenian 
Hamster IgG 
5 (1:40) 82.5 2.5 
 
B) Myeloid Panel 
 
CD marker  Fluorochrome Isotype  Volume required/ 
test  
(µl)  





Ly-6C Brilliant violet 
(421) 
Rat IgG2c 5 (1:40) 82.3 2.5 
LY-6G Brilliant violet 
(510) 
Rat IgG2a 5 (1:40) 82.3 2.5 
CD11b Alexa Fluor 
(488) 
Rat IgG2b 1 (1:200) 16.5 0.5 
F4/80 PE Rat IgG2a 5 (1:40) 82.3 2.5 




APC Rat IgG2b 1 (1:200) 16.5 0.5 
CD11c PE/CY7 Armenian  
Hamster IgH 
1 (1:200) 16.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        0.5
 
2.10 Flow cytometric gating strategy for analysis of intra-hepatic 
immune cell subsets.  
 
 
Hepatic infiltrating immune cell subsets (lymphocytes and monocytes) were isolated 
from mouse liver using OPTIPREP gradient medium (as described previously). All 
antibodies, including the isotype controls used in this study are listed in (Table 2-2). All 
data were analyzed using the Flow Jo software (http://www.flowjo.com). Flow 
cytometric gating strategy for analysis of monocytes and lymphocytes population is 




Figure 2-5 Flow cytometer analysis of lymphocyte sub-populations in mouse liver. 
Lymphocyte populations were gated on the side scatter and forward scatter. Debris and dead 
cells were determined and excluded. From the total live cells NK cells were excluded by 
CD49b+ expression.  From the CD49b- population, two distinct populations were gated based 
on CD19+ (B cells) and CD3+ expression. From the CD3+ population, I gated CD4+ and 
CDB+ cells. Finally, the CD4+ cells were gated for further analysis of the expression of Treg 
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Figure 2-6 Flow cytometer analysis of monocytes in mouse liver. Monocyte populations 
were gated as follows. Debris and dead cells were determined and excluded. I identified several 
populations after gating the live cells with CD11b+. A) F4/80+ cells (total macrophage), B) 
Gr-1 + cells (neutrophil). Total macrophages were divided into classic (M1) and alternative 
macrophages (M2), as shown in C and D respectively. Both cells stained with (C11b+, F480+, 





























































2.11 Tracking of hUC-MSCs in vivo after infusion.  
 
2.11.1 Cryo-imaging of UC-MSCs labeled with Quantum Dots 
 
In order to label MSCs for in vivo cell tracking, I used Qtracker Cell Labeling Kits 
(Qtracker® 625 Cell Labeling Kit, Invitrogen, A10198) and the labelling procedure was 
performed according to the manufacturer’s instructions. I prepared a 10 nM labeling 
solution by mixing 1 µL each of Qtracker Component A and Component B in a 1.5 mL 
micro-centrifuge tube (1 µL of each component/1X106 cells).  Both compounds were 
mixed and incubated for 5 minutes at room temperature. For each 1x106 cells, 0.2 mL of 
fresh complete growth medium was added to the tube and vortexed for 30 seconds. The 
cell suspension was then added to the tube containing the labelling solution. The samples 
were incubated at 37 °C for 45–60 minutes in dark. After incubation, labeled cells were 
washed twice with complete growth medium and resuspended in normal saline for 
infusion. Cells were kept on ice until ready for injection. Injections were performed 
intravenously via tail vein using standard techniques. Following cell injection, mice were 
culled by CO2 at various time points and whole mice were embedded in fresh mounting 
medium (O.C.T. compound; VWR Chemicals, UK) and kept on dry ice until frozen. The 
whole mice were then stored at -80 °C until shipment for analysis. All mice were analyzed 
by BioInVision Inc, Cleveland, USA.  BioInVision’s CryoViz™ cryo-imaging system 
was used to study bio distribution of QD labelled-MSCs in organs and in the whole mouse 
by serial sectioning and imaging. The CryoViz™ technology picked up the signal of 
clusters of Qtracker 605 quantum particles, which were internalized in the hUC-MSC. 
Labelled cells were analyzed by co-registration of bright field and confocal images to 
generate three-dimensional anatomical and molecular fluorescence videos of the frozen 
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whole mice samples. Cell counts in organs and whole mouse were quantified using 











2.12 Liver histology: Haematoxylin and Eosin (H&E). 
 
After culling mice, mice liver lobes were harvested and fixed in 10% formaldehyde for a 
few days, then embedded in paraffin, and liver sections cut at 4µm thickness. For 
histological examination and to assess changes in liver structure, liver sections were 
rinsed three times in xylene (to dissolve all the wax away) and then dehydrated with serial 
dilution of alcohol (99%, 95%, and 70%) for 5 minutes periods. Slides were washed twice 
and sections were stained with haematoxylin and eosin (VWR International, UK). 
Following H&E staining, slides were passed through different dilutions of alcohol and 



























mounting medium and left for few hours to dry. Liver sections were scanned at ×20 
magnification using an automated fashion and identical settings on an AxioScan Z1 
(Zeiss) slide scanner. 
 
2.13 Immunohistochemistry (IHC). 
 
All slides used were paraffin sections. Slides were de-waxed and rehydrated as described 
previously. I carefully drew a ring around the section using a wax pen and then placed 
the slides in a humidified plastic chamber. To block endogenous peroxidase activity 
150µl of Dako peroxidase blocking solution was added to each section and incubated for 
a further 40 minutes on a rocker. After incubation, slides were washed twice with 
TBS+0.1 Tween for 5 minutes. Ttris buffered saline (TBS) was prepared by dissolving 1 
tablet of TBS (pH 7.6, sigma) in 500ml of deionized water. Antigen retrieval was 
performed to unmask antigen epitope by mixing 10ml of concentrated antigen unmasking 
solution (EDTA-NAOH, pH 8.0) with 990ml of distilled water in plastic bucket and 
microwaved at high power for 5 minutes to heat the solution. Slides were transferred into 
a plastic bucket and heated for 15 minutes. After heating, slides were washed two times 
with TBS+0.1 Tween for 5 minutes. Non-specific staining was blocked by addition of 
150µl of casein buffer (diluted x10 stock in DW) to each section and incubation of the 
slides on a rocker for 30 minutes. Sections were incubated with primary antibody (diluted 
in TBS) for 1 hour (Table 2-3). After washing two times with TBS+T, sections were 
incubated with anti-rat IgG (Vector impress, peroxidase) for a further 30 minutes. After 
washing again with TBS+T, sections were incubated with 200µl of DAP substrate 
(prepared by adding 1 drop of chromagen to 1ml of DAP buffer) for 2-3 minutes and then 
slides gently rinsed in tap water. Finally, haematoxylin stain was added to each section 
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and incubated for 20 seconds; slides were then washed with tap water. Slides were passed 
through different dilutions of alcohol and then rinsed in different bath of xylene. Finally, 
slides were mounted using DPX mounting medium and left for a few hours to dry. Liver 
sections were scanned at ×20 magnification using an AxioScan Z1 (Zeiss) slide scanner. 
Depending on the size of the sections, more than 10 random non-overlapping fields of 
view per liver lobe were selected to measure the positive areas of these markers using 
ImageJ software. 
 
Quantification analysis of histological staining using ImageJ program 
 
In order to turn our imaging into quantifiable data, we used ImageJ program to measure 
the intensity of the immunohistochemistry staining in the liver sections. Image needs to 
be opened in the imageJ program and the following steps applied: (1) select (image-split 
channel), this will split the image into black and white which help to clearly distinguished 
between the positive and the negative staining. (2) select (image-adjust-threshold), and 
then moved the sliders manually until all the staining areas become red, the red colour 
indicate the positive area of staining.  (3) click on “set” to see the threshold of the image 
followed by selectin (analyse-measure), % of the area will be displayed in the results 
window and can be saved as the intensity measurement of the positive staining in the 
tissue section. Figure (2-8) below illustrate how to quantify the histological staining using 








Figure 2-8 overview of the analytical process of the quantification analysis of histological 
staining using ImageJ program.  
 
 


















































































































2.14 Apoptosis Staining (TUNEL assay) 
 
Liver DNA damage of apoptotic cells was verified using terminal deoxynucleotidyl 
transferase-mediated biotinylated- dUTP nick-end labeling (TUNEL) staining. Apoptotic 
cells in liver sections were identified by using the In-Situ Cell Death Detection Kit 
Fluorescence (Roche Applied Science, UK), following the manufacturer’s instructions. 
Paraffin sections were de-waxed and rehydrated as described previously. Sections were 
then rinsed with PBS for 5 minutes and antigen retrieval was performed to unmask 
antigen epitope. This was done by microwaving the solution at high power for 10 minutes. 
Non-specific staining was blocked by adding casein buffer to each section and incubated 
for 30 minutes. Sections were washed in PBS for 5 min and 50 µl of TUNEL reaction 
mixture were added to each slide and incubated for 60 min at 37 °C. The sections were 
washed three times with PBS and the nuclei were stained with DAPI staining. Finally, 
slides were mounted with coverslips using DPX and imaging for each slide was taking 
using light microscopy (Carl Zeiss AG).  
 
2.15 RNA Isolation and Quantitative Polymerase Chain Reaction 
(qPCR) Analysis 
Liver tissues were immediately snap frozen in liquid nitrogen and then stored at -80°C 
until mRNA extraction. Tissue samples were thawed on ice and mRNA extraction was 
carried out using an RNeasy mini kit in accordance with the manufacturer’s instructions 
(74104; QIAGEN). RNA was also extracted from freshly cultured MSCs using an 
RNeasy micro kit in accordance with the manufacturer’s instructions (74004; QIAGEN). 
Briefly, liver tissue (~30 mg) was transferred into gentle MACS “M” tube with 600 µl of 
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RLT buffer and homogenized using a Gentle MACS Dissociator. 600 µl of 70% ethanol 
was added to the lysate and mixed well by pipetting. The samples were transferred to an 
RNeasy spin column and placed in a 2-ml collection tube, centrifuged at 13.000 rpm for 
15 seconds, the supernatant was then discarded. Samples were washed with 600 µl RW1 
buffer then centrifuged at 13.000 rpm for 15 seconds. Samples were washed again twice 
with 500 µl and centrifuged at 13.000 rpm for 15 seconds. The RNeasy spin column was 
replaced with new collection tubes and the old collection tubes discarded. They were then 
centrifuged at 13.000 rpm for 1 min. Finally, the RNeasy spin column was placed in an 
Eppendorf and 40 µl RNase free water was added directly to the spin column membrane. 
The column was centrifuged at 13.000 for 1 min to elute the RNA, this step repeated 
twice to yield 80 µl of RNA. Following RNA extraction, mRNA concentration and purity 
of each sample was measured using a Nanophotometer (Gene flow Ltd).  
A total of 5 µg of mRNA was transcribed to complementary DNA (cDNA) using 
Superscript II reverse transcriptase kit (18064014; Invitrogen, UK) using a standard 
protocol. In brief, the final reaction was incubated for 10 minutes at 25°C, followed by 
50 minutes at 45°C, and finally by heating at 70°C for 15 minutes. The cDNA was then 
amplified by qPCR for each sample in triplicates using probes listed in (Table 2-4) and 
TaqMan Universal master mix ii kit (4304437; Applied Biosystems, UK). PCR was 
performed using a Roche Light cycler 480 machine (Roche, UK).  Initially reactions were 
incubated at 95°C for 10 minutes, followed by 50 cycles at 95°C for 10 seconds, 55–60°C 
for 50 seconds and 72°C for 1 second. Cycle thresh hold (Ct) for relative quantification 
of genes of interest were normalized to the appropriate housekeeping gene, GAPDH 
(Mm99999915_g1; Applied biosystems, UK). Relative expression levels were shown as 
fold change compared with the appropriate untreated control samples. Quantification of 
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the gene expression was calculated using the ∆∆Ct method. For each sample, the average 
of Ct values was taken, and the average Ct value for GAPDH was subtracted from the Ct 
value for the gene of interest to give ∆Ct (Ct (gene of interest- Ct control (GAPDH)). 
The ∆∆Ct value was calculated by subtract the ∆Ct for the treated sample from the ∆Ct 
of untreated. Then the relative quantification (RQ) values for each sample were 
determined using the following formula: QR= (2^-∆∆Ct). 
 
 




Gene description Species  TaqMan assay ID 
SOD1 superoxide dismutase 1 Mouse  Mm01344233_g1 
SOD2 superoxide dismutase 2 Mouse Mm01313000_m1 
SOD3 superoxide dismutase 3 Mouse Mm01213380_s1 
GSS glutathione synthetase Mouse Mm00515065_m1 
CAT Catalase Mouse Mm00437992_m1 
IHD-1 isocitrate dehydrogenase 1 Mouse Mm00516030_m1 
HO-1 heme oxygenase 1 Mouse Mm00516005_m1 
NOS2 nitric oxide synthase 2 Mouse Mm00440502_m1 
P62 sequestosome 1 ( P62 ) Mouse Mm00448091_m1 
Bcl-2 Bcl-2 Mouse Mm00477631_m1 
Cyp2e1 Cyp2e1 (cytochrome P450) Mouse Mm00491127_m1 
ICAM-1 intercellular adhesion molecule 1 Mouse Mm00516023_m1 
VCAM-
1 
vascular cell adhesion molecule 1 Mouse Mm01320970_m1 
Pecam1 platelet/endothelial cell adhesion 
molecule 1 
Mouse Mm01242576_m1 
Bcl2l1 BCL2-like 1 Mouse Mm00437783_m1 










2.16 Assessment of liver function 
 
At the indicated time points after MSC administration, mice were anesthetized with 
isoflurane in 100% oxygen for 3-5 minutes. Blood was collected by cardiac puncture and 
blood was placed in a tube until further processing. Blood was then centrifuged at 10000 
rpm for 10 minutes to separate the serum which was placed into a new Eppendorf for 
evaluation of biochemical markers. The levels of serum alanine transaminase (ALT) and 
aspartate transaminase (AST) were measured by an Olympus AU400 analyzer (Beckman 
Coulter, Brea, CA) at the clinical biochemistry laboratory of the Women’s Hospital 
Birmingham (Birmingham, United Kingdom). 
 
 
2.17 Inflammatory cytokine detection by multiplex immunoassay  
 
Blood samples were collected from each mouse and serum was obtained by centrifugation 
at 10000 rpm for 10 minutes. Serum samples were stored at -80 until the analysis day. 
Mouse Cytokine / Chemokine Magnetic Bead Panel kit (Merck Millipore, 
MCYTOMAG-70K-PMX) were used in this study to measure different cytokines and 
chemokines in mouse serum. This assay was performed according to the manufacturer’s 
instructions. Cytokines measured in this assay were granulocyte colony stimulating factor 
(G-CSF), Eotaxin, granulocyte monocyte colony stimulating factor (GM-CSF), INFg, 
IL1b, IL6, IL7, IL10, LIX, IP10, keratinocyte chemoattractant (KC), monocyte 
chemoattractant protein (MCP1), macrophage inflammatory protein (MIP1a), and TNF-





2.18 Cytokine Treatment of MSC 
 
MSCs were seeded in six-well plates at a density of 4,000 cells per square and cultured 
until 70–80% confluency. Fresh MSC media contained recombinant human TNF-α or 
IFN-γ (R&D Systems UK) at a final, concentration of 10 or 20 ng/ml. After 24 and 48 
hours of treatment, cytokines were washed with PBS buffer and MSCs were detached and 
used for gene expression analysis. 
 
2.19 Statistical analysis.  
 
Statistical analysis of all data was performed using Prism 7.00 software (GraphPad, CA). 
Normality tests were applied by using D’Agostino-Pearson omnibus or Shapiro-Wilk 
normality tests. For parametric data, statistical significance was analysed using unpaired 
Student t-test. If the data were non-parametric, the Mann-Whitney U test was applied to 
test for significance. One-way ANOVA was used to compare between two different 
groups or Kruskal-Wallis test, if the data were non-parametric. The results were reported 
as the mean ± SEM unless otherwise noted.  Differences were considered statistically 






















CHARACTERIZATION OF MESENCHYMAL STROMAL 





















3.1 Introduction  
 
 
Mesenchymal stromal cells (MSCs) are a subtype of adult fibroblast-like cells that have 
the capacity of self-renewal with high proliferative ability. They can undergo tri-lineage 
differentiation both in vivo and in vitro down connective tissue lineages to become 
osteoblasts, chondrocytes and adipocytes. Furthermore, MSCs have been defined on the 
basis of their surface antigen expression of CD105, CD73 and CD90 by flow cytometric 
analysis.  Additionally, these cells should lack expression of CD11b, CD79a, CD19, and 
HLA class II, and should not express haematopoietic markers such as CD45, CD34, and 
CD14. (Kim et al., 1994) 
 These cells are found in various human tissue, including synovial membrane(Ogata et 
al., 2015), adipose tissue (AT)(Melief et al., 2013b), umbilical cord blood (UCB)(Lee et 
al., 2004a), amniotic fluid (AF)(Zagoura et al., 2012) and placenta(LI et al., 2005). 
Umbilical cord tissue (UC) has been a particularly promising source of MSC - cells can 
be isolated from several compartments within UC including umbilical vein, umbilical 
arteries, umbilical cord perivascular tissue, Wharton’s jelly and sub-amniotic tissue. 
Furthermore, MSCs isolated from UC tissue are believed to have more proliferation 
potential than other cells isolated from other tissues and are found in higher numbers, 
ensuring this source is gaining prominence.  
MSCs are a heterogeneous population of cells that are phenotypically diverse both 
morphologically and functionally, therefore, sorting of cells based on marker expression 
has been considered to achieve a more homogenous population of cells. This could 
potentially resul in enriched subsets with different therapeutic effects. This does require 
definition of which function is being focused on, and often markers of stem-ness or 
proliferation are reported, whereas immunomodulatory actions may be more important. 
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Sorting of cells for pre-clinical studies is relatively straightforward and can use a range 
of modalities including flow cell sorting which can result in high purity cell yields.  
A recent novel marker, CD362+ (Syndecan-2), has been reported to select a homogeneous 
population of MSCs with superior immunomodulatory properties. This marker was under 
patent number (WO 20131177661 A1) and is owned by Orbsen Therapeutics, Ireland. 
Syndecan-2 is a transmembrane heparin sulphate proteoglycan, which contributes to 
several biological functions; it can contribute to zebrafish vascular development (Chen et 
al., 2004a), cellular adhesion (Canosa et al., 2017), control apoptosis in osteoblastic 
cells(Modrowski et al., 2005) and is involved in T cell biology (Teixé et al., 2008). 
Syndecan-2 is expressed in different cells throughout the body, which have different 
expression profile under normal or pathological conditions. It is expressed primarily on 
endothelial cells and fibroblasts, although it is also reported to expressed on human 
monocytes and monocyte-derived macrophages (Clasper et al. 1999). Furthermore, PCR 
data reveal that monocyte can produce syndecan-2 in culture upon stimulated with 
cytokines (TNF-a and LPS), interestingly, LPS stimulated monocytes have more 
expression potential than TNF-a stimulated cells. Additionally, syndecan-2 was also 
reported in monocyte derived macrophages (Clasper et al. 1999). Similarly, activated 
CD4 T cells were found to enhance secretion of syndecan-2 (Teixé et al., 2008). More 
recently, This marker was found to have the ability to reduce immunogenicity and play a 
role in immune regulation (De Witte et al., 2017; de Witte et al., 2015).  For example, 
Syndecan-2 has also linked to contribute to modulate T cell biology through regulation 
of  the T- cell receptor (TCR/CD3) complex expression, which can enhance the ability of 
T cell to response to any stimuli (Rovira-Clavé et al., 2012). Although Syndecan-2 was 
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reported to have possible role to control fibrosis by modulate expression of TGF-b in 
fibroblast cells (Chen et al., 2004b).  
 
3.2 Chapter Aims 
 
 
Human umbilical cord MSCs were provided by an industrial collaborator (Orbsen 
Therapeutics, Ireland). Two different cells subsets have been used in this study; unsorted 
UC-MSC and sorted UC-MSC based on expression of CD362. In this chapter, I focused 
on investigating the following:  
 
• To analyze the phenotypic characteristics of both populations of UC-MSCs by 
characterising the expression of MSC surface markers using flow cytometry. 
• Study the multi-lineage differentiation capacity of both populations of UC-MSC 
with regards to adipocyte, chondrocyte and osteocyte lineages.  
• Evaluate the expression of CD362 among MSCs isolated from different donors 















3.3 Results  
 
 
3.3.1 Phenotypic characterization of mesenchymal stromal cells in 
umbilical cord (UC-MSC) 
 
To determine whether UC-MSC had the ability to expand in culture and form a fibroblast 
like cells (spindle shape), they were cultured in AMEM and 10% FBS. The cells 
demonstrated a fibroblast-like appearance as showed in Figure 3-1 and reached 





Figure 3-1 UC-MSCs display fibroblast like cells (spindle shape) morphology (one day 
after culture in AMEM at passage 2). 
 
The presence of positive (CD105 PerCP-Cy™5.5/CD73 APC/CD90 FITC) and negative 
(CD45/CD34/CD11b/CD19/HLA-DR PE) surface antigen markers of UC-MSC was 
determined by flow cytometry. At passage 3 both unsorted (US) and CD362+ sorted UC-
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MSC expressed positive markers (CD90, CD105, CD73, and CD44) and were negative 
for (CD45, CD34, CD11b, CD19, and HLA-DR). There were no significance differences 
in the expression of these antigens between the two cell populations. Figure 3-2 and 
Figure 3-3 represent all the histograms for these markers on unsorted and CD362+ UC-
MSC, respectively. Percentage expression and median fluorescence intensity (MFI) of 







Figure 3-2 Flow cytometric analysis of positive and negative markers expressed on 
unsorted UC-MSCs. Cells were positive for CD90, CD105, CD73 and CD44, but negative 





Figure 3-3 Flow cytometric analysis of positive and negative markers expressed on 
CD362+ sorted UC-MSCs. Cells were positive for CD90, CD105, CD73 and CD44, but 
negative for CD45, CD34, CD11b, CD19 and HLA-DR. 
 
 
Table 3-1  Comparison between percent of expression and median fluorescence intensity 











Unsorted   
cells 
Markers Expression (%) Median Fluorescence 
intensity (MFI) 
CD90 99.97 936.60 
CD105 99.93 67.64 










CD 362 sorted cells 
CD90 100 149.19 
CD105 99.99 60.90 










3.3.2 Unsorted and CD362 sorted UC-MSCs demonstrated 
multipotent differentiation potential in vitro. 
 
To investigate the tri-lineage differentiation potential of UC-MSCs, unsorted and 
CD362+ cells were cultured under standard adipogenic, chondrogenic and osteogenic 
differentiation conditions.  
Adipogenesis: Cells from passage 3 were cultured in 12 well-plates for 14 days in 
adipogenic medium. Lipid vacuoles were observed microscopically in cells along with 





Figure 3-4 Adipogenic differentiation of mesenchymal stromal cells derived from 
umbilical cord tissue. Oil red staining was used to visualize lipid deposition cells. A) Control 
cells. B) US UC-MSCs in adipogenic condition showing some differentiated cells after 14 days 







Chondrogenic differentiation: 2.5 x 105 MSCs were cultured as a pellet and placed in 
chondrogenic differentiation medium. After 21 days, the pellets were snap frozen and 
prepared for frozen sections. The presence of proteoglycans and glycosaminoglycan was 
examined by toluidine blue staining (Figure 3-5). Passage 3 cells were cultured under 
osteogenic differentiation medium, and after 21 days of incubation, cells were stained 
with 1% Alizarin red staining to assess the level of calcium deposition. US and CD362+ 




Figure 3-5 Chondrogenic differentiation of umbilical cord tissue derived mesenchymal 
stromal cells (US vs CD362+ MSCs). A) Control cells. B-C) UC-MSCs (US) and (CD362+) 
cells stained with toluidine blue after chondrogenic induction for 21 days, also the same cells 
were stained with H&E. The entire picture was taking using lower magnification (X10). 
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Figure 3-6 . Osteogenic differentiation of mesenchymal stromal cells derived from 
umbilical cord tissue. Alizarin red staining was used to visualize calcium deposition cells. A) 
Control cells. B) UC-MSCs (US) in adipogenic condition showing low level of differentiated 
cells after 21 days of culture. C) CD362+ UC-MSCs represent trace number of osteocyte-
differentiated cells stained by Alizarin red. 
 
3.3.3 Source and selection of UC-MSCs  
 
 
Using flow cytometry, we investigate the expression of CD362 of MSCs derived from 
different sources, Bone Marrow (BM) and umbilical cord (UC). Notably, MSCs derived 








found to downregulated in BM-MSCs as the number of passage number increase to 
passage 3. However, we observed a stable expression of CD362 in UC-MSCs at the same 
passage number. These results suggested that UC-MSCs have the capacity to express 
CD362 at different passage numbers, whereas BM-MSCs have no expression ability after 
passage 2. Figure 3-7 displays CD362 expression between bone marrow and umbilical 






Figure 3-7 Respresentative histogram of CD362 expression on MSCs  by flow cytometry. 
Expression of CD362 derived from bone marrow ( red line ) and umbilical cord (black line) 
was assessed from different passage number ( P2 and P3). The gray line indicates isotype 











Human Umbilical Cord - Alternative Source of CD362+ MSCs 















3.3.4 CD362 expression pattern differences in UC-MSC donors  
 
To confirm the expression of CD362 from different donors, we performed flow cytometry 
analysis on three donors at different passage numbers (P3 and P4). Based on flow 
cytometric analysis of CD362, I found some differences in the expression of CD362 
between different donors as reported in Figure 3-8. MSCs from donor 1, 2, and 3 
expressed different levels of CD362 (25.4%, 54.1%, and 41.2%, respectively). Similarly, 
the same observation of CD362 expression was also variable between donors at passage 
4 MSCs.  The highest expression in all three donors was in donor 2 (49%), whereas donor 
1 and 3 expressed 34.6% and 44.5%, respectively, as shown in Figure 3-8.    
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Figure 3-8 Screening of CD362 expression in umbilical cord derived mesenchymal 
stromal cells (hUC-MSCs) in different donors. A) a histogram of flow cytometry analysis of 
CD362 expression from different donors ( 1,2, and 3) at different passages (P3 and P4). B) 




3.3.5 Passaging of hUC-MSCs downregulated the expression of CD362 
in culture.  
To see whether culturing has effects on CD362 expression, I then determined the 
correlation between CD362 expression and the culture passage number. I used different 
passage numbers from different donors and the expression of CD362 was investigated 
using flow cytometry. As a result, no changes in CD362 expression were reported in 
MSCs between P3 and P4. In contrast, as shown by Figure 3-9, I determined a significant 
reduction in CD362 between P4 and P5. Percentage expression of CD362 at different 
passages of MSCs is presented in Table 3-2. 























Figure 3-9 Flow cytometry analysis of CD362 expression at the indicated passages ( 




Table 3-2 Flow cytometry analysis of CD362 expression in UC-MSCs from different 
donors and different passages.  
 
 
CD362 expression % 
 P3 P4 P5 
Donor 1 25.4 34.6 21.5 
Donor 2 54.1 49 17.9 






3.4 Discussion  
 
 
Human mesenchymal stromal cells are a sub-type of adult stem cell which was first 
described from bone marrow by Friedenstein et al, in 1968(Friedenstein et al., 1968), and 





















differentiate into several specialized cells with specific functions. Several studies have 
reported the successful isolation of MSC from different tissues, including synovial 
membrane(Ogata et al., n.d.), adipose tissue(Yañez et al., 2006), umbilical cord blood 
(Bieback et al., 2004), amniotic fluid (Antonucci et al., 2011), and placenta(Fukuchi et 
al., 2004). Mesenchymal stromal cells were successfully isolated from human umbilical 
cord and represent an attractive source of MSCs for use in clinical studies. Here, I studied 
two different cells subsets; unsorted UC-MSC and sorted UC-MSC based on expression 
of CD362 (syndecan-2), and the phenotypic characteristics were investigated according 
to the ISCT minimal criteria (Dominici et al., 2006). The morphology of these cells was 
fibroblast-like with spindle shape, resembling MSCs isolated from bone marrow. Flow 
cytometric analysis of expression markers on UC-MSCs in both cells population 
(unsorted and CD362+) confirmed that they expressed (CD90, CD73, CD105, and CD44), 
but did not express hematopoietic markers (CD45, CD34), and some other markers such 
as CD11b, CD19, and HLA-DR. Thus, these findings confirmed that MSCs isolated from 
umbilical cord tissue are similar to other sources of MSCs. 
 
The potential of UC-MSC to differentiate into the adipogenic, chondrogenic, osteogenic 
lineages was investigated. Under chondrogenic culture conditions, hUC-MSC also had 
the ability to form cartilage cells. Osteogenic differentiation of WJ-MSCs was found to 
be not effective with only a small number of cells differentiating under osteogenic 
medium conditions. These findings confirmed a previous study by Ishige et al, that 
indicated that mesenchymal stromal cells derived from hUC demonstrated low level of 
osteogenic differentiation and expressed low level of alkaline phosphatase (ALP), which 
found to have strong correlations with calcifications (Ishige et al., 2009). This finding 
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confirmed that MSCs from different origin could exhibit different level of osteogenic 
differentiation capacity. In addition, I believe we need to increase the time period of the 
osteogenic differentiation in vitro for more than two weeks as the UC-MSCs may have 
slower osteogenic differentiation ability.  
 
Karahuseyinoglu et al. reported that umbilical cord stromal cells could form adipocytes 
(Karahuseyinoglu et al., 2007). In comparison with MSC from BM-MSCs, UC-MSC 
exhibited more significant adipocyte forming cells after 21 days in culture(Baksh et al., 
2007b). In keeping with this, my results also demonstrate that UC-MSCs have adipogenic 
differentiative capacity after 14 days in culture, with lipid vacuoles clearly observed as 
Oil red positive cells. 
 
Cultured MSCs are a heterogeneous population of cells, therefore, sorting is considered 
to achieve homogenous populations of MSC. Several studies have been reported that 
some surface markers have a potential impact in biological function of the MSCs 
(Sherman et al., 2017; Pietilä et al., 2012). However, there are few surface markers that 
are functionally related to immunomodulatory properties of the MSCs.  A recent novel 
marker, CD362+ (Syndecan-2), has been reported to select a homogeneous population of 
MSCs with superior immunomodulatory properties. This marker was under patent 
number (WO 20131177661 A1) and is owned by Orbsen Therapeutics, Ireland. As a 
functional marker for enrichment of MSCs, CD362 has been suggested as a novel marker 
for purifying and sorting MSCs from umbilical cord tissue as it may have potential 
immunosuppressive properties to modulate inflammation in different clinical settings (De 
Witte et al., 2017). Interestingly, CD362 was reported to have possible role to control 
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fibrosis by modulate expression of TGF-b in fibroblast cells (Chen et al., 2004b). 
Although, it was found to upregulated after T cells activation and reported to completely 
related to p38 MAP kinase pathway. This study indicates that CD362 expressions are 
involved in the regulation of T cells proliferation and TNF-a regulation, which therefore 
play a role in immune regulation (Teixé et al., 2008).    
 
Using flow cytometry, I investigated the expression of CD362 across different MSCs 
sources (BM and UC). Both populations were shown to express CD362 at different levels. 
I also found that MSCs from different origins also expressed CD362 at different levels. 
At early passage number (P2), UC-MSCs and BM-MSCs displayed similar expression of 
CD362, although UC-MSCs had more CD362 expression than BM-MSCs after passage 
3. This observation is in line with another study which reported that CD200 was expressed 
predominantly in UC as compared to other different tissue origin of MSCs (Pietilä et al., 
2012).  
 
Additionally, and because MSCs from different donors may have possible variation in 
CD362 expression, I evaluated the expression of CD362 from different donors at the same 
passage number. After validation, I found that MSCs at passage 3 expressed different 
levels of CD362. Moreover, the results from passage four indicated that CD362 level 
varied between different donors used in this study. These differences of CD362 
expression could be due to the difference in the age of donors and the level of CD362 
could be influenced by human aging. My observation was in agreement with studies that 
indicate donor age has an effect on some biological characteristics of MSCs isolated from 
bone marrow(Alves et al., 2012). This finding was also reported in another stem cells, 
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such as hematopoietic stem cells (HSCs)(Chambers et al., 2007). Hence, my observations 
of CD362 expression could have an impact and maintaining expression of CD362 may 
be desirable to improve the quality of MSCs for therapeutic use. 
  
Similarly, some studies have reported that late passage cells may not be functionally 
suitable for transplantation due to the lack expression of relevant cell surface markers. 
Whilst no significant differences were reported in CD362 expression between MSCs from 
passage 3 and 4, my results show a significant decrease in the expression of CD362 by 
passage 5. In general, my results are similar to those reported by Hye Jin et al, who 
reported that CD146 expression markedly decreased in hUC-MSCs by late passage. Their 
marker was reported to have an essential impact on senescence in MSCs(Jin et al., 2016). 
In this respect, and due to the significant reduction of CD362 expression by passage 5, I 
decided that using late passage hUC-MSCs was not appropriate for their therapeutic use. 
 
In summary, this study has clarified that unsorted and CD362 sorted UC-MSCs show 
similar expression of MSCs markers as well as the capacity to undergo tri-lineage 
differentiation in vitro. I also demonstrated that UC-MSCs and BM-MSCs have a 
different expression profile of CD362 expression. Although I have observed a variation 
in CD362 expression, this depends on MSCs passage number, and is markedly reduced 
during longer term passage of hUC-MSCs in culture. Because this chapter was only 
focused on the study of the general characterization of the MSCs in both population, we 
believe that further characterizations of human umbilical cord from both populations are 
required for future work. In addition, investigate the effect of the cells sorting on cellular 
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4.1 Introduction  
 
 
Carbon tetrachloride (CCl4) is a well-known hepatotoxin, which is used to induce liver 
injury in mice. CCl4 is metabolized in the liver and activated by cytochrome P450 
(Noguchi et al., 1982).  This step causes reduction in one electron from the CCl4 and 
forms a highly reactive radical known as trichloromethylperoxyl (CCl3*) (Slater1 et al., 
1985).  These free radicals cause lipid peroxidation and exacerbate cell membrane 
damage (Basu, 2003). A single dose of CCl4 has been used to induce acute liver injury 
(Tuñón et al., 2009). However, the same treatment can be used for a long time, up to 8 
weeks with two injections per week, to develop liver fibrosis, and further dose repetition 
can lead to cirrhosis and, finally, hepatocellular carcinoma (HCC) (Liu et al., 2013).  
CCl4 can also induce liver inflammation by activating macrophages (Kovalovich et al., 
2000; Basu, 2003) and can produce mitochondrial dysfunction (Mitchell et al., 2009a), 
mitochondrial DNA damage, and hepatocyte apoptosis (Shi et al., 1998b). In addition to 
the many aforementioned factors that relate to CCl4 acute liver injury, hypoxia levels 
were also elevated in some studies (Szabo and Petrasek, 2015).  
A number of preclinical studies have used different animal models of acute liver injury 
to investigate the therapeutic efficacy of mesenchymal stromal cell (MSC) therapy. 
However, few studies have taken into consideration the variation observed in animal 
models following liver injury, including time to apply the stem cell injection, and the 
study endpoints in order to evaluate the therapeutic efficacy against liver injury. These 
variations could create some difficulties in drawing conclusions regarding the positive 
impact or efficacy of stem cell therapy. For example, cytokines could not be detected in 
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some animal models after MSC treatment, which could be due to the cytokines reaching 
a peak at an early time point after the injury was induced (He et al., 2016). 
In addition, because the time course of acute liver injury is very short and the regeneration 
process happens quickly, some markers are difficult to detect. I believe that the endpoint 
of liver assessment is crucial and needs to be adjusted according to the stage of the injury. 
It is, therefore, valuable to assess the efficacy of MSCs after infusion according to the 
peak of the biological parameters that need to be investigated.  
4.2 Chapter Aims  
 
 
In this chapter, I will examine the hepatic injury caused by the administration of CCl4 
treatment in mice. The hepatotoxicity of CCl4 was evaluated at different time points (12 
h, 24 h, 48 h, 72 h and 96 h) by measuring hepatic injury, inflammatory response, 
oxidative stress and antioxidants. Other aspects are also briefly discussed with respect to 
CCl4-induced liver injury. The main aims of this chapter are to:  
• Assess the level of liver injury over a four-day period post-CCl4 administration, 
including the quantitative measurement of liver enzymes as well as histological 
damage in the liver tissue.  
• Discuss chemokine and cytokine responses following liver injury, as well as the 
infiltration of immune cells during the course of the liver damage. 
• Measure the gene expression of some biological parameters, including cell 
proliferation, apoptosis, and autophagy along the time course of the injury, for up 
to three days.  
• Determine the dynamic changes in antioxidants and oxidative stress markers 
during the course of the injury.  
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4.3 Results  
 
4.3.1 Induction of CCl4 hepatotoxicity (acute liver injury)   
 
Acute liver injury was induced in mice using a single dose of CCl4. At different time 
points (12 h, 24 h, 48 h, 72 h and 96 h) following CCl4 administration, the mice were 
sacrificed and blood was collected by cardiac puncture to evaluate the level of liver 
enzymes. I observed a significant increase in the serum level of alanine aminotransferase 
(ALT) enzymes after 24 hours and 48 hours, which recovered after 72 hours. ALT activity 
returned to normal levels after 96 hours (Figure 4-1).  
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Figure 4-1 Male C57BL/6 mice show variation in liver enzyme activity at different time 
points after a single dose of CCl4. A) Design of the study: mice received a single 
intraperitoneal injection of CCl4 and liver injury was evaluated at different time points. B) 
Serum ALT was elevated after 12 h and improved with time. Representative data (> 10 mice 
for each time point, except for 5 mice at the 12 h and 96 h time points) from three independent 
experiments are shown. Each value is represented by the mean ± SD. * P < 0.05, ** P < 0.01, 
*** P < 0.001, and **** P < 0.0001.  
 
 
4.3.2 Histological examination of liver injury after injection with CCl4 
 
For the histological examination of liver damage, liver sections from the mice were 
stained with haematoxylin and eosin (H&E). The stained tissue showed massive necrosis 
24 hours after treatment with CCl4 but less necrotic damage was seen after 48 hours (as 
shown by the red arrow in Figure 4-2). Compared with the liver histology in the control 
group (M.O), the greatest amount of infiltration of inflammatory cells was observed 72 
hours after injury (the blue arrows in the figure represent the inflammatory cells).  
 
Cytochrome P450 (Cyp2e1) has been reported to be involved in CCl4 metabolism and 
has an essential role in the development of CCl4 hepatotoxicity in mice (Khan et al., 
2012).  At the beginning of investigating the role of Cyp2e1 in this injury, I found that 
CCl4 caused a significant downregulation in P450 at various stages (12–72 h), as reported 




Figure 4-2 H&E staining of liver sections following treatment with CCl4. Normal hepatic 
histology of the liver is seen from the control mice (M.O). Severe hepatic necrosis around the 
lobular and portal area was reported after 24 h. Liver tissue showed hepatic necrosis with a few 
inflammatory cells in the lobular area 48 h following injury. Massive infiltration of 





Figure 4-3 Gene expression of cytochrome P450 in the liver after CCl4 administration as 
measured by qPCR and normalized to GAPDH; n = 4 per group. Data are presented as the 
mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. 
M.O 24hrs








































4.3.3 Assessment of hepatic inflammatory cell infiltration after a 
single dose of CCl4 by injection 
To investigate the changes in hepatic cell infiltration following CCl4 injury, the 
immunohistochemical detection of CD45 was performed in liver sections across the time 
course of CCl4-induced liver injury in C57BL/6 mice. At different time points, the 
infiltration of hepatic leucocytes significantly increased following CCl4 injury, although 
it was most marked 48 and 72 hours after injury (Figure 4-4). The intrahepatic leucocyte 
count was found to have declined by 96 hours.  
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Figure 4-4 Expression of CD45 in CCl4-injured mouse liver, as determined by 
immunohistochemistry. (A) Representative images of CD45-positive cell stained liver 
sections at 12 h, 24 h, 48 h, 72 h and 96 h following CCl4 administration. In the injured group, 
CD45 expression increased at 24 h, 48 h, and 72 h after administration with CCl4.  (B) 
Percentage of CD45 immuno-positive cells increased over the different time points (24 h, 48 h 
and 72 h) and recovered by 96 h; n  = 5 per group. Data are presented as the mean ± SD. * P < 
0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. Scale bars: 200 µm. 
 
In order to address whether macrophages also infiltrate during injury, I used 
immunohistochemistry (IHC) for F4/80, a specific marker for mouse macrophages, which 
revealed that the percentage of macrophages peaked 72 hours after CCl4 treatment (Figure 
4-5), with a clear reduction after 96 hours. In comparison with the control group, similar 
expression of F4/80 was seen in the injured group at 24 hours and 48 hours, whereas a 
great number of  macrophages infiltrated to the portal area 72 hours after CCl4 treatment, 
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Figure 4-5  Time course of macrophage (F4/80) infiltration in the liver as measured by 
























































sections at 12 h, 24 h, 48 h,72 h and 96 h following CCl4 administration. (B) Infiltration of 
hepatic macrophages after CCl4 peaked at 72 h; n = 5 per group. Data are presented as the mean 
± SD. Scale bars: 200 µm. 
 
4.3.4 Effect of acute CCl4 on the circulating level of cytokines and 
chemokines at different time points 
 
Different studies have reported that leukocyte infiltration is essential for the induction of 
liver injury and depends on cytokine and chemokine expression at an early time point 
(Saiman and Friedman, 2012). In order to determine the level of different pro-
inflammatory and anti-inflammatory cytokines in CCl4-induced liver injury, I performed 
a time course study to observe the level of expression in serum at different time points 
using multiplex immunoassay. Three different pro-inflammatory cytokines were 
measured in this study (tumour necrosis factor alpha [TNFa], interleukin 1 beta [IL-1b], 
and interferon gamma [IFNg]).  
Anti-inflammatory cytokines were also measured in this study. IL-10 was found to have 
modestly increased after 24 hours, but failed to reach statistical significance, and IL-10 
expression gradually decreased with time. Figure 4-6 shows all the cytokines measured 
in this study. IFNg has been reported to have massive variation between animals and in 
some mice levels were not detected in the serum using multiplex immunoassay. Similarly, 
TNFa was found to have variation in expression across the time points tested. 
Accordingly, I performed enzyme-linked immunosorbent assay (ELISA) as a 
confirmatory test to detect the TNFa level in serum. The TNFa  level was significantly 
increased 24 and 48 hours after the CCl4-induced liver injury, as shown in Figure 4-7.  
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To further define the relative contributions of chemokines to liver injury related to CCl4 
hepatotoxicity, I found a significant overexpression of monocyte chemoattractant protein 
1 (MCP-1) and interferon-gamma-inducible protein 10 (IP-10) 24 hours after CCl4 
injection, followed by a reduction over subsequent time points. Macrophage 
inflammatory protein 1 alpha (MIP-1a) and endotoxin showed modest upregulation after 


















































































































































C) Chemokines  
 
 
Figure 4-6 Serum cytokine time course following a single dose of CCl4 treatment.  Serum 
concentrations were measured using multiplex immunoassay. The mean ± SD was used to 
represent the data and five mice were used at each time point. * P < 0.05, ** P < 0.01, *** P < 



























































































































































Figure 4-7 TNFa concentration was determined in the serum using ELISA. Each value is 
represented by the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001; n 
= 5 per group. 
 
4.3.5 Evaluation of cell proliferation, autophagy, and DNA damage in 
the CCl4-injured mice using immunohistochemistry 
 
In order to assess the amount of hepatocyte proliferation after liver injury, I quantified 
the expression of Ki-67 using immunohistochemistry. There was a clear increase in cell 





Figure 4-8 Cell proliferation in CCl4-injured mice at different time points. 
Immunohistochemistry of Ki-67 was used to indicate the number of proliferated cells in the 
liver. The proliferated cells are stained with DAB (dark brown). Scale bars: 200 µm. 
 
To assess whether autophagy was responsible for the hepatic injury induced by CCl4, the 
level of autophagy was also investigated in injured liver across the time points. I evaluated 
the gene expression level of different autophagy markers, such as P62, LC3B and Becl-
2, which play a pivotal role in autophagy progression. LC3B and Becl-2 were highly 
expressed after 24 hours and 48 hours, and LC3B was significantly increased at a later 
time point (72 h). More interestingly, I found that increased expression of P62 was 
reported at an early time point (12 h), as shown in Figure 4-9A. Furthermore, I stained 
liver sections using Beclin-2 to study the autophagy level in the liver tissue. There 
appeared to be an early increase in autophagy after 12 hours, with a peak observed after 
24 hours. Clear reductions were subsequently seen after 48 and 72 hours (Figure 4-9b).    
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Figure 4-9 Autophagy expression in mouse liver after CCl4 administration at different 
time points. A) Gene expression of P62, LC3B, and Becl-2 in the liver after CCl4 
administration, as measured by qPCR and normalized to GAPDH; n = 4 per group. Data are 
presented as the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. B) 
The Beclin-2 level was used to assess the level of autophagy in the liver using IHC. Scale bars: 
200 µm. 
 
Furthermore, I examined the level of DNA damage in the injured liver using IHC with 
Phospho-Histone H2A.X antibody. DNA damage developed early within the cells after 
12 hours, with more cells reported to have DNA damage after 24 hours. Very few cells 
were detected after 48 hours, with no DNA damage after 72 hours. The DNA damage at 
the different time points is shown in Figure 4-10. Similarly, the same observation was 












Figure 4-10 Phospho-Histone H2A.X and TUNEL assay were used to measure the level 
of DNA damage in the liver. Immunohistochemical staining of Phospho-Histone H2A. 
Arrows indicate the positive cells undergoing DNA damage.  
 
4.3.6 Upregulation in antioxidant activities in the liver after CCl4 
injection  
 
I investigated the expression of different antioxidant enzymes in the liver following a 
single dose of CCl4. qPCR was performed using primers for five selected genes to assess 
the different antioxidants and the time course of changes in the liver. Among them, 
catalase and isocitrate dehydrogenase (IDH-1) were reported to have a significant 
reduction in liver tissue 24 hours after the CCl4 liver injury (Figure 4-11). I also observed 
a significant upregulation in the catalase and IDH-1 antioxidant across time points, 
M.O 12 hrs
M.O




mainly after 48 hours and 72 hours, respectively. In addition, superoxidase dismutase 
(SOD) enzymes, including cytoplasmic superoxidase dismutase (SOD1), mitochondrial 
superoxidase dismutase (SOD2), and extracellular superoxidase dismutase (SOD3), are 
also important antioxidant enzymes which protect against oxidative stress. Here, I show 
that SOD1 and SOD2 significantly increased after 24 hours, with no change reported in 
SOD3 at the same point. However, all the superoxide dismutase enzymes were found to 
be highly expressed 48 hours following CCl4 injury (Figure 4-11). GAPDH was used as 






Figure 4-11  Liver antioxidant activities. Gene expression of antioxidant enzymes (SOD1, 
SOD2, SOD3, CAT, and IDH-1) in the liver after CCl4 administration, as measured by qPCR 



































































































































































































and normalized to GAPDH; n = 4 per group. Data are presented as the mean ± SD. * P < 0.05, 
** P < 0.01, *** P < 0.001, and **** P < 0.0001. 
 
4.3.7 Gene expression profiles of GSS, HO-1, NOS2, and HIF1-a 
during liver injury after CCl4 injection 
 
As several studies have shown that oxidative stress and reactive oxygen species (ROS) 
production are related to the liver damage associated with the induction of CCl4 in mice, 
I determined the levels of GSS, HO-1, NOS2, and HIF1-a during liver injury after CCl4 
injection using qPCR. Remarkably, GSS, NOS2, and HIF1-a showed no expression at 
the early time point (12 h) following CCl4, whereas HO-1 expression significantly 
increased and reached a peak at 12 hours. Hepatic GSS level increased in a time-
dependent manner and significantly increased at 24 hours, 48 hours and 72 hours after 
CCl4 administration (Figure 4-12A). I further analysed the dynamic changes in hypoxia 
level as reported using HIF1-a, which represents the most prevalent marker during 
hypoxia. Following CCl4 induction, I observed a markedly increased HIF1-a level at 24 
hours and 48 hours, as shown in Figure 4-12D.  
    



























































































Figure 4-12 Effect of CCl4 on GSS (a), NOS2 (b), HO-1 (c), and HIF1-a (d) expression in 
mouse liver across the time course of the injury (12–72 h); n = 4 per group. Data are 
presented as the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. 
 
4.4 Discussion  
 
 
As mentioned above, CCl4 is a hepatotoxin that has been widely used in animal 
experiments to induce acute and chronic liver injury. However, the time course of acute 
CCl4 injury has not been well defined. Here, I used a single dose of CCl4 to induce acute 
liver injury in mice. I then carried out experiments in order to understand the effects of 
CCl4 treatment at different time points. The level of liver injury in mice was assessed by 
the histological examination of liver sections and liver enzyme activity. More 
specifically, the time course experiments found significant alterations in different 
biological aspects, such as inflammatory response, oxidative stress, levels of antioxidants, 














































































later stages of the liver injury following CCl4 injection. I believe that each time point 
reflects a specific area of interest and should, therefore, be used as a particular time 
window to assess the therapeutic function of treatment against liver disease.   
Previous studies have reported an increase in liver enzymes with histological damage 24 
hours after CCl4 administration in mice (Zahedi et al., n.d.) and rats (Janakat and Al-
Merie, 2002). Our results indicate that, after a single dose of intraperitoneal (IP) CCl4, 
there was a significant increase in liver enzymes after 24 hours and 48 hours, the 
maximum effect being seen after 24 hours. The liver enzymes had recovered somewhat 
by 72 hours. Liver histology showed massive necrotic areas 24 hours and 48 hours after 
treatment with CCl4, with more infiltration of inflammatory cells observed 72 hours after 
injury. I noted that the effect of CCl4 administration in mouse liver had fully returned to 
normal 96 hours after injury.   
Leucocyte infiltration is associated with acute liver injury development and prognosis. 
Here I have demonstrated that inflammatory cells are released during a time course 
following acute liver injury using CCl4. The inflammatory response, as measured by 
CD45 expression, significantly increased after the administration of CCl4 with a 
significant increase after 48 hours and 72 hours. Similar findings have been reported by 
other groups using immunohistochemistry (Karlmark et al., 2009) and flow cytometric 
analysis (Karlmark et al., 2010). Both studies showed the maximum infiltration rate of 
leucocytes at 48 hours after treatment with CCl4; I notably observed in my experiments 
that the leucocyte infiltrates were differentially distributed, with more cells seen in the 
portal tracts than in the lobular area. A clear reduction was reported in CD45 expression 
after 96 hours. Macrophage numbers (F4/80 expression) peaked 72 hours after treatment 
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by CCl4 with clear localization around the portal tracts. However, animal models of liver 
injury have shown some remarkable heterogeneous populations of macrophages with 
distinct functions (Tacke and Zimmermann, 2014). Thus, future work is needed to 
determine which macrophage subsets are involved in responses to CCl4-induced liver 
injury.  
To define the response of inflammatory cytokines or chemokines to liver injury following 
acute CCl4 exposure, a time course study was performed to provide insight into how CCl4 
alters the hepatic expression of cytokines or chemokines at different time points. In this 
study, we used multiplex in particularly because our biological sample (mouse serum) is 
limiting and we want to measure and screen a wide variety of pro- or anti-inflammatory 
cytokines. In general, serum cytokine quantification by multiplex arrays offers the 
potential of evaluating and screen of a wide variety of pro- or anti-inflammatory cytokines 
over ELISA measurements. Despite potential advantages of this new technology, 
experience with these techniques is limited, and it has not emerged to date as the gold 
standard in inflammatory cytokines measurement due to the low specificity and 
sensitivity. In contrast, Enzyme-linked immunosorbent assay (ELISA), the most widely 
used and best validated method, is limited by its ability to measure only a single cytokine 
in each sample and the assay is time consuming and costly. 
Due the measurement issues with multiplex assays and data interpretation, we confirmed 
some parameters using ELISA, In particular TNFa. In case of measuring the TNFa level 
in mouse serum using ELISA or multiplex, we saw clear variability between the lab techs 
who were running the samples using multiplex and our ELISA results in serum TNFa 
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activity. Using ELISA assay, the serum TNFa level was significantly increased 24 and 
48 hours after CCl4 induction.  
Furthermore, IL-6 level was significantly increased 24 hours and 48 hours after CCl4 -
induced liver injury. My findings indicate that cytokine levels correlate with 
hepatocellular damage, as they increased rapidly by 24 hours and, therefore, may have 
the ability to regulate liver inflammation after CCl4 injury. In addition, the development 
of liver injury was significantly correlated with higher expression of chemokines, mainly 
MCP-1 and IP-10. My study indicates that eotaxin and MIP-1a did not show any 
alteration in the acute model of liver injury, but they may have a role in chronic liver 
injury. Further work should consider studying the correlation between these cytokines 
and the level of oxidative stress and autophagy in the acute liver injury induced by CCl4.  
The present study also illustrates that the rate of hepatocyte proliferation (as measured by 
Ki-67 IHC) also increased with time after CCl4 injury. Several studies have reported a 
strong correlation between hepatocyte proliferation and liver regeneration (Fang et al., 
1994).  As seen in liver sections stained with Becl-2, the autophagy level increased after 
24 hours. This finding indicates that necrosis is related to autophagy expression. In 
addition, real-time PCR revealed that mRNA expression of P62 in the liver was 
upregulated at 12 hours and 24 hours after CCl4 injection, and Beclin-2 reached a peak at 
72 hours. This result suggests that P62 activity occurs early in the development of liver 
injury. However, the acute administration of CCl4 in mice did not induce clear 
modifications in the levels of LC3B. The same finding has been reported in different 
studies in relation to acute liver injury. For example, autophagy was shown to increase 
with concanavalin A-induced liver hepatitis (Yang et al., 2010). They found that CCl4 
toxicity induced DNA damage after 12 hours and 24 hours, but few cells were observed 
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in the later points. I believe that the UC-MSC may have some role in DNA repair and 
possibly whether UC-MSC can trigger autophagy to enhance liver regeneration. 
Therefore, the above findings indicated a time point to use for my in vivo experiment.  
Oxidative stress and ROS production play a key role in the progression of the liver 
damage associated with the induction of CCl4 in mice. The present study revealed that 
CCl4 induction in mice markedly increased the expression of GSS, HO-1, and NOS2 
during the time course of liver injury. Remarkably, GSS and NOS2 showed no expression 
at 12 hours following CCl4 induction, whereas HO-1 expression significantly increased 
and reached a peak at 12 hours. Hepatic GSS level increased in a time-dependent manner 
and significantly increased at 24, 48, and 72 hours after CCl4 administration. These 
findings clearly show that oxidative stress induced by CCl4 was correlated with other 
aspects explained earlier, such as cytokines, chemokines, and apoptosis.  
In agreement with the upregulated gene expression of oxidative stress after CCL4 
administration, hypoxia activity was examined using HIF1-a in the liver across the time 
course of the injury. I observed an upregulation of HIF1-a expression at 24 hours and 48 
hours. In this regard, the culture of MSCs under hypoxia has been shown to have a 
potential impact on MSC migration and differentiation (Mohyeldin et al., 2010). 
Accordingly, I suggest that MSCs may play a more important biological function in the 
hypoxic microenvironment.  
In addition, I have reported for the first time a study to evaluate the gene expression of 
five different antioxidants in an injured liver throughout the time course of the injury. I 
found that the levels of antioxidant enzymes exhibited significant variation at different 
time points, with an initial elevation followed by a gradual decline in expression. The 
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variation trends of SOD and catalase at the various times were different. Across the 
antioxidant enzymes tested, I observed that they were expressed the highest on the third 
day, with the greatest reduction observed in catalase and IDH-1 at 12 hours, followed by 
a slower increase. These two antioxidants could be the ones that contribute most to the 
nature of the defence against liver injury. In addition, SOD1, SOD2 and SOD3 peaked 
48 hours after CCl4 induction and then gradually declined at 72 hours. This may have 
resulted from the different factors having different reaction times and secretion peaks, 
which is in line with prior studies. In parallel observations, a previous report demonstrated 
a higher expression of antioxidants following an acute liver failure model induced by D-
galactosamine/LPS (Gal/LPS) (Zeng et al., 2015). In addition, the same finding was 
reported in patients undergoing treatment of acute liver injury.  
 
In summary, the future of developing MSC-based therapies for liver diseases lies in 
understanding the interactions between MSCs and the microenvironment of the injured 
liver. In this in vivo study, I have been able to provide useful evidence of the dynamic 
cellular changes and disease activities involved in acute CCl4-induced liver injury over 
different time points. Following CCl4 injury, a cascade of cellular changes occurs over 
the course of an injury, causing destruction of the liver architecture, enhanced apoptosis, 
oxidative stress, and subsequent infiltration of immune cells to the injured area of the 
liver. The findings of this chapter have important implications for defining the most 
effective study endpoints to use for my in vivo experiment, which aimed at improving the 
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5.1 Introduction  
 
Acute liver failure (ALF) is a common cause of mortality and morbidity. The most 
common aetiologies of ALF are viral hepatitis (B and C) and hepatotoxicity induced by 
overdose of chemicals such as acetaminophen. The latter has been shown to be the most 
common cause of acute liver failure in Western Europe (Bernal and Wendon, 2013) .The 
clinical symptoms of ALF are defined by a rapid loss of hepatocellular function in the 
absence of pre-existing chronic liver disease. Symptoms include hepatic encephalopathy 
and the development of failure in multiple organs (Forbes et al., 2015). In order to treat 
these diseases, liver transplantation is the primary and most effective treatment, however, 
due to the lack of donor organs and difficulties related to immune rejection, alternative 
therapies must be comprehensively studied. Cell-based therapies, and in particular MSC 
therapy, are promising new ways to treat liver diseases.  
 
Stromal cell therapy represents a promising means of treating different liver diseases, and 
is reported to have special characteristics, potentially including the ability to perform self-
renewal, proliferation and differentiation potential compared to more specialised cells 
(Volarevic et al., 2014). Mesenchymal stromal cells from a variety of tissues have been 
shown to support and promote liver resolution after acute injury (Christ et al., 2015). In 
particular, mesenchymal stromal cells derived from human umbilical cord (hUC-MSCs) 
have been used, both in vivo and in vitro, as cell therapy for hepatic disease. Human 
Wharton’s jelly-derived mesenchymal stromal cells have been shown to have a 
significantly higher expression of hepatic-developed markers compared with other 
sources of MSCs, such as bone marrow and adipose tissue (Buyl et al., 2014). The 
efficacy of UC-MSCs in liver disease has been studied in vivo in a mouse model of partial 
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hepatectomy, where, a few weeks after transplantation, UC-MSCs were seen to express 
some hepatic markers, such as albumin and alpha-fetoprotein (AFP). This finding may 
give more insight towards using UC-MSCs as a potential source for treatment of liver 
diseases (Campard et al., 2008).  Another study looked at the ability of hUC-MSCs to 
reduce acute liver injury in mice by either the transplantation of hUC-MSCs or adult 
human hepatocytes (AHHs). In this study, both treatments reduced markers of liver 
injury, although, as supported by other groups, there was a more significant reduction in 
inflammatory cytokines with undifferentiated hUC-MSCs (Zhang et al., 2012). hUC-
MSCs require further studies to better understand their potential efficacy and associated 
mechanism of actions in the setting of liver disease.  
 
Given the above evidence for the effectiveness of MSCs in liver diseases, we investigate 
the possibility of using human umbilical-derived MSCs to repair acute liver injury in 
mice. As we reported previously in Chapter 4, we developed a mouse model to induce 
acute hepatotoxic injury using a single dose of CCl4, and we have successfully 
investigated a time course study to evaluate the biological changes during the time course 
of liver injury. In this study, we examined the therapeutic role of UC-MSCs to protect 
against liver damage caused by CCl4 induction. In addition, we hypothesize that 
enrichment approaches are considered to achieve more homogeneous populations of 
MSCs which may enhance their beneficial effects in liver disease. We used CD362+ 
(Syndecan-2) marker, which has been identified as a novel marker to select a 
homogeneous population of MSCs with enhanced immunomodulatory properties and has 
been recently investigated for its ability to reduce immunogenicity and enhance the 
immunomodulatory ability in liver inflammation (De Witte et al., 2015; 2017). 
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Previously, we demonstrated that the expression of CD362+ was more prominent in 
MSCs isolated from umbilical cord than bone marrow. In addition, we found that the 
expression of CD362+ in the UC-MSCs was gradually decreased after multiple passages 
in culture. Furthermore, we demonstrated that CD362+ suppression was stable until about 
the fifth passage in culture.  To our knowledge, no study has specifically investigated a 
direct comparison of the immunomodulatory properties of unsorted UC-MSCs and 
CD362+ sorted UC-MSCs in vivo. Here, we test the hypothesis that sorting human MSCs 
with CD362 marker would enhance their anti-inflammatory properties. 
 
5.2 Chapter Aims 
 
 
In this chapter, we aim to investigate the immunosuppressive characteristics of 
unsorted/purified human UC-MSCs in vivo using the CCl4 model of acute liver injury. 
The main aims of this chapter are to: 
• Explore the safety and efficacy of MSCs in CCl4 animal model  
• Study the immunomodulatory properties of unsorted (US) UC-MSCs and CD362+ 
sorted UC-MSC to modulate the number of hepatic infiltrating lymphocytes and 
monocytes using flow cytometry analysis  
• Investigate the antioxidant activities of CD362+ sorted UC-MSCs in the CCl4 
animal model 
• Investigate whether UC-MSCs can modulate the autophagy level to improve 




5.3 Results  
 
5.3.1 Examining the correlation between the number of transplanted 
MSCs and the resulting liver function 
 
Different animal models have been used to study the therapeutic potential of MSCs in 
liver diseases. In this chapter, the efficacy of human MSCs was used in acute hepatic 
injury induced by CCl4. Previously, our result showed that the peak of inflammation, as 
reported by hepatic CD45 and F480 expression was 72h after CCl4 induction of liver 
injury. Hence, we decided to analyse the data at 72 hours post-infusion. Four hours after 
CCl4 treatment (1ml/kg body weight), UC-MSCs (US) were infused systemically via the 
tail vein and the effects recorded 72 hours after UC-MSCs infusion; animals were 
sacrificed and blood and liver tissues collected for further investigation (Figure 5-1A). 
 
To optimise MSCs treatment in this animal model, a dose-response with varying infusions 
of unsorted UC-MSCs (2.5x105, 5x105 and 1x106) was undertaken. The activity of liver 
enzymes (ALT) was measured for each animal in order to evaluate the liver injury. As 
shown in Figure 5-1B, the serum ALT levels in the injured mice (CCl4) were clearly 
increased compared with non-injured group (treatment with mineral oil). There was no 
significant decrease in ALT level in both 2.5x105 and 1x106 groups but animals appeared 
to have the same level of improvement. In contrast, the 5x105 showed a variation between 
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Figure 5-1  Analysis of ALT liver enzyme after infusion of different doses of MSCs (US) 
in mice with Acute CCl4. A) Experimental design used in this study, CCl4 or mineral moil 
treatment (1ml/kg body weight) were injected to mice, followed by MSCs infusion after four 
hours. Animals were sacrificed for serum and tissue collection for further study.  B) Serum 
ALT level in normal group with mineral oil (non-injured), injured group (CCl4), and treatment 
groups (CCl4+MSCs). Data are expressed with median value and represent >10 
animals/group. ANOVA with post-hoc analysis was performed. Data are presented as the 




































5.3.2 Unsorted UC-MSC versus CD362+ sorted UC-MSC for the 
treatment of acute liver injury induced by CCl4 injection 
 
 
After CCl4 acute liver injury, unsorted UC-MSC and CD362+ sorted hUC-MSCs were 
infused at two dose levels - 2.5x105 and 1x106.  Liver enzyme (ALT) was measured to 
evaluate the liver injury in each animal. A significant reduction was observed with 
2.5x105 unsorted UC-MSC and CD362+ sorted UC-MSC (Figure 5-2). ALT level was 
reduced after infusion with unsorted UC-MSC and CD362+ sorted MSCs compared with 
CCl4 injury only. We also observed a reduction with 1x106 CD362+ sorted UC-MSC, but 
this did not reach statistical significance. In this study, we also used heat-inactivated 
MSCs, as control group, by heating human MSCs for 10 minutes to 55oC; cells were then 
washed with PBS and used for future experiment. Using flow cytometry, all heated MSCs 

































































Figure 5-2 Analysis of ALT liver enzyme after infusion of two doses of unsorted hUC-
MSCs and CD362+ sorted hUC-MSCs in mice with acute CCl4 injury.  Graph indicates 
serum ALT level in different groups of mice. Data are expressed with median value and 
represent >10 animals/group. ANOVA with post-hoc analysis was performed. Data are 




Figure 5-3 Respresentative histogram of APC/CY7 expression on MSCs  by flow 
cytometry. Expression of APC/CY7 of the unheated (blue line) and heated MSCs (red line). 
Heated MSCs were heated in a heating block for 10 minutes.  
 
 
Histological examination using H&E staining (Figure 5-4) showed a normal structure in 
the control group (treatment with mineral oil) and an abnormal hepatic injury (extensive 
area of necrosis) after treatment with CCl4. In comparison with the injured mice, there 
was less cellular damage in the liver structure with fewer inflammatory cells observed 








Figure 5-4 H&E staining of liver sections after treatment with 2.5x105 of hUC-MSCs. 
Represents structure of the liver sections after control mice (M.O).  CCl4-injured mice, and 
mice undergoing MSCs transplantation following liver injury; a clear improvement of necrotic 
area was noticed with both MSCs treatment group. Scale bars: 200 µm. 
 
5.3.3 Effect of unsorted and CD362+ sorted UC-MSCs infusion on 
hepatic lymphocyte and monocyte populations in CCl4-induced 
liver injury  
 
The immunosuppressive effect of hUC-MSCs from two populations (unsorted hUC-
MSCs and CD362+ sorted hUC-MSCs) on immune cell sub-sets in liver and blood were 




5.3.3.1 Sorted CD362+UC-MSCs reduce hepatic CD45+ immune cells 
 
To examine whether infusion of MSCs could ameliorate liver inflammation of CCl4-
injured mice, we compared the therapeutic potential of unsorted hUC-MSCs and CD362+ 
sorted UC-MSCs after administration of 2.5x105 MSCs by intravenous injection. We 
analysed expression of CD45+ in the liver sections via immunohistochemistry (Figure 5-
5A) and found that both unsorted MSCs or CD362+ sorted MSCs resulted in a significant 
reduction in CD45+ expression in mice injured with CCl4 injection (Figure 5-5A). To 
further show the functionality of transplanted cells, we quantified all CD45 positive 
immune cells isolated from the liver and the blood using flow cytometry analysis. CD362+ 
sorted UC-MSCs-treated mice exhibited significant reduction in hepatic CD45 positive 
cells compared to US UC-MSCs-treated mice. However, we found no significant 
differences in the CD45+ positive cells isolated from blood (Figure 5-5B). 
 












Figure 5-5 CD362+UC-MSCs reduce hepatic CD45+ immune cells. A) Representative 
immunohistochemical (IHC) staining for hepatic CD45+ cells expressed as a percentage of the 
surface area of the field view analysed using ImageJ software (8 animals per group). Scale bars: 
200µm. B) cells were gated from live CD45+ cells isolated from fresh mice livers and blood. 
Data are expressed as the number of infiltrating cells per gram of fresh liver tissue and per 1µl 
of blood (>8 animals per group, 4 animals in the H/A group). Data are presented as the mean 









































































































5.3.3.2 CD362+UC-MSCs reduce total hepatic lymphocytes, non-NK 
cells, and B cells 
Increases of NK, non-NK and B cells can directly contribute to the inflammation 
associated with acute liver injury in mice (Mehal and Friedman, 2007). I further 
investigated the influence of MSCs administration on these immune cells across different 
tissue sources, mainly liver and blood. I show that MSCs transplantation reduces the total 
number of lymphocytes as shown in (Figure 5-6A). In addition, both population of MSCs 
showed significant reduction in hepatic non-NK (CD49-) and B cell (CD19+) numbers. 
(Figure 5-6A). However, administration of US and CD362+ sorted MSCs did not lead to 
changes in the hepatic nor circulating number of NK cells (Figure 5-6B). These results 
provide strong evidence that UC-MSCs decrease the number of hepatic non-NK cells as 
well as B cells.  
 














































































































































































































































































































































Figure 5-6 Analysis of lymphocyte population using flow cytometry analysis. A) Number 
of NK, non-NK and B cells represents a different NK, non-NK and B lymphocyte isolated from 
mouse liver after transplantation with US and CD362 UC-MSCs. Data are expressed by the 
number of infiltrating cells per gram of fresh liver tissue.  B) Number of NK, non-NK and B 
cells in circulating blood following administration of US and CD362 UC-MSCs. Data are 
expressed as the number of infiltrating cells per 1µl of blood.  (>8 animals per group, 4 animals 




Having demonstrated by flow cytometry that there was a significant reduction in the 
number of the non-NK and B cells, I further examined the potential of hMSCs to reduce 
the number of CD3+, CD4+ and CD8+ cells in CCl4-injured mice, but I could not observe 
any significant differences with any of the MSC groups. More importantly, I could not 
report any significance difference between the healthy and CCl4-injured groups in this 
animal model.  Interestingly, significant reductions were observed in circulating numbers 
of CD3+, CD4+ and CD8+ cells 3 days following MSCs treatment, as shown in Figure 5-7.  
 
Because several studies have reported that MSCs can modulate liver inflammation 
through the induction of regulatory T cells (Sivanathan et al., 2015), I investigated 
whether unsorted UC-MSCs and CD362 UC-MSCs could further modulate the 
suppression of T cells through induction of Treg cells. As shown in Figure 5-8, my data 
reported that none of the MSCs (unsorted and sorted CD362 cells) had a significant 
impact on hepatic regulatory T cells (Tregs), as reported by expression of CD3+, CD4+, 
CD25+ and FOXP3+. Overall, my findings indicate that the therapeutic effect of MSCs 
(US and CD362) on CCl4 acute liver injury failed to suppress CD3+, CD4+ and CD8+cells, 
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and to induce the generation of Tregs in the liver. I did however observe an effect of MSC 






Figure 5-7 The numbers of infiltrating CD3+, CD4+ and CD8+ cells in the livers and blood 
of CCl4-injured mice were quantified by flow cytometry three days after treatment with 
UC-MSCs.  All cells were gated from live cells isolated from the fresh mice livers and blood. 
Data are expressed as the number of infiltrating cells per gram of fresh liver tissue and by the 
number of infiltrating cells per 1µl of blood.  (>8 animals per group, 4 animals in the H/A 
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Figure 5-8 The generation of regulatory T cells following UC-MSCs infusion. (A)  
representative diagram shows the gating strategy used for analysis of Tregs. B) The generation 
of regulatory T cells in the liver of CCl4-injured mice was quantified by flow cytometry. All 
cells were gated from live CD3+CD4+CD25+FOXP3+ cells isolated from the fresh mice livers. 
Data are expressed as percentages (%) and the number of cells per gram of fresh liver tissue. 
(>8 animals per group, 4 animals in the H/A group). Data are presented as the mean ± SD. *P 
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5.3.3.3 Flow cytometric analysis of intrahepatic monocyte sub sets in 
mice with CCl4-induced liver injury after treatment with UC-
MSCs  
 
Following CCl4, the number of hepatic infiltrating macrophages peaked at 72 hours (as 
reported previously in Chapter 4). I further analysed the ability of MSCs to modulate 
monocyte subsets in mice with acute CCl4 liver injury. Three days following intravenous 
administration of MSCs, immune cells were isolated from mouse liver and blood and 
analysed using flow cytometry. I observed a remarkable increase in the total CD11+ cells 
and CD11+ F4/80+ in CCl4-injured mice when compared to the normal mice treated with 
mineral oil (Figure 5-9A). In comparison to the CCl4-injured mice, I reported that US and 
CD362 MSCs significantly downregulated the number of macrophages (CD11+ F4/80+) 
in the liver, but did not show any significant observation in circulating monocytes (Figure 
5-9A). Further quantification of F4/80 positive cells on liver section using IHC provided 
a similar observation, which resulted in a decreased level of macrophages following 
CD362+ MSCs administration (Figure 5-9B). Together, these results indicated that 
CD362+ sorted MSCs reduce the number of hepatic macrophages, suggesting that MSCs 
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Figure 5-9 CD362+UC-MSCs reduce hepatic F4/80+ immune cells in mice injured with 
CCl4 induction. A) Cells were gated from live CD11b+ F4/80+ cells and isolated from fresh 
mice livers and blood. Data are expressed by the number of infiltrating cells per gram of fresh 
liver tissue and per 1µl of blood (>8 animals per group, 4 animals in the H/A group). B) 
Representative immunohistochemical (IHC) staining for hepatic F4/80+ cells expressed as a 
percentage of the surface area of the field view analysed using imageJ software (8 animals per 
group). Scale bars: 200µm. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01 and 
***P < 0.001. 
 
 
5.3.3.4 Administration of UC-MSCs fails to induce macrophage 
polarisation from classically-activated M1-phenotype towards 
alternatively-activated M2-phenotype in inflamed murine liver. 
 
 
To further characterise the changes in the infiltrated macrophages, I quantified and 
phenotyped different macrophage populations using flow cytometry. In the present study, 
the macrophage markers (F4/80) and (Ly6C) were used to identify two distinct 
populations of macrophages; CD11b+ F4/80 Ly6Chi was used to characterise the pro-
inflammatory M1-phenotypes (classical macrophages) whereas CD11b+ F4/80 Ly6Clo 
(Alternative macrophages) was used for anti-inflammatory M2-phenotypes (Figure 
5-10A). To determine the role of MSCs function in macrophage polarisation, I compared 
the immunosuppressive ability of US and CD362 UC-MSCs on M1 and M2-like cells 
isolated from mouse liver. Based on the flow cytometry data, MSCs had no effect on the 













Figure 5-10 The effect of UC-MSCs infusion on the M1 and M2 macrophages.                                    
A) Representative diagram shows the gating strategy used for analysis M1 and M2-like cells. 
B) The total number of CD11b+ F4/80 Ly6Chi classically-activated pro-inflammatory M1-
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injured mice were quantified by flow cytometry analysis. The percentage of M1 cells, M2 cells 
of fresh liver tissue of CCl4 mice receiving either 250K US UC MSC or CD362+ UC MSC were 
quantified and compared to the injured group. M1/M2 ratio expressed the proportion of M1 
and M2 cells in the liver tissues. Data are expressed as percentages (%) of fresh liver tissue. 
(>8 animals per group, 4 animals in the H/A group). Data are presented as the mean ± SD. *P 
< 0.05, **P < 0.01 and ***P < 0.001. 
 
 
Next, I further analysed the influence of CD362+ MSCs as well as US MSCs on the levels 
of neutrophils in liver and blood at 72 hours post-CCl4 injury. Compared with that in the 
CCl4-injured group, the degree of infiltration of CD11b+ Ly6G+ cells (neutrophil) was 
markedly decreased in both MSCs treatment, but I observed a significant reduction in the 




Figure 5-11 The effects of UC and CD362 MSCs on expression of the inflammatory 
neutrophil in the liver and blood at 72 hours post-CCl4 treatment. Neutrophils were gated 
from live CD11b+ and Ly6G+ cells isolated from the fresh mice livers and blood. Data are 
expressed by the number of infiltrating cells per gram of fresh liver tissue and per 1µl of blood 
(>8 animals per group, 4 animals in the H/A group). Data are presented as the mean ± SD. *P 
























































































5.3.4 Evaluating the oxidative stress and antioxidant markers in CCl4 
mice undergoing MSC transplantation 
 
Oxidative stress and free radicals are two main observations in the mouse liver following 
CCl4 induction. Oxidative stress can be measured by the quantified number of free 
radicals in the liver. Here, I used the Thiobarbituric acid reactive substances (TBARS) 
assay to detect the level of oxidative stress using liver lysates from CCl4-injured liver 
following MSCs injections. Three days following MSCs administration, a pattern of 
increase in TBARS contents in the liver samples was observed but did not reach statistical 
significance (Figure 5-12A). Moreover, additional experiments were performed to 
investigate other markers, such as HO-1, GSS and HIF1-a, in the mouse liver using 
qPCR. I found that hepatic expression of HO-1 was significantly down regulated 
following MSCs injections (Figure 5-12B). Another contradictory finding was reported 
in HIF1-a expression, which was shown to have significantly increased with MSCs 
treatment as compared with the CCl4-injury mice treated with PBS, as shown in  Figure 
5-12B.  GSS gene expression levels were still elevated after 72 hours of CCl4 treatment 
and declined slightly after exposure to MSCs infusion.  
 
Antioxidants provide a first line of defence against oxidative stress derived from injured 
tissue. In this experiment, I examined whether MSCs could modulate oxidative stress 
through secretion of antioxidants to treat the liver damage caused by CCl4 induction. In 
line with my previous findings, I found that antioxidants levels were changed gradually 
through the time course of the injury, with variation across the different antioxidants 
tested. Accordingly, I used two time points (24 and 72 hours) to evaluate the correlation 
between MSCs and antioxidants level in the liver. Data indicated that, after MSCs 
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administration, the CCl4-injured mice exhibited different expression profiles of SOD1, 
SOD2, SOD3, IDH-1, and catalase after 24 hours of MSCs infusion (Figure 5-13). No 
differences were observed between the untreated and MSCs-treated mice at this time 
point (24 hours). However, expression of IDH-1 gene appeared to have significantly 
increased after 72 hours of MSCs injection, whereas SOD2 exhibited a pattern of low 
expression (p 0.0684) compared to the untreated group. I did not notice any changes in 
the expression of SOD1, SOD3 and catalase. 
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Figure 5-12 Evaluation of in vivo oxidative stress in liver samples obtained from mice 
undergoing MSCs transplantation. A) TBARS levels were measured from liver lysate 72 
hours following MSCs administration (7-8 animals per group). Gene expression of GSS, HO-
1 and HIF1-a in the liver after MSCs administration in CCl4-injured mice was measured by 
qPCR and normalised to GAPDH B. (>8 animals per group, 4 animals in the H/A group). Data 
























































































































































































































































































































































































































































































































































Figure 5-13 Analysis of gene expression of antioxidant in the liver at 24 and 72 hours 
following MSCs treatment. Changes in the hepatic gene expression of SOD1, SOD2, SOD3, 
IDH-1 and catalase in CCl4-treated mice receiving 250K CD362+ UC MSC quantified by q-
PCR (4-8 animals per group). Data are presented as the mean ± SD. *P < 0.05, **P < 0.01 and 
***P < 0.001. 
 
 
5.3.5 Evaluating the anti-apoptotic markers in CCL4 mice undergoing 
MSC transplantation 
 
I next performed experiments to investigate whether anti-apoptotic markers related to 
MSCs administration may be critical in these experimental conditions. Figure 5-14 
presents the qPCR results of Birc5 and Bcl2l1 in mouse liver form both injured as well 
as the MSCs treatment group.  The expression of Birc5 gene was found to be extremely 
high three days following liver injury induced by CCl4, whereas Bcl2l1 expression was 
not found to change. I compared the expression of Birc5 and Bcl2l1 three days following 
MSCs transplantation, with no difference observed when compared to injured mice 
treated with PBS (Figure 5-14).  










































































Figure 5-14 Birc5 and Bcl2l1 gene expression in CCl4-injured liver after treatment with 
MSCs. (4-8 animals per group). Data are presented as the mean ± SD. *P < 0.05, **P < 0.01 
and ***P < 0.001. 
 
5.3.6 Effect of MSC transplantation on the expression of surface 
adhesion molecules  
Two adhesion molecules, in particular, intracellular adhesion molecule (ICAM)-1 and 
vascular cell adhesion molecule (VCAM)-1, have shown to mediate the 
immunosuppressive function of MSCs via direct adhesion of MSCs to the immune cells 
(Chamberlain et al., 2011).  To assess whether adhesions molecules were expressed in 
the hepatic injury induced by CCl4, I evaluated the expression of ICAM and VCAM 
markers using qPCR as well as IHC. I found that ICAM and VCAM were highly 
expressed after 72 hours of CCl4. More importantly, I explored the role of MSCs 
transplantation in the level of ICAM and VCAM adhesion molecules 72 hours following 
MSCs infusion.  I observed a similar induction of ICAM (Figure 5-15) and VCAM (Figure 
5-16) in the MSCs-treated mice as compared to CCl4-injured mice treated with PBS.  
 










Figure 5-15 Effect of CD362+UC-MSCs treatment on the hepatic ICAM-1 expression in 
the murine model of acute CCl4. A) representative immunohistochemical (IHC) staining for 
hepatic ICAM+ cells. B) quantification of ICAM+ cells expressed as a percentage of the surface 
area of the field view analysed using imageJ software (8 animals per group). C) Changes in 
hepatic ICAM-1 mRNA expression in CCl4-treated mice receiving 250K CD362+ UC MSC 
quantified by q-PCR (4-8 animals per group). Scale bars: 200µm. Data are presented as the 












































































Figure 5-16 Effect of CD362+UC-MSCs treatment on the hepatic VCAM-1 expression in 
the murine model of acute CCl4. A) Representative immunohistochemical (IHC) staining for 
hepatic VCAM+ cells. B) quantification of VCAM+ cells expressed as a percentage of the 
surface area of the field view analysed using imageJ software (8 animals per group). C) 
Changes in hepatic VCAM-1 mRNA expression in CCl4-treated mice receiving 250K CD362+ 
UC MSC quantified by q-PCR (4-8 animals per group). Scale bars: 200µm. * Data are 







The therapeutic potential of hUC-MSCs has been previously reported, but few studies 
have reported their effects in different animal models of acute liver injury (Burra et al., 
2012; Zhu et al., 2013). These studies reported that transplanted mesenchymal stromal 
cells migrated to the site of chronic liver injury.  
 
To address whether UC-MSCs have a therapeutic role in liver injury, I used a CCl4-






























































MSCs in a liver injury model induced by CCl4 using CD362+ sorted UC-MSC and 
unsorted UC-MSCs. In this study, an efficacy dose-response with hUC-MSCs (2.5x105, 
5x105 and 1x106) was assessed in acute CCl4 liver injury. I observed that both 2.5x105 
and 1x106 dose appear to have the same level of improvement, however, the 5x105 dose 
shows extensive variation between animals, with an increase in ALT in some mice. 
Accordingly, I excluded the 5x105 dose and used 2.5x105 and 1x106 in my further 
experiments.   
The liver injury, as measured by serum ALT level, was not statistically significant in the 
dose response study (Figure 5-1), we can claim that it may simply related to using MSCs 
with late passages or lack of experience which caused technical limitation, especially in 
the MSCs infusion in vivo.  We believe we overcome these limitations with more 
improvement in the technical skills and performed our in vivo experiment using MSCs 
with low passage number. 
According to the above finding, head-to-head comparison between unsorted and CD362+ 
purified hUC-MSCs was performed using two different doses (2.5x105 and 1x106). A 
significant reduction in serum ALT was reported with infusion of 2.5x105 CD362+ UC-
MSCs as well as US MSCs. My results indicate that the sorted cells have similar efficacy 
as unsorted cells in liver injury and that the low dose (250x103) effectively reduced 
inflammatory liver injury. In addition, my pathological examination of liver morphology 
by H&E staining revealed that liver necrosis resulted from CCl4 injury is reduced after a 
single dose of UC-MSCs.  
 
According to the above findings, I suggest that MSCs derived from umbilical cord could 
have immune regulatory properties to reduce the liver injury induced by CCl4, and I 
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believe this could be a potential mechanism to further explain. As I have previously 
shown (Chapter 4), acute liver injury induced by CCl4 is characterised by increased 
infiltrating of immune cells in the liver tissue. Here, I further investigated the correlation 
between the acute liver injury and immune cells using flow cytometric analysis; 
circulating immune cells were also reported in this study. In response to injury, I found a 
significant increase in the immune cells, expressed by CD45+ isolated from liver, with no 
difference reported in the immune cells isolated from the blood. I also found that 
circulating immune cells did not correlate with the number of CD45+ cells isolated from 
the liver. I believe that MSCs could have recruited some immune cells from circulation 
to the inflamed liver. 
 
Recent evidence has  shown that MSCs have an immunomodulatory function mediated 
by an interaction between immune cells in the tissue microenvironment and transplanted 
MSCs (Shi et al., 2012). The present study was designed to investigate if CD362+ enriched 
MSC had superior efficacy to unsorted MSC. There was no convincing difference 
although CD362+ sorted MSCs did not occasion have greater efficacy. This marker was 
found to play an essential role in immune regulation by reducing the immunogenicity (De 
Witte et al., 2017; de Witte et al., 2015). It has linked to contribute to modulate T cell 
biology through regulation of  the T- cell receptor (TCR/CD3) complex expression, which 
can enhance the ability of T cell to response to any stimuli (Rovira-Clavé et al., 2012), 
and reported to have possible role to control fibrosis by modulate expression of TGF-b in 
fibroblast cells (Chen et al., 2004). According to the CD45 immunohistochemistry 
staining, the expression of leukocytes at the injured area of the liver was significantly 
decreased in the CD362+ MSCs treatment group compared to US MSCs. This was 
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confirmed by the total of CD45 positive immune cells isolated from the liver using flow 
cytometry. According to the flow cytometry data, we only observed reduction in the 
CD45+ with the CD362 sorted MSCs. The reason why the unsorted cells did not reduce 
the hepatic CD45 positive cells is could be due to the low sample size in the unsorted 
MSCs treatment group comparing to the CD362+ sorted cells. More interestingly, MSCs 
in both conditions failed to modulate systemic immune cells.  
 
The improvement in the liver injury following MSCs transplantation in this study could 
come from the ability of MSCs to modulate the liver inflammation through reduction in 
NK, non-NK and B cells. I compared the effects of MSCs on T cell lymphocyte obtained 
from different sources of CCl4-injured mice (peripheral blood and liver). Three days after 
systemic perfusion of US and CD362 MSCs, a significant reduction in the non-NK cell 
as well as B cells was observed, as compared to CCl4-injured mice treated with PBS. A 
similar phenomenon has also been reported by several studies, showing that MSCs can 
inhibit the proliferation and activation B cell as well as differentiation of B cell to plasma 
cells with immunoglobulin production ability (Corcione et al., 2006).  Consistent with 
this, it has been shown by Ribeiro et al. (2013) that MSCs can indirectly inhibit B cell 
function by hampering their proliferation and activation. In the normal liver, B cell 
counting for up to 8% among all the lymphocyte population and get expanded in high 
number following liver inflammation (Robinson et al., 2016). Although another study 
reported that B cells were found to accumulate in the liver fibrosis and increased disease 
progression (Novobrantseva et al., 2005).  
 
 154 
The potential cause for the differences observed in intra-hepatic B cells could come from 
the inhibitory effect of MSCs on B cell proliferation, activation, or ability to differentiate 
to plasma cells. This suppressive effect on the B cells could be associated with expression 
of some molecules on MSCs. For example, PD-L1 and CCL2 were reported to MSCs 
inhibition of B cells (Ribeiro et al., 2013). It is still unknown whether these factors 
released by MSCs on direct contact with B cells or required activation signal from B cells 
to enhance their immunoregulatory action.  Another interesting point that remains to be 
studied in the future is the potential of MSCs to induce pro-tolerogenic B cell subsets in 
the liver microenvironment that have themselves provide immunomodulatory properties. 
 
Furthermore, significant reduction was reported in the same immune cells isolated from 
peripheral blood. These findings could represent a possible explanation for the capacity of MSCs 
to reduce inflammation in the liver injury in this murine model. These observations indicative 
of endocrine or/and paracrine between MSCs and circulated immune cells and vice versa. 
We believe the changes induced by MSCs in the peripheral blood immune cells are 
associated with cytokines profiles released after MSCs administration. Abroad spectrum 
of factors produce by MSCs have been reported in different study, including HGF, EGF, 
VEGF, stromal cell-derived factor-1, IL-10, and IL-6 (Chao et al., 2014). Further study 
using  UC-MSC-conditioned medium are necessary to confirm that paracrine factors of 
UC-MSCs alone could enhance the liver injury through several mechanisms. In addition, 
Use of MSC-derived exosomes or microvesicles in different diseases condition have 
shown therapeutic potential such as the ability to avoid transfer of apoptotic cells which 
may have influence in the activation of the local immune system. Also, exosomes or 
microvesicles are small and circulate easily whereas MSCs are too large to circulate easily 
through capillaries and many not get to the site of injury.  
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Concerning the ability of MSCs to immune modulate the T cell subpopulation, MSCs 
from different sources have been reported to inhibit proliferation of CD3+, CD4+ and 
CD8+ lymphocyte in vivo and in vitro ( Li et al., 2012; Bernardo and  Fibbe, 2013). In 
line with these previous findings, I evaluated the therapeutic efficacy of MSCs to reduce 
T cell subpopulations by investigating the effect of US and CD362 sorted MSCs on CD3+, 
CD4+ and CD8+ T lymphocytes. I showed that the hepatic expression of CD3+, CD4+ and 
CD8+ were not changed by MSCs treatment, this could be due to the failure of these mice 
to develop a significant increase in CD3+, CD4+ and CD8+ after inducing CCl4 injury.  
 
More interestingly, I found that US and CD362 sorted MSCs equally targeted blood 
circulation of CD3+ and CD4+ causing a significant reduction of their number in vivo. 
This beneficial result could be explained by the fact that UC-MSCs enhanced their anti-
inflammatory properties through secretion of chemokines, or could trigger the secretion 
of angiogenetic factors, such as VEGF, FGF, and CXCL9 (Gu et al., 2017) . Another 
possible action could come from the fact that that microenvironment of the inflammation 
could trigger the MSCs to recruit more anti-inflammatory cells or differentiate some 
immune cells towards a regulatory phenotype to modulate the immunomodulatory 
function. Another reason might be that CD362+ MSC secreted more cytokines and 
chemokines compared with US UC-MSCs; these factors could directly promote the 
recruitment of CD4 and CD3 lymphocyte from circulation to the inflamed liver.  
 
Overall, I believe that MSCs may have a primary paracrine effect, but not through a direct 
interaction with injured liver cells.  Further work needs to be considered to investigate 
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the therapeutic potential of a cell free condition medium derived from MSCs and confirm 
the potential of MSCs to act in a paracrine manner. In parallel observations, recent studies 
have shown that MCSs’ paracrine function could be considered as a primary mechanism 
for the therapeutic effect of MSCs against tissue injury (Ranganath et al., 2012).  
 
Consistent with results obtained in CD3+, CD4+ and CD8+, I did not show any significant 
differences in the CD4+ CD25+ FOXP3+ Tregs isolated from mouse liver following MSCs 
treatment, although there were no significant differences in the percentage of the Tregs 
following administration of US and CD362 sorted MSCs. Together, the above findings 
clearly demonstrate that in this model MSCs were not able to promote the generation of 
regulatory T cells and suggests that other regulatory mechanisms are involved in the 
immunosuppressive properties of the MSCs in the CCl4 acute liver injury. Therefore, an 
interesting possibility is that a number of MSCs did not reach the injured site or there is 
a need to have more cells to enhance the number of regulatory T cells in vivo. More 
interestingly, our group has recently found that using the same type of MSCs with the 
same dosage was able to significantly improve the expansion of the hepatic Tregs in the 
MDR2 KO animal model (unpublished data). We further reported whether MSCs 
treatment has the ability to modulate both the cell numbers as well as the activation state 
of macrophages in vivo.   
 
Within the innate immune system, macrophages have been reported to play an essential 
role in acute liver injury, and are normally enhanced by cellular components released 
from necrotic cells and acute tissue damage microenvironment (Luster et al., 2005). In 
the acute CCl4 model used in this study, macrophages have clearly contributed to the liver 
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inflammation induced by CCl4.  In my in vivo experiment, flow cytometry data, together 
with the immunohistochemistry of F4/80, proved that CD362 UC-MSCs treatment 
decreased the number of macrophages in the liver. In addition, my data showed a decrease 
in macrophage numbers in the liver of the injured mice upon MSCs treatment with US or 
CD362 sorted cells. This reduction in macrophages could likely be associated with the 
ability of MSCs to interact with the innate immune response and improve their 
immunosuppressive behaviour or by secreted soluble factors which, therefore, promote 
tissue anti-inflammatory response. I believe that the reduction in macrophage infiltration 
by MSCs treatment is associated with the liver improvement in this CCl4 animal model.  
 
On the other hand, my study also demonstrates no changes in the monocyte numbers in 
the blood circulation following MSCs treatment.  In contrast to our previous finding about 
the ability of MSCs to reduce the circulation of CD3 and CD4 T cells in vivo, I believe 
that UC-MSCs could secrete some factors which could have a specific function to recruit 
the circulation of lymphoid but not myeloid cells. Furthermore, macrophages polarisation 
plays an important role in the immunomodulation of several disease conditions 
(Lawrence and Natoli, 2011). Accordingly, the hepatic population of M1-like cells and 
M2-like cells was characterised and investigated in this study using flow cytometry. A 
very interesting finding in this study was that both US and sorted CD362 were unable to 
convert the M1 macrophages into M2 macrophages. This finding could suggest that one 
reason for the failure of the MSCs to modulate the macrophage polarisation might be due 
to the short time frame of the acute liver injury induced by CCl4. Our group has recently 
found that UC-MSCs, both sorted and unsorted, were able to polarise the M1-like cells 
to M2-like cells in a murine model of liver fibrosis MDR2 (unpublished data), which we 
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believe could be a new mechanism that makes MSCs exhibit more anti-inflammatory 
properties in the treatment of liver disease. Another possible reason could come from the 
short observation period in our study; the effect of MSCs to polarise macrophages 
requires a long time and, therefore, MSCs could have greater potential in macrophages 
polarisation in chronic injury than in acute injury. In addition, analysis of the infiltrated 
neutrophil showed a pattern of reduction in the liver following MSCs treatment. In my 
model, a significant decrease in hepatic neutrophil was observed post-transfusion of US 
UC-MSCs. In contrast, I could not observe any beneficial effect of MSCs injection on the 
circulating number of neutrophils.  
 
In addition to the ability of MSCs to reduce acute liver injury via immunosuppressive 
properties, several studies have reported that MSCs could have another therapeutic 
potential in different disease conditions through decreasing the generation of reactive 
oxygen species caused from the damaged tissue. These therapeutic functions could come 
from the ability of MSCs to secrete some factors with anti-oxidant properties. In order to 
evaluate the potential of UC-MSCs to reduce oxidative stress released from the liver 
injury, both TBARS and glutathione oxidised (GSS) states were analysed in the liver 
following MSCs treatment. My study confirmed that MSCs were unable to modify the 
intracellular oxidative stress in the liver. However, I observed a remarkable increase in 
TBARS following MSCs injection.  
 
Given its known pathological nature of ROS production, the finding of upregulation on 
ROS level post-MSCs infusion could suggest the important role of ROS production in 
maintaining stromal cell functions (Wang et al., 2013). Furthermore, a very interesting 
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finding in my study is that HIF-1a was significantly upregulated in UC-MSCs compared 
with the CCl4-injured group. This finding may suggest that HIF1-a could be a new 
mechanism that improves the ability of UC-MSCs to exhibit a more potent anti-
inflammatory effect in in vitro and in vivo studies. Another finding of this study could 
highlight that hypoxia stress could improve the generation of liver injury. My 
observations are in agreement with previous reports indicating that MSCs under hypoxic 
condition can induce expression of HIF-1a.   
 
In addition, my study reported that MSCs were not capable of changing the antioxidant 
levels, as reported by gene expression. SOD1, SOD2, SOD3 and catalase were the most 
important antioxidants which mediated the oxidative stress in different disease 
conditions. In vivo, it remains unclear which cellular ratio will be achieved during MSCs 
and T-cells interactions, as MSCs are in low number in vivo. The presence of MSCs at 
sites of inflammation and injury is well-known, but the relative number and sources of 
MSC that are mobilised remain to be determined. Interestingly, as an important 
component of the antioxidant system, the IDH-1 antioxidant enzyme was found to be 
upregulated in the injured mice treated with MSCs. This is an important metabolic 
enzyme located in the cytosol and with an important role in the liver to protect against 
ROS accumulation and suppress liver inflammation (Itsumi et al., 2015). An important 
paper highlighted a critical role for IDH-1enzyme in the control of liver injury in vivo 
(Itsumi et al., 2015). By using IDH-1 deficient KO mice, greater development in liver 
injury was shown to increase  oxidative stress in hepatocytes and increased serum 
inflammatory cytokines, such as IL6 and TNFa (Itsumi et al., 2015). This information 
suggested that IDH-1 plays a role in regulation of the cellular damage related to liver 
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injury. Future studies are warranted to identify pathways that are regulated by IDH1 and 
to perform MSCs transduced with IDH-1 to evaluate the biological consequences of 
MSCs function. Other possible work suggests that MSCs could be genetically modified 
to overexpress IDH-1 for an effective strategy to enhance the MSCs function during liver 
injury.    
 
As some studies have reported that acute CCl4 injury is associated with an accumulation 
of apoptotic cell death, I hypothesised that MSCs could be effective in acute liver injury 
through their anti-apoptotic properties. In my studies there were significant differences in 
the expression of two anti-apoptotic genes, in particular of Birc5 (also known as servivin) 
and Bcl2l1, between control and CCl4-treated mice, Birc5 gene expression was 
upregulated after exposure of mice to CCl4, as compared to control mice treated with 
mineral oil. In fact, the higher levels of the anti-apoptotic activities have been reported in 
different liver injury in response to the MSCs treatment. Daan et al. (Van Poll et al., 2008) 
demonstrated that MSCs treatment supports the regeneration of liver injury through a 
reduction in hepatocellular apoptosis. Similarly, another study with bone marrow MSCs 
showed that they reduced apoptotic cells by 50% in the ischaemic region of the stroke 
injury 3-24 hours following MSCs administration, and were accompanied by an 
upregulation of the protein level of Bcl-2 and servivin (van Velthoven et al., 2012). In 
contrast to the previous studies, three days following systemic infusion of MSCs in CCl4-
injured mice, I failed to confirm an association between MSCs and the anti-apoptotic gene 
used in this study. These results indicate that administration of MSCs in the very early 
phase after ischaemic brain injury is neuroprotective and, thereby, improves functional 
outcome. One of the potential explanations may be that the anti-apoptotic function by the 
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MSCs could be related to the number of transplanted cells, for example injecting 1×106 
MSCs rather than 2.5×105 may have more potential improvement in the anti-apoptotic 
efficacy of MSC.  
 
Adhesion molecules promote the close interaction between the movement of T cells and 
MSCs, which is essential to suppress the immune response. In addition,  inflammatory 
cytokines released in response to inflammation can activate the endothelial cells to secret 
adhesion molecules (Wilson et al., 2018). Using immunohistochemistry and qPCR, I first 
found that, compared with the liver from normal animal treated with mineral oil, CCl4-
injured mice showed a significant increase in the expression of ICAM-1and VCAM-1 in 
the liver. However, in this current study, I confirmed that these two adhesion molecules 
were not altered following MSCs treatment, as compared to the CCl4-injured mice. 
According to this finding, I believe that cell-to-cell contact is essential to enhance the 
level of adhesion molecules in the microenvironment of the injured cells. In line with 
these findings, a study by Ren et al. (2010) reported that ICAM and VCAM expression 
have been shown to increase the interaction between MSCs and T cells, which 
subsequently enhanced the immunosuppressive function of the MSCs in vitro (Ren et al., 
2010). Moreover, MSCs have been found to release adhesion molecules after stimulation 
with inflammatory cytokines (Shi et al., 2012). 
 
In summary, because of their immunomodulatory ability, MSCs administration is a 
promising candidate for the treatment of liver diseases. Herein, the therapeutic effects of 
US and sorted CD362 umbilical cord MSCs were reported in CCl4-induced acute liver 
injury. I showed that US and CD362 MSCs improve the hepatic injury of acute hepatitis, 
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following by down-regulation in hepatic CD45+ infiltrating cells, as well as a reduction 
in non-NK cells and B cells, both in the injured liver and in the circulation. However, 
macrophage polarisation and induction of Tregs was not altered by MSCs therapy. My 
data highlights MSCs also increased IDH-1 enzymes, which could have a specific 
mechanism related to MSCs’ immunosuppression functions. Finally, the different 
therapeutic effects of MSCs can be due to the specific microenvironment in each disease 















































IN VIVO EFFICACY OF HUMAN UMBILICAL CORD 
MSCs IN THE OVA-BIL MOUSE MODEL OF 















6.1 Introduction  
 
 
In an animal model of acute liver injury, I previously investigated the efficacy of human 
UC-MSCs in acute hepatotoxic liver injury induced by CCl4. I found that administration 
of hUC-MSCs had the ability to reduce liver damage, as indicated by a reduction in liver 
enzymes, as well as modulating hepatic inflammation. Studies have suggested that the 
mechanisms MSCs use in mediating immunosuppression effects could differ between 
various animal models of acute liver injury (Christ et al., 2015). Thus, I planned to study 
another animal model in which MSCs could potentially modulate the immune reaction in 
acute liver injury.  
 
The model in this study was chosen due to its unique features, where inflammation was 
developed to target the biliary area in the liver specifically. The Ova-Bil animal model 
was developed by Buxbaum et al. and was associated with hepatobiliary injury (Buxbaum 
et al., 2006). In this animal model, Ova-Bil transgenic mice were tolerant to the 
overexpression of ovalbumin (OVA) antigen in their biliary epithelium and developed 
normally without any clinical development of hepatic inflammation or injury. However, 
hepatobiliary injury was induced by the adaptive transfer of splenocytes isolated from 
OT-I (OVA-specific CD8+ T cells) and OT-II (OVA-specific CD4+  T cells)  transgenic 
mice into male Ova-Bil transgenic mice. Inflammation in the liver was specific without 
targeting any other organs in the Ova-Bil transgenic mice. In addition, the authors 
reported that this hepatobiliary inflammation is CD8+ dependent, and no response was 
reported with CD4+ cells alone. In general, this animal model shows increased damage in 
the bile duct with more inflammation around the portal area. In this study, we examined 
 165 
the therapeutic role of UC-MSCs in protecting against liver damage caused by 
alloimmune liver injury.  
 
6.2 Chapter Aims 
 
 
In this chapter, I examined the extent of hepatic injury and inflammatory response caused 
by the adaptive transfer of OT-I and OT-II cells into Ova-Bil transgenic mice. More 
importantly, to the best of my knowledge, this study was the first to investigate the 
immunosuppressive potential of unsorted/purified human UC-MSCs in vivo using the 
Ova-Bil model of acute liver injury. The main aims of this chapter were to: 
 
• Explore the safety and efficacy of human UC-MSCs in the Ova-Bil animal model.  
• Specifically, study the ability of unsorted UC-MSCs and CD362+ sorted UC-
MSCs to modulate the number of hepatic infiltrating lymphocytes and monocytes, 
using flow cytometry analysis.  
• Investigate whether UC-MSC administration can modulate activational status of 














6.3 Results  
 
6.3.1 Development of biliary inflammation in Ova-Bil transgenic mice 
 
The Ova-Bil mouse strain used for this study was inbred and maintained as heterozygotes 
on a C57Bl/6 background in our animal unit. Routine genotyping for heterozygous apical 
sodium-dependent bile acid transporter (ASBT)-membrane-bound ovalbumin (mOVA) 
in animals was carried out using real-time PCR (Transnetyx, Inc., Tennessee, USA). The 
OT-II mouse strain was maintained as homozygous and routine genotyping was carried 
out using real-time PCR (Transnetyx, Inc., Tennessee, USA). 
This chapter details how alloimmune hepatobiliary injury was developed by the transfer 
of T cells from OT-I and OT-II transgenic mice into male Ova-Bil mice. Briefly, 10–12 
week-old male OT-I and OT-II mice were sacrificed and their spleens harvested for 
splenocyte isolation. Splenocytes obtained from these mice were injected 
intraperitoneally (IP) into Ova-Bil mice. Ten days after OT-I and OT-II T-cell infusion, 
the animals were sacrificed and their blood and liver tissue collected for further 
investigation.  
 
6.3.2 ALT level after the adoptive transfer of 10x106 OT-I and/or 
10x106 OT-II splenocytes into OVA-BIL mice 
 
To determine the functional consequence of transferring different populations of OT-I 
and OT-II splenocytes into Ova-Bil transgenic mice, a comparison study was conducted 
to determine liver injury and hepatic inflammation in Ova-Bil mice following the adaptive 
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transfer of 10x106 splenocytes from OT-I, OT-II or OT-I and OT-II. Figure 6-1A briefly 
describes the design of this experiment. 
 
As demonstrated (Figure 6-1B), the serum level of the ALT enzyme confirmed liver injury 
as indicated by the adaptive transfer of 10x106 OT-I and OT-II splenocytes or through the 
induction of a single population of 10x106 OT-I splenocytes, which is consistent with 
previous published data (Derkow et al., 2007). However, the 10x106 OT-I and OT-II 
splenocyte group reported more significant injury compared with Ova-Bil mice injected 
with only 10x106 OT-I splenocytes. In contrast, the adaptive transfer of 10x106 OT-II 
splenocytes alone demonstrated a similar level of injury when compared with the ALT 
level in Ova-Bil mice treated with PBS. These findings confirm that OT-I splenocyte 
transplantation is directly associated with the development of liver injury in this animal 
model. More interestingly, the induction of OT-I splenocytes together with OT-II 
splenocytes exhibited the most effective treatment of induced liver injury in Ova-Bil 
transgenic mice.  
 





Male, 8- 10 week old
Ova-Bil
day 10
Splenocyte injection ( IP )
(10X106)
PBS      OT-I+OT-ll OT-l     OT-ll
Harvested blood and liver 
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Figure 6-1 Male Ova-Bil mice show variation in liver enzyme activity after the induction 
of OT-I and OT-II. A) Design of the study. B) In mice that received intraperitoneal injections 
of 10x106 of OT-I and OT-II, 10x106 of OT-I, and 10x106 of OT-II, serum ALT activities were 
elevated after 10 days. Representative data (3 mice for each time point). Each value is 
represented as the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. 
 
6.3.3 ALT level after the adoptive transfer of different doses of OT-I 
and OT-II splenocytes into OVA-BIL mice 
 
To optimize the level of injury in this animal model, a dose response study was performed 
with varying numbers of OT-I and OT-II splenocytes. I performed an experiment in which 
Ova-Bil mice were intraperitoneally injected with different doses of OT-I and OT-II 
splenocytes. Figure 6-2 illustrates the three different groups of animals injected with 








































splenocytes (this dose was described by Buxbaum et al. 2006); 2) 15x106 OT-I and 6x106 
OT-II splenocytes; and 3) 10x106 OT-I and 10x106 OT-II splenocytes.  
As shown in Figure 6-2, I noted that injections of 10x106 OT-I and 10x106 OT-II 
splenocytes demonstrated more hepatic injury, as shown by the increased ALT levels 
compared with other OT-I and OT-II splenocyte doses. In addition, less variation in ALT 
levels was reported for the same doses in both female and male mice. These findings 
demonstrate that the level of liver injury in Ova-Bil mice correlates with the number of 





Figure 6-2 Analysis of ALT liver enzymes after infusion of different doses of OT-I and 
OT-II into Ova-Bil mice. Serum ALT level in Ova-Bil mice treated with different doses of  
OT-I and OT-II splenocytes (4–5 animals per group ). Data are presented as the mean ± SD.     













































6.3.4 Expression of Vα2 in the liver after the adoptive transfer of OT-I 
and OT-II splenocytes  
 
As found earlier, liver injury in Ova-Bil mice developed following administration of OT-
I and OT-II splenocytes. As reported by the authors who developed this animal model, 
splenocytes isolated from OT-I and OT-II transgenic mice were reported to express Vα2 
on their surface receptors, whereas splenocytes from C57Bl/6 expressed < 2% Vα2 on 
their surface (Buxbaum et al., 2006). Accordingly, Vα2 monoclonal antibody was used 
to detect the OT-I and OT-II splenocytes transferred into Ova-Bil mice. Ten days 
following the adoptive transfer of OT-I and OT-II splenocytes, flow cytometric 
evaluation was performed to investigate the number of OT-I and OT-II splenocytes found 
in the liver and to track which population of splenocytes caused the liver injury. Our 
results indicated that the parentage of Vα2+ cells was significantly increased in the Ova-
Bil mice adoptively transferred with OT-I and OT-II or with only OT-II splenocytes 
(Figure 6-3A). However, Ova-Bil recipient mice treated with OT-II splenocytes did not 
show any Vα2-positive cells in their liver and were similar to the control Ova-Bil mice 
treated with PBS. These data clearly indicate that the transfer of OT-I splenocytes was 
shown to have a correlation with an increased expression of Vα2+ cells in the liver, and 
we believe this population (OT-I) triggers the inflammation caused in the Ova-Bil model. 
In contrast, OT-II splenocytes failed to generate Vα2+ cells in the liver, but these cells 
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Figure 6-3 Expression of Vα2-positive cells after the adaptive transfer of OT-I and OT-
II cells into Ova-Bil mice. (A)  Flow cytometry representative diagram showing the 
percentage of Vα2+ cells after the adaptive transfer of OT-I and OT-II. B) The percentage of 
Vα2 cells in the liver of Ova-Bil mice was quantified by flow cytometry. All cells were gated 
from live CD3+ Vα2 + cells isolated from fresh mouse livers (3 animals per group). Data are 











































6.3.5 Increase in lymphocyte population following the adoptive 
transfer of OT-I and OT-II splenocytes  
 
To investigate the inflammatory response following the adaptive transfer of OT-I and 
OT-II splenocytes into Ova-Bil mice, flow cytometry analysis was performed to examine 
the lymphocytic immune cells isolated from mice with adoptivel transferred OT-I and 
OT-II splenocytes. Ten days after the induction of OT-I and OT-II in the Ova-Bil mice, I 
saw a remarkable increase in the number of NK, non-NK and B cells in the liver compared 
with the control group (Ova-Bil with PBS). Interestingly, I also observed significant 
differences in NK cells as well as B cells following the adoptive transfer of OT-I 
splenocytes alone (Figure 6-4A). As expected, I reported no inflammatory response 
following the adoptive transfer of OT-II cells alone and observed a similar number of 
inflammatory cells when compared with the control group.  
 
I then further investigated the influence of OT-I and OT-II transfer on CD3+, CD8+, and 
CD4+ immune cells isolated from the livers of Ova-Bil mice. I clearly showed that the 
adoptive transfer of OT-I and OT-II splenocytes, as well as OT-I alone, significantly 
increased the total number of CD3+ and CD8+ lymphocytes in the liver (Figure 6-4B). In 
addition, OT-I alone was able to enhance the number of hepatic CD4+ cells, compared 
with the induction of OT-I and OT-II together. However, the transfer of OT-II cells alone 
did not lead to changes in the number of hepatic CD3+, CD4+ and CD8+ T cells. These 
observations illustrated that OT-I splenocytes directly contributed to the inflammation 
associated with acute liver injury in mice. Generally, the hepatic inflammation of this 













Figure 6-4 Analysis of lymphocyte populations using flow cytometry analysis. A) 
Represents NK and non-NK B lymphocytes isolated from mouse liver after the adoptive 
transfer of OT-I and OT-II. B) The numbers of infiltrating CD3+, CD4+ and CD8+ cells in the 
livers of Ova-Bil  mice were quantified by flow cytometry 10 days after the transfer of OT-I 
and OT-II. Data are expressed as the number of infiltrating cells per gram of fresh liver tissue 







































































































































































































































































































6.3.6 Increase in monocyte populations following the adoptive transfer 
of OT-I and OT-II splenocytes in Ova-Bil mice 
 
 
I further analysed the ability of OT-I and OT-II to modulate the monocyte subsets in Ova-
Bil mice with liver injury. Ten days after the IP administration of OT-I and OT-ll cells, 
immune cells were isolated from mouse liver and analysed using flow cytometry. I 
observed a remarkable increase in the total CD45+ (Figure 6-5A), CD11+ (Figure 6-5B) 
and CD11+ F4/80+ (Figure 6-5C) cells in Ova-Bil mice in response to the adoptive transfer 
of OT-I and OT-II splenocytes when compared with the normal mice treated with PBS. 
In comparison with OT-I and OT-II treated mice, I noticed an increase in CD45+, CD11+ 
and CD11+ F4/80+ cells following the adaptive transfer of a single population of OT-I 
splenocytes. Further quantification of neutrophil (CD11b+ Ly6G+) and eosinophil 
(CD11b+ Gr-1Lo-neg SSCHI) cells was also reported in this study. I conducted a similar 
observation, which resulted in a significant increase in hepatic neutrophil and eosinophil 
cells in Ova-Bil mice following OT-I and OT-II transplantation (Figure 6-5D and E). In 
contrast, as found previously, the induction of OT-II cells did not lead to changes in the 
number of hepatic CD45+, CD11+ and CD11+ F4/80+ cells, nor in neutrophil and 
eosinophil cells. Together, these results indicate that OT-I and OT-II were shown to 
induce a significant number of hepatic monocytes significantly, suggesting that hepatic 
monocyte infiltration of this animal model required OT-I splenocyte (OVA-specific CD8+ 
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Figure 6-5 Flow cytometry analysis of immune cells following induction of OT-l and OT-
ll cells in Ova-Bil mice by day 10. A) Cells were gated from live CD45+ cells isolated from 
fresh mouse livers. B) Cells were gated from live CD11b+ and F4/80+ cells (C). D) Neutrophils 
were gated from live CD11b+ and Ly6G+ cells isolated from fresh mouse livers. E) Eosinophils 
were gated from live CD11b+ Gr-1Lo-neg SSCHI cells isolated from fresh mouse livers. All data 
are expressed as the number of infiltrating cells per gram of fresh liver tissue (3 animals per 
group). Data are presented as the mean ± SD. * P < 0.05, ** P < 0.01 and *** P < 0.00. 
 
6.3.7 Study of the anti-inflammatory role of human UC-MSCs in the 
Ova-Bil murine model 
 
As previously demonstrated, UC-MSCs have been found to have a therapeutic effect in a 
mouse model of acute hepatotoxic liver injury. In this chapter, the efficacy of human 
MSCs was assessed in an Ova-Bil animal model with acute hepatobiliary 
inflammation. As stated earlier, this liver injury was developed through the adoptive 
transfer of OT-I and OT-II splenocytes into Ova-Bil mice. In addition, 4 days after the 
induction of alloimmune liver damage by the adoptive transfer of OT-I and OT-II into 
Ova-Bil mice, UC-MSCs were infused intravenously via the tail vein and the mice 
sacrificed 6 days later. Finally, all mice underwent terminal anaesthesia to allow the 
collection of blood via cardiac puncture and were then sacrificed (cervical dislocation) to 
allow harvesting of the liver and other organs for analysis. Figure 6-6 A briefly describes 
the design of this experiment.  
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6.3.7.1 Examination of the correlation between the number of 
transplanted MSCs and the resulting liver function 
 
As I found in the previous CCl4 animal model, the dose response to MSC injection is 
essential to optimize the dose for better therapeutic efficacy. Accordingly, a dose response 
experiment was performed with varying infusions of unsorted UC-MSCs (2.5x105, 5x105 
and 1x106). The activity of liver enzyme (ALT) was measured for each animal in order 
to evaluate the liver injury. As shown in Figure 6-6B, the serum ALT levels in the injured 
Ova-Bil mice treated with both 2.5x105 and 1x106 MSCs were not found to show a clear 
reduction in ALT activity compared with the injured mice treated with PBS. However, 
animals appeared to show better improvement following an infusion of 5x105 MSCs 
(Figure 6-6B). Collectively, my data suggest that a 5x105 dose of MSCs could be the 















Figure 6-6 Analysis of liver enzymes after the infusion of different doses of MSCs (US) in 
Ova-Bil mice with hepatobiliary injury. A) Experimental design used in this study. OT-I and 
OT-II splenocytes were injected into Ova-Bil mice, followed by an IV MSC injection after four 
days. Animals were sacrificed at day 10 for serum and tissue collection for further study.  B) 
Serum ALT level in Ova-Bil mice treated with different doses of UC-MSCs. Data are expressed 
as the number of infiltrating cells per gram of fresh liver tissue (5–3 animals per group). Data 
are presented as the mean ± SD. 
 
6.3.7.2 CD362+ sorted UC-MSCs have potential efficacy in treating 
injury induced in an Ova-Bil model 
 
Following the induction of liver injury in Ova-Bil mice through the adoptive transfer of 
OT-I and OT-II splenocytes, I examined the functional ability of MSCs to ameliorate 
liver injury in this animal model. In this study, animals received an intravenous dose of 
5x105 human unsorted UC-MSCs or CD362+ sorted UC-MSCs at day 4 following the 
induction of liver injury in Ova-Bil mice. ALT enzyme activity in the serum at day 10 
was measured to evaluate the liver injury in response to MSC treatment. Significant 

































demonstrated that the ALT level was significantly reduced after the infusion of CD362+ 
sorted MSCs compared with Ova-Bil injury treated with PBS (Figure 6-7). I also observed 
a reduction with unsorted UC-MSCs, but this did not reach statistical significance. These 
data suggest that CD362+ sorted MSCs have a potential effect on liver injury in this 
animal model, and unsorted cells could have a less direct impact on improving liver 




Figure 6-7 Analysis of ALT liver enzymes after infusion of human unsorted UC-MSCs or 
CD362+ sorted UC-MSCs in Ova-Bil mice. The graph indicates serum ALT levels in 
different groups of mice treated with unsorted or CD362+ sorted UC-MSCs. Data are expressed 
as the median value and represent > 10 animals/group. Data are presented as the mean ± SD. * 
P < 0.05, ** P < 0.01, and ***P < 0.001. 
 
Histological examination using H&E staining of Ova-Bil mice by day 10 following the 
transplantation of OT-I and OT-II showed damage in the bile duct area with more 

















































mice, less cellular damage was seen in the liver microscopically with fewer inflammatory 
cells observed after MSC administration. 
 
 
Figure 6-8 H&E staining of liver sections after treatment with different doses of hUC-
MSCs. Represents the structure of liver sections of control mice (Ova-Bil ), Ova-Bil mice with 
liver injury induced by OT-I and OT-II and treated with PBS, and mice undergoing MSC 
administration following Ova-Bil liver injury; a clear improvement in necrosis is seen with the 
MSC treatment group. Scale bars: 200 µm.  
 
6.3.7.3 Effect of UC-MSC infusion on hepatic lymphocyte and monocyte 
populations in the Ova-Bil mouse model  
In addition to the ability of human UC-MSCs to immunosuppress liver inflammation in 
acute CCl4 liver injury, this chapter also examines if human UC-MSCs have a similar 
feature to modulate the inflammation in the Ova-Bil model. In this chapter, I examine the 
immunomodulatory function of US UC-MSCs and CD362+ sorted UC-MSCs in the liver 
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as well as in the circulation and lymphatic tissues, such as the spleen. The lymphocyte 
and monocyte interaction with MSCs was tested in this study using flow cytometry and 
immunohistochemistry.  
 
6.3.7.4 Effect of human UC-MSCs on CD45+ immune cells from 
different tissue sources of Ova-Bil mice 
 
 
In order to evaluate the ability of human UC-MSCs to modulate liver inflammation in 
Ova-Bil mice, I assessed the effect of using unsorted hUC-MSCs and CD362+ sorted UC-
MSCs through the intravenous injection of 2.5x105 MSCs into Ova-Bil injured mice. I 
analysed the expression of CD45+ cells isolated from the liver as well as the spleen and 
blood using flow cytometry analysis. As reported in Figure 6-9A, the unsorted and 
CD362+ sorted UC-MSC-treated mice exhibited no significant reduction in hepatic 
CD45+ cells compared with Ova-Bil mice treated with PBS. The same observation was 
also found in CD45+ cells isolated from the spleen and blood. To further show the 
functionality of transplanted cells, I quantified CD45+ in the liver sections following 
treatment of MSCs using immunohistochemistry (Figure 6-9B). I found that 
administration of CD362+ sorted MSCs resulted in a significant reduction in CD45+ 
expression in Ova-Bil mice compared with unsorted UC-MSCs. These results show that 
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Figure 6-9 Flow cytometry and IHC analysis of CD45+ cells post-MSC infusion into Ova-
Bil mice. A) Cells were gated from live CD45+ cells isolated from fresh mouse liver, spleen 
and blood. Data are expressed as the number of infiltrating cells per gram of tissue (liver and 
spleen) and per 1 µ of blood (> 8 animals per group). B) Representative IHC staining of hepatic 
CD45+ cells expressed as a percentage of the surface area of the field view analysed using 
ImageJ software (8 animals per group). Scale bars: 200 µm. Data are presented as the mean ± 
SD. * P < 0.05, ** P < 0.01, and *** P < 0.001. 
 
6.3.7.5 Effect of UC-MSC infusion on lymphocyte populations in the 
Ova-Bil liver injury model  
 
I further investigated the influence of MSC transplantation on NK, non-NK and B 
lymphocytes from different tissue sources: mainly, liver, spleen, and blood. I clearly show 
that MSC transplantation from neither population (US or CD362) did not reduce the total 
number of NK (CD49-) and non-NK (CD49-) cells or B cell (CD19+) lymphocytes (Figure 
6-10 and Figure 6-11). In addition, MSCs showed no significant reduction in the NK, non-
NK, and B lymphocytes isolated from spleen and blood compared with the Ova-Bil mice 
treated with PBS. 
 
 











































































































Figure 6-10 Analysis of total lymphocyte and NK-cell populations using flow cytometry 
assay. Represents the total lymphocytes and NK (CD49+) lymphocytes isolated from the liver, 
spleen, and blood of Ova-Bil mice after administration of US or CD362 UC-MSCs. Data are 
expressed as the number of infiltrating cells per gram of liver and spleen tissue or by the number 
of infiltrating cells per 1 µ of blood (> 8 animals per group). Data are presented as the mean ± 






























































































































































































































































































































Figure 6-11 Analysis of non-NK cells and B lymphocytes using flow cytometry assay. 
Represents a difference in non-NK T cells (CD49-) and B lymphocytes (CD19+) isolated from 
the liver, spleen, and blood of Ova-Bil mice after administration of US or CD362 UC-MSCs. 
Data are expressed as the number of infiltrating cells per gram of liver and spleen tissue or by 
the number of infiltrating cells per 1 µ of blood (> 10 animals per group). Data are presented 
as the mean ± SD. * P < 0.05, ** P < 0.01, and *** P < 0.001. 
6.3.7.6 CD362+ UC-MSCs enhance CD4+ expression in the liver of 
Ova-Bil mice with hepatobiliary inflammation  
 
The potential of MSCs to suppress the proliferation of CD3+, CD4+ and CD8+ T cells was 
examined in Ova-Bil mice with hepatobiliary injury. The quantification of the hepatic 






































































































































































































MSC-treated and untreated Ova-Bil mice. The same finding was reported in CD3+ and 
CD8+ T cells isolated from spleen and blood (Figure 6-12). Interestingly, analysing the 
number of CD4+ T cells in the liver displayed a significant increase in the presence of 
MSC treatment. However, my results indicate that US and CD362 sorted MSCs had equal 
induction effects on hepatic CD4 T cells in Ova-Bil mice compared with the untreated 
group (Figure 6-13). In contrast, I did not observe any efficiency in MSCs in the 
upregulation of the number of CD4 T cells isolated from blood or spleen.  
 
In accordance with my findings regarding the ability of MSCs to upregulate CD4+ cells 
in the liver, I investigated whether this observation could relate to the ability of MSCs to 
induce the generation of regulatory T cells (Tregs). Thus, I further tested whether MSCs 
could immunosuppress liver inflammation via the induction of Tregs. As shown in Figure 
6-14, my data reported that neither kind of MSC (unsorted and CD362 sorted cells) 
transplantation had a significant impact on hepatic Tregs, as reported by the expression 
of CD3+, CD4+, CD25+ and FOXP3+.  
 
Together, my findings indicate that the therapeutic effect of MSCs (US and CD362) in 
the Ova-Bil animal model failed to suppress CD3+ and CD8+ cells and induced the 
generation of Tregs in the liver, as well as in the spleen and blood. In contrast, I found 
greater efficiency in MSC treatment in upregulating hepatic CD4+ T cells in Ova-Bil mice 








Figure 6-12 Numbers of infiltrated CD3+ and CD8+ cells in the liver, blood and spleen of 
Ova-Bil injured mice, quantified by flow cytometry. All cells were gated from live cells 
isolated from fresh mouse livers, spleen, and blood. Data are expressed as the number of 
infiltrating cells per gram of fresh tissue and by the number of infiltrating cells per 1 µ of blood  
(> 10 animals per group). Data are presented as the mean ± SD. * P < 0.05, ** P < 0.01, and 
*** P < 0.001. 
 









































































































































































































































































































Figure 6-13 Numbers of infiltrated CD4+and CD25+ cells in the liver, blood and spleen of 
Ova-Bil injured mice, quantified by flow cytometry. All cells were gated from CD3+ cells 
isolated from fresh mouse liver, spleen and blood. Data are expressed as the number of 
infiltrating cells per gram of fresh tissue and by the number of infiltrating cells per 1 µ of blood 
(> 10 animals per group). Data are presented as the mean ± SD. * P < 0.05, ** P < 0.01, and 
*** P < 0.001. 
 
 









































































































































































































































































































Figure 6-14 Generation of regulatory T cells following UC-MSC infusion. The generation 
of regulatory T cells in the liver of Ova-Bil mice was quantified by flow cytometry. All cells 
were gated from live CD3+, CD4+, CD25+ and FOXP3+ cells isolated from fresh mouse liver 
and spleen. Data are expressed as the number of cells per gram of fresh liver tissue (> 10 
animals per group). Data are presented as the mean ± SD. * P < 0.05, ** P < 0.01, and *** P < 
0.001. 
 
6.3.8 Flow cytometric analysis of myeloid subsets in mice with Ova-Bil  
liver inflammation after infusion of UC-MSCs 
 
I further analysed the ability of MSCs to modulate the myeloid immune cells in Ova-Bil  
injured animals. Following the intravenous administration of MSCs, immune cells were 









































































































































































































isolated from mouse tissue and circulation and analysed using flow cytometry. I observed 
a remarkable increase in the total CD11+ F4/80+ following adoptive transfer of OT-I and 
OT-II when compared with the control group of Ova-Bil mice. In addition, my flow 
cytometry data showed that US and CD362 MSCs had no ability to modulate the number 
of macrophages (CD11+ F4/80+) in liver compared with the Ova-Bil injured mice (Figure 
6-15A). However, further quantification of F4/80+ cells in liver sections using IHC 
provided another observation, which showed a decreased level in macrophages following 
US and CD362+ sorted MSC administration (Figure 6-15B). Together, these results 
indicated that MSCs were shown to reduce the number of hepatic macrophages 
infiltrating the liver section, suggesting that MSCs could play a role in liver injury through 
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Figure 6-15 CD362+ UC-MSCs reduced hepatic F4/80+ immune cells in Ova-Bil mice with 
acute liver injury. A) Cells were gated from live CD11b+ F4/80+ cells isolated from fresh 
mouse liver, spleen and blood. Data are expressed as the number of infiltrating cells per gram 
of tissue (liver and spleen), and per 1 µ of blood (> 8 animals per group). B) Representative 
IHC staining of hepatic F4/80+ cells expressed as a percentage of the surface area of the field 
view analysed using ImageJ software (8 animals per group). Scale bars: 200 µm. Data are 
presented as the mean ± SD. * P < 0.05, ** P < 0.01, and *** P < 0.001. 




































In order to fully characterize the different phenotypes of the infiltrated macrophages, I 
quantified the different populations of macrophages using flow cytometry. As mentioned 
in the previous chapter, macrophage markers CD11b+ F4/80 Ly6Chi and CD11b+ F4/80 
Ly6Clo were used to identify classical and alternative macrophages, respectively. To 
investigate the role of MSCs in macrophage polarization, I compared the 
immunosuppressive ability of US and CD362 UC-MSCs on M1 and M2-like cells 
isolated from mouse liver. Based on my flow cytometry data, the MSCs did not show any 
change in macrophage phenotype between M1 and M2-like cells (Figure 6-16).  
 
Another population of myeloid cells was investigated in this study. I analysed the 
influence of CD362+ MSCs as well as US MSCs on the levels of neutrophils from 
different tissue sources (liver and spleen) and the blood of OBA-BIL mice. Compared 
with the control group, the degree of infiltration of CD11b+ Ly6G+ cells (neutrophils) did 
not change in response to either MSC treatment. This result was reported in liver as well 











































































































































Figure 6-16 Effect of UC-MSC infusion on M1 and M2 macrophages. The total number of 
CD11b+ F4/80 Ly6Chi classically activated pro-inflammatory M1-phenotypes and CD11b+ 
F4/80 Ly6Clo anti-inflammatory M2-phenotypes in the livers of Ova-Bil injured mice were 
quantified by flow cytometry analysis. The percentages of M1 cells and M2 cells in fresh liver 
tissue of Ova-Bil mice receiving either 250K US UC-MSCs or CD362+ UC-MSCs were 
quantified and compared with the injured group. The M1/M2 ratio expressed the proportion of 
M1 and M2 cells in the liver tissues. Data are expressed as percentages (%) of fresh liver tissue 
(> 8 animals per group). Data are presented as the mean ± SD. * P < 0.05, ** P < 0.01, and *** 







Figure 6-17 Effects of UC and CD362 MSCs on the expression of inflammatory 
neutrophils in Ova-Bil mice with liver injury. Neutrophils were gated from live CD11b+ and 
Ly6G+ cells isolated from fresh mouse livers, spleen, and blood. Data are expressed as the 
number of infiltrating cells per gram of fresh liver tissue and per 1 µ of blood (> 8 animals per 













































































































































































6.3.9  CD362+ UC-MSC downregulated hepatic endothelial cell 
activation (expression of ICAM and VCAM) in Ova-Bil mice 
with liver injury 
 
 
To assess whether hepatic endothelial cells are activated in the hepatic injury of Ova-Bil 
mice I studied the expression of ICAM and VCAM in the liver using qPCR as well as 
IHC. ICAM-1 and VCAM-1 adhesion molecules have been shown to mediate the 
immunosuppressive function of MSCs through the direct adhesion of MSCs to immune 
cells (Chamberlain et al., 2011).    
In this study, I found that ICAM and VCAM were highly expressed in Ova-Bil mice 10 
days after liver injury. To explore the role of MSCs in the modulation of ICAM and 
VCAM expression in vivo, I analysed the level of ICAM and VCAM adhesion molecules 
using IHC and qPCR 6 days following MSC infusion. Interestingly, I observed a 
significant reduction in ICAM expression in liver sections of Ova-Bil mice treated with 
CD362+ MSCs compared with mice treated with PBS (Figure 6-18A). Similarly, I found 
that Ova-Bil mice treated with CD362 MSCs had significantly less expression of VCAM, 
as demonstrated by the quantification of the percentage of VCAM+ cells in mouse liver 
sections, as shown in Figure 6-19A. To further confirm the previous findings, the 
expression of ICAM and VCAM mRNA in the mouse liver was investigated in the 
presence of MSC treatments, using qPCR. I confirmed a significant decrease in the 
expression of ICAM (Figure 6-18C) and VCAM (Figure 6-19C) in the liver of Ova-Bil 
mice treated with CD362 MSCs, as measured by qPCR. I observed a trend towards a 
decline in ICAM and VCAM in OVA-BIL mice treated with US MSCs but without any 
statistical significance recorded.  
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Figure 6-18 Effect of MSC treatment on hepatic ICAM-1 expression in the Ova-Bil 
murine model. A) Representative IHC staining of hepatic ICAM+ cells. B) Quantification of 
ICAM+ cells expressed as a percentage of the surface area of the field view analysed using 
imageJ software (8 animals per group). C) Changes in hepatic ICAM-1 mRNA expression in 
Ova-Bil mice following injection of US and CD362+ UC-MSCs quantified by qPCR (8 animals 
per group). Scale bars: 200 µm. Data are presented as the mean ± SD. * P < 0.05, ** P < 0.01, 
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Figure 6-19 Effect of MSC treatment on hepatic VCAM-1 expression in the Ova-Bil 
murine model. A) Representative IHC staining of hepatic VCAM+ cells. B) Quantification of 
VCAM+ cells expressed as a percentage of the surface area of the field view analysed using 
imageJ software (8 animals per group). C) Changes in hepatic VCAM-1 mRNA expression in 
Ova-Bil mice following injection of US and CD362+ UC-MSC quantified by q-PCR (8 animals 
per group). Scale bars: 200 µm. Data are presented as the mean ± SD. * P < 0.05, ** P < 0.01, 






















































































6.3.10 Cytokine production following MSC induction in Ova-Bil mice 
with liver inflammation 
 
Two cytokines, in particular, TNF-a and INF-g, were shown to have a remarkable 
upregulation following the adoptive transfer of OT-I and OT-II, as shown in Figure 6-20. 
I further assessed the immunosuppressive function of MSCs in modulating cytokines in 
the livers of injured mice.  I explored the therapeutic role of MSC administration on TNF-
a and INF-g cytokine secretion 6 days following infusion. I observed minimal induction 
in INF-g with no difference in TNF-a in the MSC-treated mice when compared with Ova-
Bil mice treated with PBS (Figure 6-20).  
 
Figure 6-20 Analysis of gene expression of inflammatory cytokine expression in the liver 
following MSC treatment. Changes in the hepatic gene expression of TNF-a and INF-g in 
Ova-Bil mice receiving MSCs, quantified by q-PCR (8 animals per group). Data are presented 

































































































6.4 Discussion  
 
 
The therapeutic potential of human UC-MSCs has been reported in the repair of injured 
tissue. In some clinical studies, MSCs were found to be safe, with features indicating a 
potential to treat human diseases (Suk et al., 2016b; Houlihan and Newsome, 2008). 
There are several ongoing clinical trials to demonstrate the clinical efficacy of MSCs in 
different disease conditions. Several research groups have reported beneficial effects of 
MSC infusions in different animal models of acute liver injury (Zhu et al., 2013; 
Milosavljevic et al., 2017b). I previously reported beneficial effects of MSC infusions in 
animal models of acute liver injury. To further address whether UC-MSCs have a 
therapeutic role in liver injury, I used an Ova-Bil model of liver injury with hepatobiliary 
inflammation. Based on a previously developed animal model (Buxbaum et al., 2006), I 
developed hepatobiliary injury in Ova-Bil mice by adoptively transferring T cells from 
OT-I and OT-II transgenic mice. However, the course of the inflammation has not been 
well defined. Here, I found the most effective dose of OT-I and OT-II to induce liver 
injury and inflammation. Further experimentation was conducted in order to understand 
the immune phenotype changes in the liver following the induction of OT-I and OT-II. 
In this study, I reported the effectiveness of the transplantation of human UC-MSCs into 
Ova-Bil mice following the adoptive transfer of OT-I and OT-II cells. The most effective 
dose of MSCs was defined and two populations of MSCs were investigated. The 
beneficial therapeutic effect of US and CD362+ sorted MSCs was found to reduce liver 
injury in Ova-Bil mice induced by OT-I and OT-II. I demonstrated that the potential effect 
of MSCs to protect liver injury was mediated by the ability of MSCs to enhance CD4+ 
cells in the injured liver. In addition, it has been reported that CD362 sorted MSCs might 
enhance the therapeutic effect of MSCs to modulate liver injury through the 
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downregulation of adhesion molecules. Taken together, these findings provide a 
promising indication for using MSCs to treat liver diseases, as they were reported to be 
safe and for their ability to immunomodulate liver inflammation as well as regulate 
adhesion molecules.    
 
An Ova-Bil animal model of liver injury was developed in which the antigen ovalbumin 
in hepatocytes (Derkow et al., 2007) or biliary epithelium cells (Buxbaum et al., 2006) is 
highly expressed. In both studies, inflammation was developed by the adoptive transfer 
of splenocytes isolated from OT-I and OT-II transgenic mice. This animal model was 
found specifically to target liver tissue and induce hepatobiliary inflammation. As 
mentioned above, I used Ova-Bil transgenic mice with overexpression of ovalbumin 
(OVA) antigens in their biliary epithelium, as described by Buxbaum et al. In agreement 
with the aforementioned study, Ova-Bil mice were, prior to the induction of OT-I and 
OT-II, reported to have a normal liver structure without any injury observed, as 
demonstrated by a normal serum ALT level. The level of injury in Ova-Bil mice has been 
reported as showing remarkable changes in response to different doses of OT-I and OT-
II splenocytes. Initially, I used 10x106 OT-I and 4x106 OT-II splenocytes as described in 
the previous study. However, I observed clear variations in liver ALT levels between 
mice, with no inflammatory response observed in some animals. To overcome this issue, 
I performed an experiment with different doses of OT-I and OT-II splenocytes. I noted 
that injection of 10x106 OT-I and 10x106 OT-II splenocytes demonstrated more hepatic 
injury, as shown by increased activity of ALT enzyme, when compared with other doses 
of OT-I and OT-II splenocytes. This observation demonstrated that the level of liver 
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injury in Ova-Bil mice is correlated with the number of OT-I and OT-II splenocytes 
injected in a dose-dependent manner. 
Interestingly, I found that liver injury was triggered by the adaptive transfer of OT-I and 
OT-II splenocytes. On the other hand, the induction of a single population of OT-I 
splenocytes had the ability to develop liver injury in OVA-VIL mice, whereas OT-II 
splenocytes alone functioned effectively in developing liver injury in the same animal. 
This finding  is consistent with previously published data (Buxbaum et al., 2006). These 
and our results confirm that CD8+ specific T cells initiated the liver injury in this animal 
model.  
 
In addition to their effect on liver injury, I noted that the highest proportion of the cells 
that migrated to the liver were OT-I cells, as reported by the percentage of Vα2+ in the 
OVA-BIL mice transferred with OT-I and OT-II or with only OT-I splenocytes. Our 
observations are in line with a previous study, which reported that CD8+ T cells were 
trapped in the liver and caused hepatitis even in the absence of CD4+ T cells (Derkow et 
al., 2007). However, I probably observed minor differences with the previous study that 
are likely to be associated with the different routes of administration of OT-I and OT-II 
cells, as well as the OT-I and OT-II purified following isolation from the spleen. 
Collectively, these findings confirm that OT-I splenocyte transplantation is directly 
associated with the development of liver injury in this animal model. More interestingly, 
the induction of OT-II splenocytes alongside OT-II splenocytes exhibited more liver 
injury in Ova-Bil transgenic mice. This suggests that OT-II cells could be required to 
induce hepatobiliary inflammation in Ova-Bil mice. However, this feature could be 
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specific to this model, as CD4+ cells have been reported as inducing sufficient liver injury 
in NOD mice (Irie et al., 2006). 
 
To determine the inflammatory response of this interaction, I examined the different 
populations of immune cells isolated from the livers of Ova-Bil mice in the presence of 
OT-I and OT-II splenocytes. As expected, the numbers of hepatic NK, non-NK and B 
cells in the liver were found to be normal in Ova-Bil mice prior to the induction of OT-I 
and OT-II. The transfer of OT-II cells alone had a similar inflammation profile to that 
reported in the control group. Interestingly, I reported an increase in hepatic NK cells as 
well as B cells following the adaptive transfer of OT-I splenocytes alone. In addition to 
the previous findings, OT-I alone significantly increased the total number of CD3 and 
CD8 lymphocytes in the liver. However, the latter cells were further able to enhance the 
number of hepatic CD4+ cells, compared with the induction of OT-I and OT-II together. 
However, the induction of OT-II cells did not lead to changes in the number of hepatic 
CD3, CD4, and CD8 T cells. These observations illustrated that OT-I directly contributed 
to the inflammation associated with acute liver injury in mice. Generally, the hepatic 
inflammation in this model was dependent on or required OT-I splenocytes (OVA-
specific CD8+ cells), and OT-II splenocytes (OVA-specific CD4+ cells) were not able to 
induce liver inflammation in Ova-Bil mice. One reason could be the low number of CD+4 
cells reaching the injured liver following IP injection, or this could be due to the lack of 
MHC-II expression in hepatic antigen-presenting cells (APCs), which could place CD+4 
in a steady state without activation.  
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In addition to the upregulation of adaptive immune cells in this liver model, I observed a 
remarkable increase in innate immune cells following OT-I and OT-II transplantation.   
My data illustrated the total number of hepatic CD45+, CD11+ and CD11+ F4/80+ cells in 
Ova-Bil mice in response to the adoptive transfer of OT-I and OT-II splenocytes when 
compared with normal mice treated with PBS. In comparison with OT-I and OT-II treated 
mice, I noticed an increase in CD45+, CD11+ and CD11+ F4/80+ cells following the 
adaptive transfer of a single population of OT-I. However, there were significant numbers 
of hepatic neutrophil (CD11b+ Ly6G+) and eosinophil (CD11b+ Gr-1Lo-neg SSCHI) cells in 
the Ova-Bil mice following OT-I and OT-II transplantation. In contrast, as found 
previously, the induction of OT-II cells did not lead to changes in the number of CD45+, 
CD11+ or CD11+ F4/80+ hepatic cells or in neutrophil or eosinophil cells. Together, these 
results indicate that OT-I and OT-II have been shown to induce a significant number of 
hepatic monocytes, suggesting that the hepatic monocyte infiltration of this animal model 
requires OT-I (OVA-specific CD8+ cells) as well as OT-II (OVA-specific CD4+ cells) 
splenocytes to enhance the inflammatory response. More importantly, this animal model 
is important in understanding the role of CD8 and CD4 in the development of liver injury, 
as well as hepatic inflammation. Another feature of this animal model is that it can be 
used to determine the interaction of CD8 and CD4 with innate immune cells and the 
underlying mechanisms of liver injury, which opens another area of study.   
 
In the previous chapter, I demonstrated that human UC-MSCs have the ability to improve 
the hepatic injury of acute hepatitis caused in hepatotoxic acute liver injury induced by 
CCl4. To validate whether this efficacy persisted in vivo, I further analysed the therapeutic 
role of UC-MSCs in Ova-Bil mice, which is another murine model of inflammatory liver 
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disease. As I had previously reported the variation in efficacy of the dose response in the 
CCl4 model, I conducted a similar study using varying infusions of hUC-MSC dosages 
(2.5x105, 5x105 and 1x106). In this study, the injured Ova-Bil mice treated with both 
2.5x105 and 1x106 were not found to have a clear reduction in ALT activity, whereas 
5x105 MSCs appeared to show a better improvement in liver injury. Collectively, my data 
suggest that a 5x105 dose of MSCs could be the most effective dose which is able to 
improve the liver injury in this animal model. Interestingly, this finding was in contrast 
with our previous data on CCl4, as 2.5x105 and 1x106 doses appeared to show more 
efficient sufficient improvement and a 5x105 dose showed major variation between 
animals. This finding highlighted that the optimal effective dose depends on 
understanding each disease condition, as well as the mechanism of MSCs in modulating 
injury. I believe that a high dose of cells is not required to have greater therapeutic 
efficacy. I further suggest that a high dose of injected MSCs could enhance the 
inflammatory and immune responses from the host immune system. In contrast with the 
above finding, it has been suggested that repeated MSC infusions have the potential for 
therapeutic outcomes in graft-versus-host disease (GVHD) animals when compared with 
a single dose of MSCs (Nauta and Fibbe, 2007). Furthermore, another study found that 
three subsequent doses of MSCs reduced the collagen deposition in a mouse model with 
liver fibrosis, which could be due to that animal model being chronic, and suggests 
repeated doses for better treatment (Fiore et al., 2015).  
 
In accordance with the above finding, a comparison study between unsorted and CD362+ 
purified hUC-MSCs was performed in this study using intravenous doses of 5x105 human 
unsorted UC-MSCs or CD362+ sorted UC-MSCs at day 4 following the induction of liver 
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injury in Ova-Bil mice. ALT enzyme activity in the serum at day 10 was measured to 
evaluate the liver injury in response to MSC treatment. A significant reduction in serum 
ALT was reported with infusions of CD362+ sorted UC-MSCs. My results indicate that 
CD362+ sorted cells have more efficacy in liver injury compared with unsorted cells. 
These data suggest that CD362 sorted MSCs have potential positive effects in liver injury 
in this animal model and I hypothesize that purifying MSCs may lead to more efficacy in 
the treatment of liver disease. In addition, my H&E staining of liver morphology revealed 
that liver preserved a normal structure with fewer leucocytes infiltrated around the portal 
area after exposing the animal to a single dose of UC-MSCs. In accordance with the above 
findings, I suggest that MSCs derived from umbilical cord could have 
immunosuppressive properties to reduce liver injury in OT-I and OT-II induction, and I 
believe this could be a potential mechanism to further study.   
 
In our previous study in CCl4 model, I found that intravenous injections of human UC-
MSCs attenuated the inflammation associated with liver injury induced by CCl4 
treatment. Here, I examined whether human UC-MSCs had a similar feature to modulate 
inflammation in the Ova-Bil model. Following the inflammation induced by the induction 
of OT-I and OT-II cells, I analysed the expression of CD45+ cells isolated from the liver, 
spleen and blood, using flow cytometry analysis. My data found that unsorted and 
CD362+ sorted UC-MSC-treated mice exhibited no significant reduction in hepatic 
CD45+ cells compared with Ova-Bil mice treated with PBS. The same findings were 
reported in CD45+ cells isolated from the spleen and blood. On the other hand, Ova-Bil 
mice showed specific hepatic expression of CD45+ cells around the portal area, as 
reported by IHC. Interestingly, in response to CD362 sorted MSCs, we reported a 
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significant reduction in the number of CD45+ cells in the liver sections of Ova-Bil mice 
compared with mice treated with unsorted UC-MSCs. These results show that only 
CD362+ sorted UC-MSC transplantation rescued the hepatic inflammation in the Ova-Bil 
mice. The high level of expression of the CD362+ marker may have a positive impact on 
the efficacy of UC-MSCs in liver inflammation associated with the Ova-Bil model, 
possibly because CD362 may secrete more endogenous cytokines, which promotes the 
anti-inflammatory function in this animal model.  
 
I conducted further experiments to define the influence of MSC treatment on NK, non-
NK and B lymphocytes isolated from different tissue sources, in particular, liver, spleen, 
and blood. After systemic perfusion of US and CD362 MSCs, I observed no changes in 
non-NK, NK, and B cells isolated from mouse liver, when compared with Ova-Bil mice 
treated with PBS. However, my results found that MSCs did not have an effect on 
immune cells isolated from peripheral blood and spleen. These findings could represent 
a possible explanation for the capacity of MSCs to reduce inflammation in the liver injury 
in this murine model. The opposite observation was recorded for CCl4, as reported by the 
ability of MSCs to reduce the B and non-NK cells in the liver. This could be explained 
by the two animal models used in this study having different levels of inflammation, as I 
believe that CCl4 is less severe when compared with the OBA-BIL mice. Based on this 
present study, I suggest research into whether MSCs have equal ability to engraft to 
injured liver when comparing two animal models following systemic infusion, and to 
report if MSC engraftments are correlated with the efficacy of MSCs to reduce liver injury 
in this animal model.   
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I analysed the translation potential of MSCs to suppress the proliferation of CD3+, CD4+ 
and CD8+ T cells in Ova-Bil mice with hepatobiliary injury. My data indicate that the 
hepatic infiltration of CD3+ and CD8+ T cells in Ova-Bil mice showed no differences 
between treated and untreated MSCs in these animals. A similar finding reported that 
MSCs isolated from bone marrow had no direct effect on CD8+ cells, but had some 
influence on the proliferation of T cells (Ramasamy et al., 2008). Interestingly, analysis 
of the number of CD4+ T cells in the liver showed a significant increase in the presence 
of MSC treatment. However, my results indicated that US and CD362 sorted MSCs 
reported equal induction effects on hepatic CD4 T cells in Ova-Bil mice compared with 
the untreated group. In contrast, I did not observe any ability of MSCs to upregulate the 
number of CD4 T cells isolated from blood or spleen. It is possible that the increase in 
CD4 expression could be associated with an increase in IL-10 in the circulation by MSCs. 
MSCs have been shown to secrete more IL-10 in response to activated T cells when 
compared with MSCs under normal culture conditions.  Several studies have reported that 
MSC treatment could cause more CD4+ cells to polarize towards Tregs with a positive 
expression of FOXP3. Accordingly, I assessed if MSCs could immunosuppress liver 
inflammation via the induction of Tregs. Surprisingly, my data indicate that MSCs had 
no significant impact on hepatic Tregs in this animal model.   
 
Within the liver, macrophages have a great effect on the pathogenesis of liver diseases, 
with essential functions in homeostasis and the progression of different liver diseases 
(Tacke and Zimmermann, 2014). In a previous chapter, I found that MSCs suppressed 
macrophage activity in mouse liver with hepatotoxic injury but failed to polarize the 
macrophages towards an anti-inflammatory phenotype. Here, I further analysed the 
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ability of MSCs to modulate the myeloid immune cells in Ova-Bil injured animals. My 
flow cytometry data reported that US and CD362 MSCs had no ability to modulate the 
number of macrophages (CD11+ F4/80+) in the liver. In addition, the circulating 
macrophages isolated from peripheral blood, as well as spleen, were not shown to change 
following MSC treatment. In contrast, quantification of F4/80+ cells in liver sections 
found a decreased level of macrophages following US and CD362+ sorted MSC 
transplantation. Furthermore, I compared the immunosuppressive ability of US and 
CD362 UC-MSCs in M1 and M2-like cells isolated from mouse liver. Based on my flow 
cytometry data, the MSCs did not show any change in the macrophage phenotype 
between M1 and M2-like cells. This could be due to UC-MSCs lacking secretion of IL-
6, which is reported to have a positive impact towards the differentiation of monocytes 
from macrophages with anti-inflammation phenotypes (Chung and Son, 2014). Another 
possible factor is the time period that MSCs require for this therapeutic feature. M1-like 
cells have been found to have early activation within 3 days and later to polarize to M2-
like cells by the day following MSC injection (Arnold et al., 2007). In my animal models, 
my endpoints following MSC administration were 6 days in the Ova-Bil and 3 days in 
the CCl4 animal model. Thus, I may have missed the ability of MSCs to have this 
polarization capacity and suggest considering later time points in future study. In addition, 
further experiments are suggested to study cell-to-cell contact via the direct culture of 
immune cells isolated from injured liver and MSCs, as applying exosomes from MSCs 
to the same cells could answer the paracrine efficacy of MSCs in vitro.  
 
ICAM-1 and VCAM-1 adhesion molecules have been shown to mediate the 
immunosuppressive function of MSCs through the direct adhesion of MSCs to immune 
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cells (Chamberlain et al., 2011).  Using IHC and qPCR, the transfer of OT-I and OT-II 
cells in Ova-Bil mice clearly promoted the expression of ICAM and VCAM in the liver, 
when compared with normal Ova-Bil mice. Interestingly, one major advantageous 
observation in the present study is that, upon MSC infusion, I observed a significant 
reduction in ICAM and VCAM expression in liver sections from Ova-Bil mice treated 
with CD362+ MSCs compared with mice treated with PBS. In addition, the above 
observations were confirmed by a significant decrease in the hepatic mRNA expression 
of ICAM and VCAM in Ova-Bil mice treated with CD362 MSCs. I observed a trend 
towards a decline in ICAM and VCAM in Ova-Bil mice treated with unsorted MSCs. My 
finding shows, for the first time, that human CD362 purified MSCs show superior 
properties compared with normal MSCs. I could not show a significant therapeutic effect 
of unsorted UC-MSC transplantation in either of the animal models used in this study. 
This may relate to biological variation and the need for additional experiments, or it may 
reflect the inferiority of unsorted MSCs. My results are not in line with our previous 
ICAM and VCAM data from CCl4 models, which suggests that MSCs have a 
multifunctional effect and could relate to the pathophysiology of the disease itself. In the 
Ova-Bil model, the improvement in liver function following MSC transfusion could be 
mainly due to a reduction observed on ICAM and VCAM expression in the injured liver. 
We believe that our findings begin to elucidate how multiple classes of factors releasing 
by MSC cooperate to promote liver improvement. Additional studies, both in vitro and in 
vivo, are needed to improve our understanding the mechanisms of action of this potential 
mechanism. In particular, future work is required to demonstrate if MSC can modulate 
ICAM and VCAM expression on hepatic T cells or hepatic endothelial cells and the 
consequence in the therapeutic efficacy of MSC in liver disease. In addition, 
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understanding the interaction between MSCs and ICAM and VCAM could be one of the 




Finally, two cytokines, in particular, TNF-a and INF-g, have been shown to be produced 
following activation of T cells (Ito et al., 2010). In addition, the two cytokines have been 
found to induce the expression of  ICAM in liver injury (Afford et al., 2014). In this 
model, following the adoptive transfer of OT-I and OT-II, we reported increased 
expression of TNF-a and INF-g. In addition, I observed a minimum induction in INF-g 
with no difference in TNF-a in MSC-treated mice compared with untreated animals.  
In summary, MSC transplantation is a promising candidate for the treatment of liver 
diseases. In this in vivo study, I have provided useful evidence of inflammation activities 
related to the induction of OT-I and OT-II in Ova-Bil mice. Following the induction of 
liver inflammation, subsequent infiltration of immune cells to the injured area of the liver 
was reported. The findings of this chapter provide an important explanation for defining 
the in vivo experiment, which aimed at improving the therapeutic efficacy of 
mesenchymal stromal cells in liver injury. Here, the therapeutic effects of US and CD362 
sorted UC-MSCs were reported in this study in Ova-Bil mice with hepatobiliary 
inflammation. I showed that CD362 MSCs improved the hepatic injury of Ova-Bil mice 
with acute inflammation, followed by the downregulation of hepatic CD45+ infiltrating 
cells, as well as F4/80 macrophages in the liver histology. The capacity of macrophage 
polarization and the induction of Tregs were not altered by MSC therapy. MSCs also 
demonstrated a remarkable increase in hepatic CD4+ cells, which could have a specific 
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mechanism related to MSC immunosuppression functions. Given the immunosuppressive 
properties of MSCs, it was clearly that purifying MSCs with CD362+ cells would 
enhance the ability of MSCs to reduce the level of adhesion molecules (ICAM and 
VCAM), which makes MSCs a more promising candidate in the treatment of liver 
diseases. Finally, the different therapeutic effects of MSCs could be due to the specific 
microenvironment in each disease condition, as well as the mechanisms which control 





















































IN VIVO TRACKING AND MONITORING OF THE HOMING OF 




















7.1 Introduction  
 
 
MSCs offer great potential for the treatment of different diseases and conditions and could 
have therapeutic benefits. Moreover, the homing of infused stromal cells has been 
reported in several studies. For example, several studies have reported that MSCs are 
trapped in the lung after systemic administration (Lee et al., 2009; Galleu et al., 2017), 
while others have found that MSCs have the ability to migrate to a site injury and offer 
therapeutic improvement. In contrast, the route of MSC administration, such as 
intraperitoneal (IP), intramuscular, subcutaneous (SC) or intrahepatic injections, has been 
shown to be another important aspect in the literature and seems to have a role in 
achieving better therapeutic applications (Uccelli et al., 2008; van Velthoven et al., 2012). 
In addition, a direct comparison between different routes of MSC injection has shown 
that intramuscular administration results in a prolonged survival of MSCs compared to in 
vivo injection (Braid et al., 2017).   
 
The accurate quantification and determination of numbers of infused stromal cells are 
still not fully defined. Therefore, many recent researchers have reported different methods 
for studying the homing of transplanted stem cells in vivo. Magnetic resonance imaging 
(MRI) was reported to be a good technique for tracking infused cells in animals. Sheng 
Hong Ju et al. successfully studied the migration of labelled bone marrow MSCs (BM-
MSCs) to the liver using MRI and found that the labelled cells were localized in the liver 
after three hours and then showed a gradual reduction after 3, 7 and 14 days (Ju et al., 
2007). Another technique that has been used in an animal study is an in vivo imaging 
system (IVIS), which represents a reliable optical system for detecting the migration of 
infused cells (Eisenblätter et al., 2009). Using this technique, labelled MSCs are infused 
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by several routes and the cells detected using the IVIS system. The MSCs were found to 
disappear within a few days following IV injection, but were detected at 3–4 weeks when 
injected intraperitoneally or subcutaneously (Braid et al., 2017). Another study has 
determined the homing of MSCs administered by intravenous (IV) injection by testing 
the DNA expression of human albumin using qPCR. They reported different expressions 
among different tissues with the greatest expression in the lung (Briquet et al., 2014). 
More recently, an advanced system was developed that provided very high-resolution 
images for a whole mouse using CryoViz technology. This device is a fully automatic 
machine which has the sensitivity to detect a single live cells, and can provide a 3D 
structure for the whole animal or a specific organ of interest (Roy et al., 2009). In addition, 
one unique feature of this technique is the ability to quantify the number of live cells in 
vivo after fluorescent labelling of cells prior to injection.  
 
In the present work, I performed a biodistribution study of human MSCs (hMSCs) 
following injection into an animal model with liver injury. Side-by-side comparison of 
the homing of MSCs was reported between an Ova-Bil animal model and a CCl4 animal 
model.  Briefly, CD362+ sorted MSCs were labelled with quantum dots (Q-605) and 
adoptively infused via the tail vein into mice to investigate their biodistribution at 
different time points after infusion. Next, I determined the fate of infused labelled cells 
by using the CryoVizTM system (BioInVision, Cleveland, USA). Here, I showed that 
studying the cryo-imaging of a whole mouse demonstrated that UC-MSCs infused 
intravenously were detected in the lung, liver and spleen, and that most of the MSCs were 
trapped in the lung and rapidly cleared by 24 hours, with few cells remaining in the 
different organs. I did not notice any liver-specific increase in the number of MSCs. 
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7.2 Chapter Aims  
 
 
In the present study, I used UC-MSCs labelled with quantum dots (Qdots) in two mouse 
models of liver injury to assess the biodistribution as well as the fate of the injected MSCs. 
In addition, I hypothesized that the homing of MSCs to the site of liver injury was 
necessary for greater therapeutic efficacy. The aims of this study were to: 
 
• Monitor and track the engraftment of MSCs in vivo.  
 
• Quantify and determine the number of infused cells accurately. 
 
• Examine whether infused cells migrated to the site of injury or home to different 
parts of the body.   
• Determine how long transplanted MSCs stay in the body following systemic 
infusion.  
• Establish in which part of the liver injected MSCs can be identified (e.g., the 


















7.3 Results  
 
 
7.3.1 Qdots have high labelling efficacy and do not affect the viability 
or enhance the apoptosis of MSCs 
 
Identification of the distribution of infused UC-MSCs in vivo would provide a better 
understanding of the mechanism of action of these cells and their homing, after systemic 
infusion. Here, mice received an IV injection of MSCs labelled with Qdots. Qtracker Cell 
Labelling Kits (Qtracker® 625 Cell Labelling Kit, Invitrogen, A10198) were used to label 
MSCs for in vivo cell tracing (the labelling procedure was reported previously in chapter 
2). Briefly, MSCs were incubated with Qdots at 37 °C for 45–60 minutes, and the cells 
washed twice with complete growth medium and resuspended in normal saline for 
infusion. 
In order to address whether Qdots have an effect on the viability of MSCs, I determined 
the viability of the MSCs one hour after labelling with Qdots by using flow cytometry. 
My results demonstrated that the viability of MSCs was about 84% following labelling 
with Qdots. This result clearly showed that Qdots had no observable effect on the viability 
of MSCs in vitro (Figure 7-1A). More importantly, it was essential to determine the 
efficiency of Qdots when labelling MSCs for cell tracking. In order to confirm the 
efficiency of Qdot-labelled MSCs, I studied the expression of Qdots one hour after 
staining using flow cytometry. My FACS data showed that > 90% of the MSCs were 
labelled with Qdots, as shown in Figure 7-1A. A representative image of MSCs labelled 
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Figure 7-1 Efficacy and cell viability following quantum dot labelling of MSCs. A) Cell 
viability was measured by flow cytometry of Qdot-labelled MSCs 1 hour after staining. 
Following the Qdot-labelled MSCs for 1 hour, I observed > 90% of cells were stained with 








To further optimize the presence of Qdot-labelled MSCs in vivo, I directly injected Qdot-
labelled MSCs into lung tissue harvested from mice and visualized the cells using the 
CryoViz™ technique. A large number of Qdot-labelled MSCs were clearly observed in 
the lung tissue, which indicated that our Qdots were a good labelling dye to use for my 





Figure 7-2 Representative image of bright and florescent lung tissue following direct 
induction of MSCs labelled with Qdots (arrows denote the MSCs labelled with Qdots). 
 
7.3.2 Biodistribution of Q-605-labelled UC-MSCs in CCl4 and OVA-
BIL animal models 
7.3.2.1 Study design  
 
 
Two animal models of liver injury were investigated in this study in order to assess the 
homing of infused MSCs in vivo. The biodistribution of human UC-MSCs labelled with 
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Qdots was assessed by injecting them intravenously in both CCl4 and OVA-BIL animal 
models. Animals were then sacrificed for whole-body imaging at different time points.  
In the CCl4 animal model, UC-MSCs labelled with Qdots were injected 4 hours after the 
induction of liver injury using CCl4. Following intravenous injection of 250x103 Qodt-
labelled MSCs, the mice were sacrificed at different time points (1 h, 3 h, 1 day, 2 days, 
3 days, and 7 days), and whole mouse bodies were snap frozen in optimal cutting 
temperature (OCT) medium and stored at -80 °C until the day of the analysis. A schematic 
diagram of the study design is shown in Figure 7-3A. The other model examined in this 
chapter to investigate the fate of MSCs post-systemic perfusion was the Ova-Bil animal 
model. After the induction of liver injury in Ova-Bil mice using OT-I and OT-II cells, a 
single infusion of Qdot-labelled MSCs was given on day 4 and the mice were sacrificed 
at 1 hour, 1 day, and 5 days following MSC injection (Figure 7-3B). In both models, 
labelled cells were quantified in different organs (lung, liver, and spleen) and the 
percentage of detected cells was calculated from the global cell count at 1 hour. In 
addition, whole-body images and 3D fluorescence structures were detected at different 
time points using the Cryo-Imaging System (BioInVision, Cleveland, USA). 
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Figure 7-3 A) Illustration of the study design. A) Animals were treated with CCl4. After 4 
hours, mice received an intravenous injection (250x103) of human MSCs labelled with Qdots. 
Animals were then sacrificed at different time points (1 h, 3 h, 1 day, 2 days, 3 days, and 7 
days) and then snap frozen in OCT medium for further analysis. B) Ova-Bil mice received 
adaptive transfer of OT-I and OT-II cells. After 4 days, the mice received an intravenous 
injection (500x103) of UC-MSCs labelled with Qdots. Animals were then sacrificed at different 
time points (1 h, 1 day, and 5 days) and then snap frozen in OCT medium for further analysis. 
 
 
7.3.2.2 Global hMSC retention at different time points following MSC 
infusion  
 
In the CCl4 model, the mice received an intravenous injection of 250x103 UC-MSCs and 
were sacrificed at different time points (3 h, 1 day, 2 days, 3 days, and 7 days). Labelled 
cells were quantified in different organs, in particular, the lung, liver, and spleen. The 
percentage of cells detected was calculated from the total global number of live cells 
found 1 hour after MSC infusion. The global cell retention count in the whole body was 
found to be 91% within 1 hour of MSC infusion, and then reduced slightly to 70% 3 hours 
after MSC induction. Interestingly, cell retention was observed to decline massively after 
day 0
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day 4
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24 hours of infusion such that only 6% of total live cells could be detected. By days 2, 3, 
and 7, the total live cells reported was < 4%, as shown in Figure 7-4A.  
In addition to the above finding, I considered whether the above observation was seen in 
another animal model of liver injury. Here, the liver injury in the Ova-Bil mice was 
developed by the induction of OT-I and OT-II cells. By day 4, the Ova-Bil mice received 
an intravenous injection of 500x103 UC-MSCs and were sacrificed at different time points 
(1 h, 1 day, and 5 days). As explained above, the total cell retention was calculated based 
on the global cell count at 1 hour post infusion. As expected, I detected a similar number 
of cells in vivo at 1 hour with a total of 90%. At 24 hours and 5 days following MSC 
infusion, the cell retention detected was 8%–4%, respectively (Figure 7-4B). My 
observation clearly demonstrated that the injected MSCs were found to have decreased 
markedly after 24 hours, by approaching 80%, which suggested that the cells could 

































































Figure 7-4 Qdot-labelled MSC retention at different time points in CCl4 and Ova-Bil 
mouse models of liver injury. A) MSC retention at different time points in the CCl4 injured 
mice after IV induction of Qdot-labelled MSCs (n = 3–5/time point). B) MSC retention at 
different time points in the Ova-Bil injured mice after IV induction of Qdot-labelled MSCs (n 
= 3 mice in each time point). Data are presented as the mean ± SD. The percentage of cells 
were calculated and normalized to the global cell number 1 hour after MSC injection.  
 
7.3.2.3 Biodistribution of Qdot-labelled MSCs in the lung, liver, and spleen at 
different time points following induction of liver injury    
 
Next, I assessed the in vivo biodistribution of Qdot-labelled MSCs following systemic 
induction in two animal models of liver injury. One hour after infusion of MSCs into CCl4 
injured mice, the majority of the live cells detected were found in the lung (> 90%) with 
a small number of cells observed in the liver (3–4%), as shown in Figure 7-5A.  
Furthermore, my data showed that a small percentage of cells were found in the lung 24 
hours after MSC treatment (5%) compared with the MSCs detected in the lung at 1 and 3 















































subsequent time points (2 days, 3 days, and 7 days); 0.8% of total quantified cells were 
detected in the whole body after 7 days (Figure 7-5A).    
Interestingly, the distribution pattern of MSCs in the Ova-Bil mice was found to be the 
same as that reported in the CCl4 animal model. As shown in Figure 7-5B, 80% of Qdot-
labelled MSCs appeared to home to the lung 1 hour after systemic infusion, with 20% 
migrating to the liver in the same period. At 24 hours following MSC treatment, more 
than 90% of the MSCs injected were undetectable. However, I found that 2% of the cells 
were in the lung and 6% of the live injected cells were detected in the liver. Despite the 
low number of engrafted cells in the liver after 24 hours, I detected more engraftment of 
MSCs in the liver compared with the lung at 24 hours. This finding could demonstrate 
that, in both models, less than 0.5% of MSCs were found in the spleen across all the time 
points. I found that MSCs were engrafted to the lung at a higher rate within 1 hour of 
injection. In addition, I did not observe any evidence in this study that injected MSCs 
















































Figure 7-5 Biodistribution of Qdot-labelled MSCs in the lung, liver, and spleen at 
different time points. A) Number of MSCs homing to the lung, liver, and spleen were 
quantified after different time points in CCl4 mice with hepatotoxic injury (3–5 animals per 
group). B) At 1 hour, 1 day, and 5 days, MSCs homing to the lung, liver, and spleen were 
quantified in Ova-Bil mice (3 animals per group). The percentage of cells was calculated and 
normalized to the global cell number 1 hour after MSC injection. Data are presented as the 
mean ± SD.  
 
7.3.2.4 MSCs do not home to the site of liver injury 24 hours after MSC injection   
 
I compared the engraftment efficiencies of MSCs in healthy mice at 24 hours with animals 
with liver injury in CCl4 and Ova-Bil animal models. In the CCl4 model, my data showed 
that infused MSCs were reported to have equal distribution patterns between the control 
animals (M.O) and the injured mice (CCl4) within the lung, liver, and spleen at 24 hours 
post-MSC injection (Figure 7-6A). In addition, the engraftment of systemic infused MSCs 
was determined in the Ova-Bil mice at 24 hours. Surprisingly, I observed a remarkable 
decrease in the number of MSCs detected in the lungs and livers of Ova-Bil mice 




































healthy mice (Figure 7-6B). This pattern of reduction suggested that MSC engraftment in 










Figure 7-6 Percentage of MSCs detected at 24 hours in different organs of healthy mice 
and liver-injured mice. A) Number of MSCs homing to the lung, liver, and spleen were 
quantified at 24 hours and compared between healthy mice and CCl4 mice with liver injury (3 
animals per group). B) At 24 hours, MSCs homing to the lung, liver, and spleen were quantified 
in Ova-Bil  mice with or without OT-I and OT-II induction (3 animals per group). The 
percentage of cells was calculated and normalized to the global cell number in the lung 1 hour 


























































7.3.2.5 Whole-mouse cross-section images for the in vivo detection of 
infused MSCs across different organs at different time points 
 
To monitor the fate of infused MSCs over time, whole-body images were evaluated at 
different time points using the Cryo-Imaging System (Figure 7-7A and B). In both animal 
models, Qdot-labelled MSCs were detected at different time points in different organs in 
the mice. As reported in Figure 7-7A and B, the majority of Qdot-labelled MSCs were 
observed in the lung within one hour of a systemic injection, following by significant 
reductions across the later time points. I observed the same reduction in both the CCl4 
and Ova-Bil animal models. However, I did not detect more cells migrating to the site of 
injury or inflammation, which I thought would provide a trigger for MSC migration.  
For the further evaluation of MSCs detected in vivo, I confirmed the previous finding by 
using a 3D cryo-imaging system which has the ability to detect Qdot-labelled MSCs 
injected in mice in different organs at several time points. In Figure 7-8, the high-
resolution 3D fluorescent images show that most of the injected cells accumulated in the 
lung within one hour of MSC infusion, as reported in the CCl4 and Ova-Bil animal 
models. However, I reported more MSCs engrafted in the livers of Ova-Bil mice 1 hour 
after infusion compared with livers from CCl4-injured mice (Figure 7-8A and B). 
However, my 3D images showed that MSCs were no longer detected in any of the organs 
5 and 7 days post infusion. These time points indicated that most MSCs were detected in 
the lung in the earlier time points and declined with time. I also detected that Ova-Bil 














Figure 7-7 Representative images of the biodistribution of intravenously injected MSCs 
in vivo at different time points. A) Visualization of MSC distribution in whole mice after 
intravenous injection of MSCs at different time points in CCl4 mice with hepatotoxic injury.    
B) Representative sections showing whole-body MSC distribution in Ova-Bil mice at 1 hour, 














Figure 7-8 3D fluorescent CryoViz™ images of in vivo detection of infused Qdot-labelled 
MSCs in different organs at different time points. A) Visualization of MSC distribution in 
a 3D bright field in the lung, liver, and spleen after intravenous injection of MSCs at different 
time points in CCl4 mice. B) Representative 3D images showing MSC distribution in the lung, 




7.3.2.6 Qdot-labelled MSCs localized in the hepatic parenchymal area in the CCl4 
model across time points  
 
To further verify the distribution and localization of Qdot-labelled MSCs in the liver, I 
performed histological analysis of liver sections using the CryoViz™ imaging system. 
Representative bright field and fluorescent images of MSCs were detected in liver 
sections from CCl4 mice and were noted in vivo at different time points post-MSC 
injection. Interestingly, MSCs were found predominantly near the parenchymal area in 
the liver sections, as seen in Figure 7-9. I did not find that cells migrated specifically to 
the portal area. In addition, I observed a greater number of MSCs 1 hour after MSC 
injection, followed by reductions in MSC numbers with time. My data suggest the 
possibility that MSCs had interacted with hepatocytes as well as with other immune cells 




Figure 7-9 Representative bright field and fluorescent images of Qdot-labelled MSCs in 
the liver sections of mice with CCl4 injury.  Visualization of the presence of MSCs in liver 
sections after intravenous injection of MSCs at different time points (1 h, 1 day, and 7 days) in 
CCl4 mice. Pink circles represent Qdot-labelled MSCs detected in liver sections. 
 
7.3.2.7 Visualizing Qdot-labelled MSCs outside the major organs (lung, liver and 
spleen) 1 hour after systemic infusion in Ova-Bil mice  
 
Finally, I performed whole-body cryo-imaged mouse sections to further define other 
specific organs to which MSCs may have engrafted following systemic infusion of MSCs 
in the Ova-Bil mouse model. As shown in Figure 7-10, I found that some MSCs engrafted 
to different organs in the mouse body, such as the kidney, ribs, and adrenal glands, 1 hour 
after intravenously infused MSCs.  
 
Figure 7-10 Representative sections showing whole-body MSC distribution to different 
parts of the body in Ova-Bil mice at 1hour post-MSC infusion. Red circles represent 





7.4 Discussion  
 
 
MSCs hold promising therapeutic potential for several clinical applications. However, 
several barriers in the field of cell therapy have been intensively reported in order to 
understand the engraftment as well as the viability of cells following in vivo induction. In 
addition, the homing of infused MSCs has been reported in several studies, and different 
techniques used to quantify the number of cells (Pritchard, 2016). In this study, I 
investigated the dynamic homing of MSCs by using a new imaging system that has been 
developed recently and can provide very high-resolution images with a 3D view of a 
whole mouse (Roy et al., 2009). I used hMSCs isolated from the umbilical cord and 
systemically infused in two animal models with liver injury. I found that most of the 
injected MSCs were trapped in the lung within 1 hour and showed a remarkable decline 
in numbers after 24 hours. My findings are in line with previous results that demonstrated 
MSC engraftment as well as the quantification observed across time points of the 
systemic induction of MSCs.  
In order to evaluate the homing ability of MSCs in vivo, I used Qdots, which are 
fluorescent nanoparticles with a size range of 2–10 nm (Ferreira et al., 2008). In this 
study, and prior to the in vivo induction of MSCs, I investigated the viability of MSCs 
following culture with Qdots in vitro and assessed the efficiency of MSCs labelled with 
Qdots. My flow cytometry data reported that MSCs were labelled with Qdots for one hour 
and resulted in high labelling efficiency (92%), with no effects reported regarding the 
viability of the MSCs. Similar findings have been reported by other groups, which found 
that Qdots showed high efficiency in labelling mouse embryonic stem cells (85%) and 
reported no dead cells detected in response to the Qdot-labelling procedure (Rak-
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Raszewska et al., 2012). In contrast, another study reported lower efficiency (70%) 
following the labelling of hMSCs with Qdots (Auletta et al., 2015). Another report found 
that MSCs labelled with Qdots decreased after co-culture in vitro for 24 hours. 
Accordingly, in my in vivo experiments, the Qdot-labelled MSCs were injected 
immediately after the one hour labelling procedure and injected intravenously (Muller-
Borer et al., 2007). I found Qdots to be a safe and feasible material for cell labelling to 
track MSCs after infusion in vivo. My in vitro characterization also led me to hypothesize 
that Qdots had high labelling efficiency with no direct effect on MSC viability. This 
demonstrated that Qdots would be a more beneficial and suitable material to use for 
tracking MSCs in vivo in terms of fully understanding their engraftment ability and 
potential in cell therapy. Future analysis is, however, essential to evaluate the cytotoxicity 
of Qdots after internalization by MSCs.  
 
In this study, I analysed the fate of MSCs labelled with Qdots after systemic infusion in 
two animal models of liver injury. Here, I used the CryoViz™ imaging system to monitor 
the trafficking of MSCs and quantified live MSCs after infusion in mice with liver injury. 
In the CCl4 hepatotoxic model, the global cell retention count in the whole body was 
found to be 91% within 1 hour of MSC infusion and declined massively (6%) 24 hours 
after infusion. On the other hand, Ova-Bil mice with hepatobiliary injury induced by OT-
I and OT-II induction showed retention of 90% of total MSCs injected at 1 hour, followed 
by a marked reduction in MSCs (8%) at 24 hours post infusion. In line with these findings, 
using the CryoViz™ imaging system, Schmuck et al. showed that 80% of hMSCs were 
detected within different organs 1 hour after systemic infusion and this dropped to < 
0.06% within 2 days post infusion (Schmuck et al., 2016). In a similar finding, umbilical 
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cord matrix stem cells were detected after 2 days but no cells were observed 6 and 12 
days after infusion (Weiss et al., 2006). In comparison with other studies, Gao et al. have 
shown that MSCs can be detected in many organs, such as the lung, heart, liver, and 
kidney, from the first hour to 7 days after intravenous injection of MSCs (Gao et al., 
2001). However, the above studies used different techniques (IVIS and MRI), which 
cannot detect the actual number of live cells and they counted the cells according to the 
intensity of florescence used to stain the cells. Notably, our data clearly demonstrated that 
MSCs remained live in the lung for a few hours after infusion and disappeared from the 
lung after 24 hours, suggesting that MSCs have a short life in the recipient mice. 
Questions remain with regard to why MSCs are trapped directly to the lung, and why 
MSCs no longer exist 24 hours after injection. 
However, the shortness of MSC viability, as well as their quick disappearance, has no 
impact on the therapeutic function of MSCs, as reported in several studies. One important 
finding could come from the idea that MSCs are cleared via lung macrophages; this was 
reported by the increased expression of the F4/80 marker in the lungs of mice undergoing 
MSC injection (Hoogduijn et al., 2013). In addition to the clean-up of MSCs by 
macrophages, a very recent study has demonstrated that MSCs might have the ability to 
induce the distribution of monocytes and show immunoregulatory ability across the body 
(de Witte et al., 2018). Furthermore, the same study showed that the majority of MSCs 
were dead 24 hours after injection with engraftment potential to the lung and liver. It was 
found that MSCs could change the phenotypic characteristics of monocytes to a non-
classical phenotype.  
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In order to achieve the short-term survival of injected cells, the local transplantation of 
an injection could provide more efficient therapy in liver disease. In addition, I suggest 
that another route of administration could be applied to investigate the potential delivery 
of injected cells to the site of injury. For example, the infusion of MSCs directly into the 
portal vein may lead to more engraftments to the local liver injury and subsequently 
improve therapeutic efficacy. The beneficial effect of the direct injection of MSCs into 
the portal vein has been reported in acute liver injury and was found to have more 
promising support of liver regeneration (Cao et al., 2012). In contrast, it is important to 
note that the local injection of MSCs in some organs, such as the brain and heart, is not 
acceptable clinically and may lead to the development of more invasive complications. 
Hence, IV delivery is less invasive and would be the most effective form of administration 
despite the low engraftment rate.  
 
In addition, the biodistribution of Qdot-labelled MSCs was calculated as a percentage of 
the cells detected at each time point normalized to the global cell count in the lung at 1 
hour. In the CCl4 model, the majority of MSCs were found in the lung after 1 hour (> 
90%) and were subsequently depleted 24 hours after injection (< 4%). However, at the 
same time point, a small number of cells were detected in the liver, with only 4% of 
injected cells. On the other hand, Ova-Bil mice with hepatobiliary injury induced by OT-
I and OT-II showed 80% of MSCs trapped in the lung at 1 hour, whereas 20% of the 
MSCs were found in the liver. My results indicated that most cells migrated to the lung 
within 1 hour and declined gradually with time, and less than 0.8% of the total quantified 
cells were detected in the whole body after 7 days. Interestingly, the findings in this study 
clearly indicated that more MSCs engrafted to the liver after 24 hours in the Ova-Bil mice 
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compared with the cells detected in the lung. This observation was in Ova-Bil mice, which 
indicated that more MSCs engrafted to the site of injury 24 hours after systemic 
implantation. Based on these findings, I speculate that the observed variations in the 
engraftment of MSCs between the CCl4 and Ova-Bil mouse models suggest that different 
factors affect the recruitment abilities of MSCs, either from the bloodstream or from the 
tissue environment of the injured site. I also believe that this could be due to the higher 
number of infused MSCs in Ova-Bil mice compared with the low number injected into 
the CCl4 mice. Thus, I anticipate that a greater number of injected MSCs could result in 
higher engraftment potential to an injured site. In line with the previous finding, a 
comparison study was conducted to investigate the number of cells injected and the 
engraftment potential. This study reported that engraftment potential is correlated to a 
high number of injected cells (Omori et al., 2008).   
 
 
The therapeutic efficacy of cell therapy could rely on the engraftment of cells to the site 
of injury. Accordingly, I conducted a comparison study of MSC engraftment between 
healthy and liver-injured mice using the CryoViz™ imaging system. In the CCl4 model, 
my data showed that infused MSCs were reported to have equal distribution patterns 
between the control animals (M.O) compared with injured mice (CCl4) within the lung, 
liver, and spleen at 24 hours post-MSC injection. In addition, the engraftment of 
systemically infused MSCs was determined in Ova-Bil mice at 24 hours. Surprisingly, 24 
hours after systemic MSC injection, I observed a remarkable decrease in the number of 
MSCs detected in the lungs and livers of Ova-Bil mice subjected to OT-I and OT-II cell 
induction (injured group) compared with the Ova-Bil healthy mice. This pattern of 
reduction suggests that MSC engraftment in Ova-Bil mice appears to be different from 
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that engrafted in the CCl4 mouse model. Similarly, a recent study reported that MSCs 
migrated from the circulation to the tumour microenvironment in mice with hepatic 
tumours, and no MSCs were found in mice with a healthy liver (Xie et al., 2017). 
Although some studies reported conflicting data about the fate of systemically infused 
MSCs in vivo, they reported that infused cells showed no differences in the migration to 
the ischemic liver injury compared to mice with normal livers (Eggenhofer et al., 2012).  
 
Following low numbers of infused MSCs showing engraftment within an injured liver, 
we further investigated the distribution of Qdot-labelled MSCs in the liver 
microenvironment and the exact location within the tissue. Interestingly, MSCs were 
found predominantly near the parenchymal area in liver sections but not in the portal area, 
as reported in the CCl4 model. My data might demonstrate that MSCs show a possible 
interaction with hepatocytes as well as with other immune cells resulting from liver 
inflammation. In addition, these results provide crucial insight that MSCs may exhibit 
local trophic or paracrine activity that could offer a consequential therapeutic effect in 
liver diseases.  
 
I reported that IV injection resulted in a small number of injected MSCs reaching the 
liver. Further routes of administration should be fully considered in future study. I believe 
that direct injection into the locale of an injured site will promote the homing of cells with 
more efficient effects. To increase MSC homing to the liver, MSCs could be modified in 
vitro for greater homing efficiency through one of the following strategies: 1) Sorting 
MSCs to enrich more purified cells with greater homing functionality (Sherman et al., 
2017); 2) Priming MSCs with factors such as cytokines and chemokines, which were 
found to enhance the recruitment of MSCs to the site of injury (Ren et al., 2011); and 3) 
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Genetic engineering or modification of MSCs has shown beneficial effects in many 
preclinical studies (Yang et al., 2015). Another important feature that would seem to 
require more investigation is to check whether the phenotype of engrafted MSCs has 
changed or remains the same in the physiological and pathological states.   
 
 
In summary, the homing of infused stromal cells has been found to be important to 
promote therapeutic regeneration as well as to treat inflammation in liver diseases. I 
analysed the fate of MSCs labelled with Qdots after systemic infusion in two animal 
models of liver injury. This study used the CryoViz™ imaging system to monitor the 
trafficking of MSCs and quantify live MSCs after infusion in mice with liver injury. I 
found that most injected MSCs were trapped in the lung within 1 hour and had cleared 
within 24 hours of systemic infusion. In addition, my findings clearly reported that more 
MSCs engrafted to the liver after 24 hours in the Ova-Bil mice compared with cells 
detected in the lung. However, I reported variations in the engraftment of MSCs in the 
liver at 24 hours between the CCl4 and the Ova-Bil mouse models, which suggests that 
different factors affect the recruitment abilities of MSCs in both CCl4 and Ova-Bil  mice. 
The data in this study will help to guide future aspects related to therapy involving the 
transplantation of MSCs in liver injury. However, I believe there still remains a major 
lack of understanding of the several mechanisms of how MSCs are engrafted and target 














































8.1 Conclusion  
 




Mesenchymal stromal cells have been successfully isolated from human umbilical cord 
and represent an attractive source of MSCs for use in clinical studies. In addition, 
maintaining heterogeneity within cultured MSCs population have been shown to be 
important for optimal therapeutic function. In chapter 3, we showed for the first time that 
unsorted and CD362 sorted MSCs isolated from umbilical cord demonstrated similar 
expression of MSCs markers as well as the capacity to undergo tri-lineage differentiation 
in vitro. I would appreciate more comparative studies to give use a better understating 
about the immunomodulatory function of the both population of MSCs as well as the 
ability to differentiate to some specialized cells such as hepatocytes in vitro.  
 
In this study, I addressed the expression of CD362 across different MSC sources (BM 
and UC) and found that MSCs from different origins expressed CD362 at different levels. 
I therefore reported that CD362 expression is predominant in umbilical cord and could 
be highly expressed in MSCs from birth-associated tissues. In addition, I also 
demonstrated that the expression of CD362 from different donors at the same passage 
number expressed different levels of CD362. This variation could come from the 
variation of donor age which I did not assess in my study, this limitation will be addressed 
in my future studies. More importantly, my results showed a significant decrease in the 
expression of CD362 by passage 5. These finding support that using late passage MSCs 
was not appropriate for their therapeutic use and may not be functionally suitable for 
transplantation. Further and in more depth in vitro studies are required to understand the 
 239 
function of CD362 expression by MSC and the significance of CD362 in the clinical use 
of MSCs.  
 
8.1.2 Time course of injury post-CCl4 administration 
 
 
The future for developing MSC-based therapies for liver diseases lies in understanding 
the interactions between MSCs and the microenvironment of the injured liver. In this in 
vivo study, I was able to provide useful evidence of the dynamic cellular changes and 
disease activities involved in acute CCl4-induced liver injury over different time points. 
These changes, therefore, are valuable to assess the efficacy of MSCs after infusion 
according to the peak of the biological parameters that need to be investigated. 
In this chapter, I reported that the maximum effect of liver injury was seen after 24 hours 
with massive necrotic areas in the liver tissue. My findings also indicate that other 
parameters such as inflammatory cytokines, oxidative stress, and autophagy are 
correlated with hepatocellular damage, as they increased rapidly by 24 hours. The 
inflammatory response increase after 48 hours and peaking 72 hours after treatment with 
CCl4 with clear localization around the portal tracts. Furthermore, I found that antioxidant 
enzymes exhibited significant variation at different time points.  
The findings of chapter 4 have important implications for defining the most effective 
study endpoints to use for my in vivo experiment, which aimed at improving the 
therapeutic efficacy of MSCs in liver injury. In addition, this could help to identify 
specific pathways to target and understand the functional effect of MSCs on the injured 
tissue microenvironment.  
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8.1.3 Therapeutic efficacy of unsorted UC-MSCs and CD362+ sorted 
MSCs in mice with liver injury   
 
The therapeutic potential of hUC-MSCs has been reported to repair injured tissue, but 
few studies have found beneficial effects of MSC infusions in different animal models of 
acute liver injury. To address whether UC-MSCs have a therapeutic role in liver injury, I 
used CCl4 and Ova-Bil mouse models of acute liver injury. As reported in chapter 5 and 
6, an efficacy dose-response with varying infusions of hUC-MSC dosages was assessed 
in animal models. I observed that both 2.5x105 and 1x106 doses appeared to have the 
same level of improvement in liver injury, whereas the 5x105 dose had superior efficiency 
in the treatment of liver injury in the Ova-Bil mice. This finding suggests that high doses 
of cells are not required for greater therapeutic efficacy, and highlights that the optimal 
effective dose depends on understanding each disease condition, as well as the 
mechanisms of MSCs in modulating injury.  
 
The therapeutic effect of CD362+ sorted UC-MSCs and unsorted UC-MSCs has not yet 
been studied in literature. Thus, I conducted, for the first time, comparison study to 
investigate the effect CD362+ sorted UC-MSCs and unsorted UC-MSCs in CCl4 as well 
as Ova-Bil mouse models. I demonstrated a significant reduction in serum ALT with 
infusions of CD362+ UC-MSCs as well as US MSCs in CCl4, whereas the liver injury in 
the Ova-Bil mice found to have improvement with CD362+ sorted UC-MSCs. This 
finding clearly demonstrated that sorted cells have potential positive effects and more 
efficacy in the treatment of liver diseases.   
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I studied the hypothesis that MSC transplantation can promote acute liver injury through 
an immunosuppressive function using UC-MSCs. I showed that transplantation of 
unsorted MSCs or CD362+ sorted MSCs resulted in significant reduction in hepatic 
CD45+ expression as well as a reduction in non-NK cells and B cells in mice injured with 
CCl4 induction. In contrast, no significant reduction in hepatic CD45+ cells reported in 
Ova-Bil mice treated with MSCs. In addition, I reported no change in the hepatic 
expression of CD3+, CD4+ and CD8+ following the treatment of CCl4 mice with MSCs. 
Interestingly, analysis of the number of CD4+ T cells in the liver of Ova-Bil mice showed 
a significant increase in the presence of US and CD362 sorted MSCs treatment. My 
results indicate that US and CD362 sorted MSCs reported equal induction effects on 
hepatic CD4 T cells in Ova-Bil mice compared with the untreated group.  In addition, I 
further analyzed the ability of MSCs to modulate the macrophages in both models 
following treatment with hUC-MSCs. We only observed that CD362 UC-MSC treatment 
have decreased the number of macrophages in the injured liver of the CCl4 mice and 
MSCs had no ability to modulate the number of macrophages in the Ova-Bil mice. Further 
experiments are suggested to study cell-to- cell contact via the direct culture of immune 
cells isolated from injured liver and MSCs, as applying exosomes from MSCs to the same 
cells could answer the paracrine efficacy of MSCs in vivo. Another interesting point that 
remains to be studies is the ability of MSCs to induce B cell subsets that could have 
proved immunomodulatory properties.  
 
In general, our results have demonstrated that MSCs have anti-inflammatory effects in 
multiple ways that appear to be related to the different microenvironments in each liver 
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injury as well as the mechanism which control their biological function in their particular 
niche.   
Interestingly, one major advantageous observation in the present study is that, upon MSC 
infusion, I observed a significant reduction in ICAM and VCAM expression in liver 
sections from Ova-Bil mice treated with CD362+ MSCs. However, an opposite finding 
confirmed that these two adhesion molecules were not altered following MSC treatment 
of CCl4-injured mice. This finding shows that CD362 purified MSCs show superior 
properties compared to unsorted MSCs. This could be due to the ability of the CD362 
MSCs to promoted tissue repair through the elevation of chemokines and cytokines to 
modulate the adhesion molecules activities in the local environment on the injured tissue 
which can promote tissue regeneration. One of the major challenge of MSC- based 
therapy is to understand the mechanism of action. Indeed, we acknowledge that further 
elucidation of the role of adhesion molecules in the immunoregulatory function of the 
MSCs will be an essential area of future study.  In addition, Further analysis of the 
molecular mechanisms in relation to the interactions between MSCs and inflammation 
will be essential for developing potential therapeutic applications of MSC-based therapies 
and for improving our understanding of pathological changes related to specific disease 
condition.  
 
It is necessary to recognize certain limitations in our present study. One limitation is that 
the study did not assess the long-term effect of MSCs is unclear. We only focused on the 
short-term effect (3-5 days) of MSC in all our in vivo studies.  The long-term effects 
remain unknown and merit further investigation. Second, although it was reported that 
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UMSCs can be induced into hepatocytes in vitro, it is still unknown if these cells really 
transdifferentiate into hepatocytes in vivo. Third, due to time and fund limitation, we were 
unable to include and explore the effect of MSCs on apoptosis and autophagy have not 
been explored in detail. Finally, we did not detect and analyze differences in expression 
level and effect among all the possible secreted therapeutic factors in both animal models 
after treatment of hUC-MSCs. 
 
 
8.1.4 Monitoring and tracking the engraftment of MSCs in vivo  
 
The homing of infused stromal cells has been found to be important to promote 
therapeutic regeneration as well as to treat inflammation in liver diseases. In my study, I 
investigated the dynamic homing of MSCs by using the CryoViz™ imaging system to 
monitor the trafficking of MSCs labelled with Qdo and quantify live MSCs after infusion 
in mice with liver injury. I found that most injected MSCs were trapped in the lung within 
1 hour and had cleared within 24 hours of systemic infusion. Questions remain with 
regard to why MSCs are trapped directly to the lung, and why MSCs no longer exist 24 
hours after injection. This rapid clearance of infused MSCs could be mediated by 
phagocytosis by recipient immune cells and subsequently activate the immune responses. 
The short-term survival of injected MSCs can be achieved by local transplantation of 
injection which could provide more efficient therapy in liver disease.  
 
In addition, my findings clearly reported that more MSCs engrafted to the liver after 24 
hours in the Ova-Bil mice compared with cells detected in the lung. However, I reported 
variations in the engraftment of MSCs in the liver at 24 hours between the CCl4 and the 
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Ova-Bil mouse models, which suggests that different factors affect the recruitment 
abilities of MSCs in both CCl4 and Ova-Bil mice, either from the bloodstream or from 
the tissue microenvironment of the injured tissue. The data in this study will help to guide 
future aspects related to therapy involving the transplantation of MSCs in liver injury. 
However, I believe there still remains a major lack of understanding of the several 















8.2 Future Work  
 
 
In this study, I found that UC-MSCs have regulatory abilities to immunomodulate the 
inflammation associated with acute liver injury. However, it should be noted that there 
are several outstanding questions that need to be addressed in order to understand the 
mechanism of action related to the role of MSCs in immunomodulating liver injury in 
vivo. Understanding the mechanism will support further development of the therapeutic 
potential of MSCs in clinical trials associated with liver injury. Based on the main 
findings in this study, I highlight below the main areas that I believe require further study.  
 
• The timing as well as the delivery route of MSCs are critical to increasing the potential 
function of these cells in the treatment of injury to different tissues. Direct or local 
injection of MSCs may promote the homing of the cells to the site of inflammation. 
In addition, the dose and duration of MSC treatment needs to be studied further in 
preclinical experiments as well as in clinical trials. Another challenge for MSC-based 
therapy is the cell source, which needs to identify whether MSCs from different tissue 
sources have different effects in response to the various inflammatory immune cells.  
 
• In addition, more advanced delivery vehicles can be applied for more effective 
treatment with MSCs. For example, exosomes, as well as MSC-derived 
macrovesicles, could have an effective function, as it has been reported in various 
studies that MSCs exhibit paracrine function to modulate damaged tissue. The 
difference between the ability of MSCs to engraft locally and secrete trophic factors 
is still unclear and needs further investigation.  
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• There are important steps in manufacturing MSCs in vitro, which could improve the 
diverse phenotypic characterization of these cells. I believe sorting cells based on 
marker expression may allow for the selection of cells with greater efficacy. In 
addition, pre-treatment of MSCs using chemokines or cytokines prior to injection is 
intended to enhance their biological properties for whichever clinical indication is 
being considered. This may include improvements in MSC immunomodulatory 
effects, homing to injured organs and/or greater expansion of cells. More importantly, 
the genetic correction or modification of transplanted MSCs represents a powerful 
approach in the use of MSCs in regenerative medicine. In addition, future work is 
required to develop more advanced techniques which could increase the persistence 
of MSCs following infusion, which could result in greater therapeutic effect. 
 
• One fundamental aspect of the future of cell therapy which could lead to more 
successful treatments is understanding the biological as well as the genetic 
abnormalities of the disease to be treated. This could help to identify specific 
pathways to target and understand if MSCs can be manipulated or genetically 
modified based on the injured tissue microenvironment. Another question which 
needs further study is whether the endogenous MSCs found in the injured 
microenvironment have a similar function to the exogenous MSCs. I believe this 
needs more advanced work and standardized protocols for identifying specific 
markers that could help to study MSCs in vivo.  
 
• One of the major impacts of MSC research lies in investigating the correlation 
between MSCs and the metabolic pathways related to liver disease. I believe that 
 247 
MSCs have a significant role in the regulation of metabolic enzymes related to the 
glucose homeostasis that is in turn related to different metabolic syndromes associated 
with liver disease. Another important piece of evidence that could be related to the 
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